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Abstract
The growth hormone secretagogue receptor-1a (GHS-R1a) is expressed in many
human tissues, most notably the hypothalamus, and causes an increase in appetite upon
activation by its endogenous ligand, ghrelin. GHS-R1a is differentially expressed in
malignant compared to benign tumours. Therefore, there is an interest in developing
GHS-R1a-targeted peptides as novel drugs to modulate signaling for diseases such as
cancer cachexia and obesity and to image the receptor for disease diagnosis and following
progression.
Chapter 2 discusses a fluorescently labelled ghrelin analogue for imaging GHSR1a in ex vivo biopsy analysis and in vivo distribution studies. The analogue was created
through side-chain cyclization resulting in an improved affinity and stability compared to
natural ghrelin. This stapled peptide was used as a cancer cell-specific fluorescent stain.
G7039, a peptidomimetic ghrelin agonist (IC50 5.2 nM/EC50 0.18 nM), underwent
structure-activity relationship studies to generate improved ligands and positron emission
tomography (PET) agents. The first generation peptidomimetic (Chapter 3) [1-Nal4,Lys5
(4-fluorobenzoyl-4-FB)]G7039 (IC50 69 nM/EC50 1.1 nM) was radiolabelled with 18F in a
radiochemical yield of 48%, radio purity of ≥ 99%, and molar activity of ≥ 34 GBq/μmol.
Despite success in radiolabelling, its solubility (cLogP = 8.76) and binding affinity
needed improvement.
The second generation peptidomimetic (Chapter 4) [Tyr4,Lys5(2-fluoropropionyl
(2-FP)]G7039 (IC50 0.28 nM/EC50 0.12 nM) had improved binding and lipophilicity
(cLogP = 4.36). Labeling of this ligand was low yielding, however, a unique H-bond
interaction was identified with molecular docking.
The third generation (Chapter 5) required a modified prosthetic group (2-FP to
ammonium methyltrifluoroborate-AMBF3) to radiolabel in higher yields, resulting in
[Tyr4,Lys5(AMBF3)]G7039 (IC50 0.85 nM). This compound was radiolabelled in a single
step and with improved radiochemical data.
Finally, in Chapter 6 a homobivalent G7039 ligand (IC50high 0.43 nM:IC50low 0.42
pM /EC50 1.8-2.1 nM) was found to bind to GHS-R1a homo-oligomer and was designed
to study GHS-R1a homo-oligomerization. Differential signalling with the GHS-R1a
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homo-oligomer was observed by measuring cellular signals such as b-arrestin, ERK, and
gene reporters. A successful series of GHS-R1a targeting probes have been synthesized
and characterized with applications driven towards imaging and therapy.
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Summary for Lay Audience
Within health care there is a growing need to better diagnose and monitor human
diseases to have the best possible outcome for the patient. Improvements in disease
diagnosis and monitoring is due to new and emerging biomarkers (human proteins) that
can be targeted by fluorescent and/or radioactive pharmaceuticals. These various
pharmaceuticals can also allow us to study a biomarker from a molecular pharmacology
standpoint (i.e. signalling and regulation). The pharmaceuticals that are designed to
image human diseases can also have the dual purpose in treating the human disease by
targeting and regulating the biomarkers.
This thesis describes the development of chemical tools that target a very
attractive G-protein coupled receptor (a specific family of human proteins): the growth
hormone secretagogue receptor-1a (GHS-R1a). This is a protein that is found on the
cellular membrane of human tissues such as the heart, lungs, and brain. GHS-R1a is an
attractive protein target because of its wide range of physiological functions in the human
body including metabolism, cardiac output, depression, and neuroprotection. This protein
is also regulated differently when there is disease present. Within malignant prostate,
ovarian, lung, and uterine cancer the GHS-R1a has greater expression. The upregulation
or downregulation of GHS-R1a can change the outcome of human diseases, leading to
worse or better prognosis. GHS-R1a is also highly promiscuous as it couples (heterooligomerizes) with many other GPCRs (i.e. dopamine, melanocortin), as well as it has
been shown to couple (homo-olgiomerize) with itself. When it couples with itself or other
GPCRs there are changes to the normal human cellular events leading to different
physiological outcomes in humans. This can alter the human disease to make the
prognosis either worse or better.
Overall in my PhD I was able to develop several different styles of drug
molecules targeting GHS-R1a. Each of these drugs was modified in such a way as to
have applications in either imaging or therapy. This work opens the doors to further drug
development to study this protein in human physiology and disease.
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Chapter 1
1 Introduction
1.1 Peptides as Molecular Imaging Tools
Abnormal expression of proteins is largely due to dysregulated or mutated genes
that can be seen across a wide variety of diseases such as cancer and cardiovascular
disease. These dysregulated proteins are considered hallmark biomarkers to track the
progression of and treat human diseases. Tracking and monitoring these biomarkers are
the reason in the development of molecular probes to monitor these biomarkers in real
time. Molecular imaging is a wide and ever-growing field that has allowed many
researchers and clinicians to be able to better understand the complexity of living
systems. It has allowed for non-invasive techniques to diagnose and treat patients in a
time sensitive manner1. This field is enabling researchers and clinicians to visualize
biochemical processes in both normal and disease states. This is performed in real time
on tissues, living cells, and whole organisms1. There are many chemical classes of
molecular imaging agents such as small molecules, peptides, aptamers, engineered
proteins and nanoparticles. However, the focus within the thesis will be the development
of peptide molecular imaging agents to target a specific cell surface receptor1. Molecular
imaging is a multidisciplinary field that involves many scientific fields such as
biophysics, biology, bioengineering, molecular biology, chemistry, and clinical sciences2.
All of these disciplines work together in designing, testing, and validating a molecular
imaging probe. However, chemistry has been a key discipline for many years in the field
of molecular imaging, and in many cases has been the rate-limiting step, due to
complications in chemical synthesis with challenges associated with chemical purity,
yields and complex synthetic routes2. Once a compound begins the crucial stages of a
clinical trial it can also fail to make it as a clinically used pharmaceutical due to the
complications that may occur in human physiology such as off target effects and toxicity.
This is also another rate-limiting step in the development of novel pharmaceuticals.
Molecular imaging is widely used in the detection and treatment of cancer and has
many advantages in this area. Molecular imaging techniques can perform whole body
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readouts in an intact system, which is more reliable than in vitro or ex vitro studies3. This
helps decrease the work load and accelerate the diagnosis and treatment plan for
patients3. By doing so the patient can have a better overall all prognosis. Molecular
imaging of cancer patients also allows for longitudinal studies being performed on the
same patient to assess the progression of the diseases state and validate the success of the
selected treatment plan3. Therefore, the detection of molecular markers such as cell
surface receptors can allow for an earlier diagnosis, earlier treatment, and an overall
better prognosis for the patient3. All imaging probes have some commonalities in that
they must be biocompatible, have target specificity, high disease-to-normal-tissue signal
ratio, and rapid clearance. There are three main components to most imaging agents; a
targeting moiety, a linker, and an imaging moiety (Figure 1.1).

Linker

Targeting Moiety

Imaging Moiety

Figure 1.1 - Typical three component imaging agents. The targeting moiety is specific
to the biomarker, the linker provides space between the targeting moiety and the
imaging moiety, and the imaging moiety allows for visualization of the biomarker
The targeting moiety is selective to only one target and typically needs to bind with a
high affinity (high ki). The targeting moiety should also possess a high selectivity, a
strong metabolic stability, and potentially membrane permeability if the target of interest
is an intracellular protein. The linker provides enough space between the targeting and
imaging moiety to ensure the imaging moiety does not interfere with binding to the
receptor.
The development of a novel molecular imaging agent has a number of key steps
in order to have a successful probe in the end. These key steps are highlighted in Figure
1.2 below. These steps are guidelines that help direct the research in a uniform fashion
towards the end goal, however in some cases these steps are altered due changes in
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project design such that the imaging agent might target another biomarker more selective
then the original choice. First (step one Figure 1.2) a disease state must be chosen, such
as a certain class of cancer. The disease state that is being targeted in this thesis is
prostate cancer (PCa). Cancer is only one type of disease that can be targeted by the use
of molecular imaging agents; however, this general scheme can be used in the
development of imaging agents used in the detection and monitoring of other diseases
such as cardiovascular disease. A biological target that is highly expressed must be
identified within the disease state chosen (step two Figure 1.2)3. Identification of this
biomarker is done through various techniques such as genotyping a population of people
with a common disease. This is usually followed up by pathology of the tissue identifying
the biomarker with an antibody or chemical stain. Typically, a target that may show
differential expression between disease states (i.e. malignant vs. benign) is preferred
along with a target that is overexpressed within the chosen disease state3 (step three
Figure 1.2). Choosing a target that is unexpressed would not be beneficial since the
expression is far too low for most imaging techniques. An imaging technique that
satisfies the signaling target must be decided upon before devising a synthetic route for
the molecular agent as the addition of the signalling entity is incorporated in the chemical
design of all the probes being studied. For instance using fluoride-18 (18F) in conjunction
with positron emission tomography (PET)2. There are several imaging modalities that
exist such as single-photon emission computed tomography (SPECT) and magnetic
resonance imaging (MRI), however the focus of this thesis is utilizing PET in conjunction
with the radioisotope 18F. The major reason for this choice is the wide spread use of both
this imaging technique and isotope among healthcare. It will be discussed later that one of
the most widely used PET imaging agents is fluorinated glucose. The next stage is the the
design and chemical synthesis of a molecular imaging probe (step four Figure 1.2). This
is because chemical synthesis is time consuming and requires careful planning to create a
target that will have a high affinity for the receptor4. This requires the consideration that
the imaging probe has a binding property with a fast on-rate (kon) and a slow off-rate
(koff)3. Also, the imaging probe will need to have appropriate pharmacodynamic and
pharmacokinetic properties for in vivo use. Pharmacokinetics is the effect the body has on
the chemical probe such as absorption, distribution, metabolism, and excretion5. These
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properties can be controlled based on the chemical structure of the probe, including the
linker, and the signalling entity. In the case of using peptides as imaging agents the
chemical nature of the amino acids can directly affect the pharmacokinetic properties.
However, pharmacodynamics refers to the chemical probes’ effects on the body such as
adverse effects and off target effects5. Again the chemical nature of the probe greatly
dictates the pharmacodynamics. In vitro assays help confirm the effectiveness of the
probe on the target under non-radioactive conditions before moving into animal studies
(step five Figure 1.2). These types of assays involve competitive radioactive probes to
assess the binding of novel chemical probes, and this competitor itself can change the
chemical and structural properties of the novel chemical probe and the target itself. In
vitro studies are able to directly assess product performance on an isolated target5.
However directly assessing an isolated target with success does not directly translate to
the same success in the initial animal models. This is because the isolated target is most
likely a purified protein or an overexpressed protein in a given cell line or membrane
fragmentation preparation. Typically experiments on a chemical probe switch between
step four to five (Figure 1.2) until an optimal molecular probe is identified with
specificity and selectivity for the given target. When designing a molecular imaging
probe, a site for labeling must be considered at this stage (step six Figure 1.2) making it
easier for a synthetic scheme to label the molecular probe with the appropriate
radionuclide such as 18F. Incorporation of the imaging modality after the design of the
core pharmacophore can leads to changes in both selectivity and specificity for the given
target leading to further optimization and synthetic challenges such as the location to
attached the imaging component. Once the compound can be successfully labelled with
high yield, purity, and reproducibility the study can progress into an appropriate animal
model for the disease being studied (step seven Figure 1.2). In vivo studies are
considered the gold standard in assessing the pharmacokinetics and pharmacodynamics
of the probe6. Increasing the animal number within all desired control groups (step eight
Figure 1.2) ensures that the images are reproducible among many trials. This sometimes
requires the study to go back to step four (Figure 1.2) to improve the pharmacokinetics
and pharmacodynamics, which in turn will improve the PET images in order to have a
higher level of confidence when identifying cancerous tissue in the image6. Then finally
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clinical studies (step nine Figure 1.2) with a lead compound will begin if there has been
success at steps one through eight. Clinical studies pose their own challenges as now the
molecular imaging agent will have been challenged against human immunity and a
potential increase in off target effects due to the larger number of biomarkers, they
regulate human pharmacology and physiology.

Figure 1.2 - The nine critical steps in designing a successful imaging probe. These
steps are just a guideline in designing a successful imaging agent. As these steps
progress changes can occur with both the imaging agent and the target of interest
1.2 Prostate Cancer
Within the scope of this thesis the disease state of interest is prostate carcinoma
(PCa). The prostate is a major male reproductive organ that is involved in the addition of
nutrients and fluid to the sperm7. It takes the shape of a walnut that is divided into right
and left lobes and is located on the ventral side of the rectum below the bladder7. Cell
growth in the prostate is modulated by testosterone, regardless whether the cells are
cancerous or healthy7. There are three zones of the prostate that include the peripheral
zone (p-zone), the central zone (c-zone), and the transitional zone (t-zone). It is known
that about 75% of malignant tumours originate in the p-zone, and typically benign masses
are found in the t-zone8-9. PCa is the most common cancer among Canadian men. The
statistic as of 2018 is that one in seven men will be diagnosed with PCa in their lifetime7.
PCa acts similar to that of all cancers as it has uncontrolled growth, abnormal structure,
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and has the ability to metastasize7. PCa can persist for many years without showing
noticeable symptoms, hence the importance in the development of imaging agents for
earlier detection7. According to Prostate Cancer Canada (PCC) there are five major risk
factors that males should be aware of in order to ensure early diagnosis of the carcinoma.
It is recommended that men over the age of 40 should be tested for prostate specific
antigen (PSA) levels to establish a baseline and monitor fluctuations as the years pass
on7. PSA is a protein produced in the prostate gland that is secreted into the seminal
fluid7. There is free PSA and complex PSA. Free PSA moves freely in the blood stream,
and complex PSA is associated with other blood proteins such as human serum albumin7.
The PSA test is a blood test that measures the amount of PSA found in blood protein a
and above 4 ng/mL is considered higher than normal. Free PSA is usually associated with
benign prostatic hyperplasia (BPH)7. However, this relatively non-invasive test cannot
stage the progression of the cancer, and also this is not a definitive diagnosis, and
therefore further testing is required7. Elevated PSA levels are also associated with
prostate inflammation, and this is highly treatable with pharmaceuticals and diet. If there
are elevated PSA levels, then a digital rectal exam (DRE) is a next logical step. This is
when the physician examines the size and shape of the prostate and feels for lumps or
hard areas within and around the prostate7. Hard areas are signs of tumour growth, where
as soft tissue enlargement is usually indicative of inflammation. If cancer tissue is
suspected, then a trans-rectal ultrasound (TRUS)-guided biopsy is performed to obtain a
small segment of prostate tissue. Pathology of the tissue can be examined to determine
whether or not it is cancerous. This is then scored from one to five depending how much
of the tissue is cancerous. This is known as the Gleason score, where a score of one
indicates mostly normal prostate tissue is observed, and a score of five is when growth
patterns of the prostate tissue is highly abnormal and considered to be an aggressive form
of prostate cancer. However, all of these techniques have sampling errors, especially with
the biopsy, leading to missed and late diagnoses7. This is why there is a need for noninvasive imaging methods to improve the disease identification through the detection of a
specific overexpressed biomarker in the disease. If this can be done at earlier stages, this
leads to improvement in patient prognosis and survival.
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1.3 Imaging Modalities
The typical imaging modality used to detect prostate cancer is magnetic resonance
imaging (MRI), and this is performed before a biopsy8-9. This technique is performed as a
whole-body scan to detect if the cancer has metastasized to other tissues. MRI uses a
magnetic field and radio waves in order to create a detailed image of organs and tissue in
a biological system10. The magnetic field temporality realigns the hydrogen atoms of
water within a tissue and the radio waves allow these aligned atoms to create signals that
are transferred to a series of detectors to reconstruct an image10. The advantages to MRI
are that there is no ionizing radiation and the images have a high spatial resolution (less
then 1 mm) without compromising the image. However, there are still signal-to-noise and
contrast-to-noise issues with MRI that need to be improved. There have been attempts to
use stronger magnets and dedicated computational software to help with contrast and
noise, but in the past 30 years it is the contrast agents (CA) that have been able to
enhance the image to provide a better diagnosis and treatment plan4. MRI contrast agents
such as gadolinium (Gd) are used to alter the longitudinal (T1) and transverse (T2)
relaxation rates of the surrounding water protons in a tissue. An MRI CA must be a
biocompatible magnetic material to be able to alter these relaxation rates, and CAs are
classified based on their magnetic properties and relaxation mechanisms. This type of
technology is used to show the invasiveness of the cancer and whether other tissues may
also need to be biopsied. However, MRI shows limited lesion detection in the central
gland of the prostate making it difficult to delineate between benign and malignant
tumours11-13. Computed tomography (CT) can also be used to localize and identify a
tumour, however it lacks accuracy, sensitivity, and specificity when identifying is the
tissue is cancerous or benign14.
1.4 Fluorine-18 Positron Emission Tomography
Positron emission tomography (PET) is another non-invasive imaging modality
with decent spatial resolution (5 to 7 mm), however it has superior sensitivity (100 to
1000 fM) compared to other imaging techniques. This sensitivity is important as very
little of the imaging pharmaceutical is used in order to have a detectable signal in the
affected tissue. This imaging method allows for the detection of a pharmacological
process in patients using a positron emitting radioisotope15. Fluorine-18 (18F) is a
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radioactive isotope with a half-life of 109 min, and a Beta+ (β+) emission. It is created by
a cyclotron by bombarding water that is enriched with the oxygen-18 (18O) isotope with
high energy protons (18 Mega-electronvolts). The desired radionuclide 18F is then created
with a highly unstable nuclease with 9 protons and 9 neutrons in the nuclease and 9
electrons. There is a production of two gamma (γ) photons of 511 keV in 180° direction
from each other after an annihilation event occurs between the radionuclide and the
electrons in surrounding tissues (releasing the β+)15. The half-life of 18F being two hours
is beneficial as the decay rate is long enough to perform a lengthier radiosynthesis route,
but short enough lived that the radiation does not persist too long in a biological system
reducing radiation exposure for patients. PET has the capability of detecting two
coincident gamma emissions simultaneously (Figure 1.3)15.

Figure 1.3 – Beta Positron Annihilation with Electron in Body Tissue to Release
Gamma Photons of 511 KeV
The images acquired from a clinical PET camera have spatial and temporal
resolution of 5-7 mm and second-minutes respectively15. PET also has a sensitivity of 1012

to 10-13 M, meaning that a very low concentration of the radiolabelled imaging probe

can be used15. All of these factors above make PET a very good imaging modality for the
clinician and patient.
Currently the most common clinical PET probe is fluorodeoxyglucose
([18F]FDG). The reason for using glucose in the detection of carcinoma is that cancerous
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cells metabolize glucose at a much faster rate than normal cells, which creates a different
contrast on the PET image, and this is known as the Warburg effect16. Since glucose
passes through the body by renal excretion, it causes a buildup of the tracer in the
bladder16. With the bladder in close proximity to the prostate, there are difficulties
associated with visualizing the disease tissue16. The current PET imaging agents are
unable to delineate between malignant and benign PCa. This is why there is a need for
more specific PET imaging agents in order to improve the accuracy in diagnosis of PCa
within patients.
1.5 Peptides as Molecular Imaging Agents
The major advantage to using peptides as imaging agents is that they show a high
binding affinity and specificity with cell receptors both in vitro and in vivo17. The other
advantage to peptides as imaging agents is that they show good pharmacokinetic
characteristics such as absorption and distribution in an in vivo scenario when targeting
cell receptors that are overexpressed in tumour cells18. Peptides are biologically
synthesized in many different organs in the body but have multiple functions else were
controlling human pharmacology and physiology18. Peptides have a particular target of
interest within a given tissue in order to elicit their response. Peptides are able to also
target proteins/peptides in cancerous tissue leading the progression or regression of
disease18. A majority of these peptide targets are overexpressed receptors called Gprotein coupled receptors (GPCRs). Peptide based radiopharmaceuticals have been in the
clinic for over 2 decades and have showed promising results in the diagnosis of cancer18.
The first peptide that showed success was 111In-DTPAO-octreotide a somatostatin (SST)
analog18. This receptor is overexpressed in neuroendocrine tumours18. This success has
led many to develop peptides as imaging agents over these past decades.
Major success has also been seen when it comes to imaging the melanocortin-1
receptor (MC1R) that is expressed in melanocytes. MC1R aids in the synthesis of
epidermal melanin pigments, as well as aids in the photoprotective response via DNArepair pathways and antioxidant defences. However, MC1R is highly overexpressed in
primary melanomas and their metastasis leading to the development of peptide imaging
probes19. The development stemmed from the natural ligand for the MC1R: αmelanocyte-stimulating hormone (αMSH). In 2014 a 18F-labelled benzamide derivative,
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[18F]N-(2-diethylaminoethyl)-4-[2-(2-(2-fluoroethoxy) ethoxy)ethoxy]benzamide
([18F]FPBZA) was developed by Shih-Yen Wu and co-workers to specifically target
primary melanomas and their metastasis in mice bearing B16F0 melanoma (nonmetastatic) or A375 amelanotic melanoma (metastatic) tumour tissue20. More recently
Chengcheng Zang and co-workers developed a lactam bridge-cyclized αMSH (Ac-Nle
(norleucine)4-cyclo(5, 10) [Asp5-Hid-DPhe7-Arg-Trp-Lys10]-NH2) analogue tagged with
gallium-68 (68Ga) via a 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)
chelator. They made a couple variants of this analogue and each of their variants showed
successful single-photon emission computed tomography (SPECT) images in mice
bearing non-metastatic and metastatic tumour tissue21. These are just a few of the
peptide-based imaging probes that have been developed in order to image disease in a
non-invasive fashion19. Currently there are over 150 peptides that are in clinical trials for
the purpose of both diagnosing and treating disease22-23.
In particular within this thesis, the peptides being developed are small therefore
allowing them to have many advantages. Small peptides are easy to synthesize, and easier
to radiolabel. They are amenable to chemical and molecular modifications and have the
ability to be conjugated to metal chelators or other imaging components on either the N
or C terminus of the peptide. They tend to have higher receptor binding affinities, higher
tumour penetration, and higher retention in the target tissue than small molecules. They
have favourable pharmacodynamics, rapid clearance from off target tissues, and the rate
and route of excretion can be modified by changing the chemical structure. They tend to
have fewer side effects, they are highly non-immunogenic, and, in some cases, they can
be used for more than one biological target of interest18-19. These are the main reasons for
using lower molecular weight peptides as imaging agents.
1.6 Modifying Peptides for Improved In Vivo Stability and Target Affinity
Peptides are natural molecules that can have several disadvantages in terms of
their oral bioavailability and lower metabolic stability. In terms of imaging agents,
bioavailability is not always a concern as the typical route of administration will be
intravenous (IV). However metabolic stability for imaging agents is highly important as
the probe must be able to make it to the target tissue in order to bind to its receptor.
Structural modifications are needed in order to inhibit or reduce enzymatic degradation.
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Exopeptidases are one of the major enzymes that hydrolyze the C and N termini of linear
peptides. One approach to prevent this degradation is to synthesize a peptide to have the
C terminus as an amide and perform an N terminal acetylation although this may cause a
reduction in binding in some cases24. Within the scope of this thesis all peptides have a C
terminus that is amidated in order to slow the degradation by exopeptidases. Hydrolyzing
peptide bonds is caused by endopeptidases that recognize the natural L-amino acid within
the peptide sequence. One particular way to prevent this is to replace L-amino acids with
D-amino acids or other unnatural amino acids. For instance, the use of D-amino acids
was highly used in the peptidomimetics designed within Chapters 3 to 5. The main choice
was unnatural aromatic D-amino acids (D-1-naphthylalanine, D-2-naphthylalanine) as
they prove to be involved in a series of hydrophobic interactions within the binding
pocket of GHS-R1a as determined by MD simulations. Other modifications are the use of
the unnatural beta and gamma amino acid substitution in comparison to the standard
alpha amino acids25. This allows the amino acid side chains to arrange in very specific
three-dimensional conformations forming helical or pleated sheet secondary structural
motifs. These are some of the modifications that can enhance in vivo stability while only
making minor changes to the natural peptide sequence in order to maintain affinity
towards the target25 (Figure 1.4).

Figure 1.4 - Stereochemistry of natural and unnatural amino acids
Pseudo peptides is another way to enhance the stability of peptides, since they contain
chemical modifications within the backbone of the peptides, therefore resulting in
improved resistance against peptidases. Examples of this are peptoids, aza-peptides, and
several amide bond surrogates (Figure 1.5)25. Peptoids or N-substituted glycine can

12
increase the peptide stability as well as the cell permeability if we are considering a target
that may be cytoplasmic or nuclear. Attachment of the peptide side chain to the backbone
nitrogen this will cause the elimination of the polar N-H bond, driving up lipophilicity to
enhance cell permeability even further. Aza-peptides refers to the replacement of one or
more alpha carbons with nitrogen25. This causes a lost in stereogenicity and reduces the
flexibility by switching the rotatable alpha carbon-C(O) bond with a rigid alpha nitrogenC(O) bond. When an aza residue is placed in the i + 1 or i + 2 position this can cause the
induction of beta turns changing the conformation and enhancing peptide stability
overall. Amide bond surrogate examples are thioamides, esters, alkenes, and
fluoroalkenes and these modifications will mimic the geometric structure of a peptide
bond but lead to an increase in peptide stability in most cases26-27. However, based on the
number of atoms and valence arrangement, thioamides most accurately mimic that of a
natural peptide bond. The drawback to thioamides is that sulphur is a poorer H-bond
acceptor in comparison to oxygen, but the nitrogen compensates for this loss in
thioamides. Ester substitution can destabilize secondary structure of a peptide since they
are unable to perform H-bond donation acting as poorer H-bond acceptors. Esters also
have the tendency to undergo hydrolysis. Alkene surrogates can mimic bond rigidity,
angle and length even though they lack a heteroatom for non-covalent interactions26-27.
Alkenes can also undergo isomerization, oxidation, and chemical liability in vivo even
though they have been incorporated into previous natural peptides and proteins to
enhance stability (e.g. C-X-C chemokine receptor 4 CXCR4 and the tripeptide RGD). 1,
2, 4-Oxadiazole, 1,3,4-oxadiazole, and 1,2,4-triazole can be used as heterocyclic moieties
mimicking amide bonds30-31. All of these modifications are highly dependent on the
overall structure of the natural peptide, the target of interest and the intent of the chemical
probe (e.g. imaging versus therapeutic). However, they all come with challenges and
disadvantages that must be considered when performing structure activity relationships
(SARs) on natural peptide sequences30-31. This process is always the limiting step but is
highly necessary in order to advance a lead peptide drug candidate towards clinical trials.
This approach can be used whether the intended chemical probe is to act as an agonist,
antagonist, inverse agonist (induces opposite response to that of an agonists), or partial
agonist (partial efficacy towards the receptor) and this can be a way to alter the chemical
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probe towards these specific pharmacological molecules. The focus for chemical
modifications within this thesis will be using unnatural amino acids, D-amino acids and a
backbone bridging technique (lactam bridge) in order to enhance the lead peptides as
possible future drug candidates in a clinical trial. The lactam bridge stabilization will be
discussed further in section 1.13.

Figure 1.5 - Backbone modifications to help increase in vivo stability of natural
peptides
1.7 Peptide Design and Structure Activity Relationship
The peptides that are being designed in this project are based on a discovery in
1977 by Bowers et al32-34. The group was interested in Met (methionine in the 5th position
of this peptide)-enkephalin (EF) analogues in order to understand structure activity
relationship (SAR) in relation to pituitary hormone secretion. The natural structure of
enkephalin is a pentapeptide and its function is in the regulation of nociception in humans
by binding to the delta and mu opioid receptors. The naturally occurring enkephalin
derivatives differ by either a Met or Leu on the C-terminus of the pentapeptide (Figure
1.6).
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Figure 1.6 - Natural occurring Met-enkephalin and Leu-enkephalin pentapeptide
structures
Bowers et al32-34 set out to design enkephalin analogues that would also be
involved in the release of growth hormone (GH) from the pituitary gland in the female
rats. They discovered early on through a series of structure activity relationship studies
that position-2 in their analogues was highly conserved for very select amino acids in
order to still maintain GH release. Two of their first analogues (H-Tyr-DTrp-Gly-PheMet-NH2 and H-Tyr-DPhe-Gly-Phe-Met-NH2) they discovered that an aromatic residue
was required in the second position (DTrp and DPhe) in order for in vitro GH-releasing
activity32-34. Seven other analogues they developed without an aromatic amino acid in the
second position didn’t have any GH-releasing activity. It was also discovered that the L
amino acids of Phe and Tyr did not cause any GH-releasing activity. Upon the discovery
of these enkephalin analogues Bowers et al created a hexamer H-His-D-Trp-Ala-Trp-DPhe-Lys-NH2 (GHRP-6). This then became the first synthetic peptide to release GH both
in vivo and in vitro32-34. From this point on many researchers began to develop peptides
that had the ability to release GH. These classes of compounds then became known as
growth hormone secretagogues (GHSs)35. They are in their own chemical class based on
the function of secreting GH from the pituitary instead of the alternative route from GH
releasing hormone (GHRH)35. These various GHSs encompassed peptides: GHRP-136,
hexarelin37, KP-102 (later designated GHRP-2)38, peptidomimetics (e.g. G703939, [1-
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Nal]4G703940and ipamorelin41) and small-molecules (e.g. L-692,42942-44and MK-06774244

). The structure of these representative GHSs can be seen in Figure 1.7.

Figure 1.7 - Chemical structures of the peptides, peptidomimetics, and small
molecules that cause GH-releasing activity in rats and/or humans
It wasn’t until 1996 that the growth hormone secretagogue recptor-1a (GHS-R1a)
was discovered by the group of R. Smith at Merck Sharp and Dohme Research
Laboratory in the United States45-47. Their discovery was made possible by various
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expression cloning methods (i.e. point mutations) and they were the first to identify that
GHS-R1a interacted with these various GHSs causing GH-releasing activity. This
receptor belongs to the rhodopsin-like family of GPCRs48. Its seven transmembrane (TM)
alpha helical domains consist of 366 amino acids having an approximate mass of 41 KDa
(Figure 1.9)46-47. GHS-R1a has a known splice variant (GHS-R1b) which only has five
TMs consisting of 289 amino acids. To date this splice variant has no known biological
activity44-48. GHS-R1a is expressed in a wide variety of tissues and organs including the
hypothalamus, pituitary gland, thyroid gland, stomach, intestines, pancreases, spleen,
ventricular myocardium, aorta, lung, adrenal gland, kidney, testis, adipose tissue, ovaries
and lymphocytes48. Because it is widely spread in so many tissues and organs it has
several human physiological outcomes that are highlighted in Figure 1.849.

Figure 1.8 - Physiological effects of GHS-R1a in humans (modified from 47,
copyright permission number 11855562)
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Figure 1.9 - Homology model of GHS-R1a. This model is based on sequence
alignment with variations of the neurotensin receptor with various ligands docked
in its pocket. The 7-alpha helical domains (in red) span the cellular membrane (in
green)
In 1999 Kojima et al isolated the natural ligand ghrelin from a rat’s stomach50.
Before this date GHS-R1a was considered to be an orphaned GPCR. Human ghrelin is a
28-amino acid peptide that is derived from a 117- amino acid sequence (preproghrelin)
and through post-translational modifications, terminating with the octanoylation of Ser-3
by ghrelin O-acyl transferase (GOAT) the active form is produced50. Without this fatty
acid chain ghrelin is unable to bind to its receptor. This is the only known instance of a
peptide being post-translationally modified with a fatty acid, and it is required for its
binding to and biologically activating GHS-R1a47 (Figure 1.10).
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Figure 1.10 - Proteolytic cleavage of preproghrelin to the 28 amino acid variant and
the enzyme GOAT catalyzing the addition of the octanoyl chain on Ser position 3
Merck then continued to investigate the interaction between ghrelin and GHS-R1a
and learned that the first 5 N-terminal amino acids of ghrelin were essential in binding to
and activating the receptor51. They discovered this through the development of truncated
versions of the ghrelin peptide by measuring the EC50 (half-maximal effective
concentration) in HEK293T cells that transiently overexpressed GHS-R1a. The EC50 was
calculated by monitoring the intracellular calcium release from the endoplasmic
reticulum downstream of the Gaq51. These truncated versions can be seen in Figure 1.11.
Since then many ghrelin derivatives have been developed and tested that have similar
properties to that of the natural ligand. Some of these include small molecules that have
been developed by Merck52, Bristol-Myers Squibb53, Sumitomo Pharmaceuticals and
Abbott Laboratories54. Also, many have worked on the development of peptidomimetic
and pseudo peptide agonists developed by Novo Nordisk (DK). When developing novel
ligands targeting this receptor certain criteria must be carefully considered55-65. Deciding
the nature of the ligand (e.g. agonist, antagonist, partial agonist, inverse agonist) is the
first major step in beginning an extensive structure activity relationship (SAR) study. The
structural nature of the ligand must be decided before beginning synthesis. This could be
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choosing the development of small molecules, peptides, peptidomimetics, proteins, or
antibodies as the initial starting framework. Then in terms of having these ligands be
suitable imaging agents one must choose the location and method of radioisotope
incorporation into the structure of the ligand.

Figure 1.11 - Derivates of ghrelin developed by Merck indicated that the first
5 amino acids are essential to binding to and activating GHS-R1a
1.8 Molecular Imaging Agents Designed to be either Agonists or Antagonists
A peptide agonist has been the most frequently used radiolabelled molecular
imaging tool when it comes to targeting overexpressed proteins in cancerous tissue.
Agonists become internalized when binding to the receptor, allowing them to accumulate
and be retained in the targeted cells66. This became a well-established concept in the
1980s being studied with the somatostatin receptors that has been shown to be
upregulated in a variety of neuroendocrine tumours67-68. For examples an indium-111
labelled somatostatin derivative developed by Reubi et al. showed specificity in targeting
the highly expressed somatostatin receptors within neuroendocrine tumours in a mouse
model68. Upon binding of an agonist such as this somatostatin derivative to its given
target a receptor-radioligand complex forms and this becomes internalized into the
tumour cell69. This allows for an increase in radioactivity in the tumour tissue compared
to other organs such as the liver, lungs and spleen. As the radioligand accumulates in the
tumour tissue there is a contrast enhancement allowing the in vivo target to be visualized
by PET. This is one of the main reasons why most decided on using agonists versus
antagonists. This is because when an antagonist binds to a receptor it has a purpose is to
block the natural ligand from interacting with its natural target68.
Others in the field of imaging probe design focus on using an antagonist as the
target entity to be tagged with a radionuclide. For example, Ginj et al. showed that a
somatostatin derivative designed to be an antagonist showed improved in vivo results

20
(less buildup of the radiotracer in noncancerous tissues) then a variety of radiolabelled
agonists70. Another example when using an antagonist as an imaging probe was Wadas et
al. and their comparison between the antagonist 64Cu-CB-TE2A-sst2-ANT and the
agonist 64Cu-CB-TE2A-Y3-TATE, when targeting the gastrin-releasing peptide receptor
(GRPr) that is overexpressed in prostate cancer (PCa). Their results indicated a reduction
in kidney and intestine uptake while maintaining tumour uptake of the imaging probe.
The preference between using an agonist versus an antagonist is receptor dependent, and
therefore when designing an imaging probe both agonists and antagonist peptides for the
same target may be beneficial to design at the chemical synthesis phase71-72.
1.9 Designing Agonist Imaging Probes Through Structure Activity Relationships.
Within this thesis it was decided to generate growth hormone secretagogues
(GHSs) as imaging agents allowing for a rapid synthesis by either manual or automated
fluorenylmethyloxycarbonyl solid phase peptide synthesis (Fmoc-SPPS). Synthesising
small molecules in most cases requires lengthier synthetic procedures. Small molecules
also typically are designed to consist mostly of the pharmacophore in order to interact
with the receptor. Slight changes to a small molecule pharmacophore can drastically
reduce its binding towards a given target. Peptides tend to have a non-pharmacophore
portion thereby allowing for the attachment of a desired radionuclide to form the imaging
agent without interfering with receptor binding. Lastly there has been a large number of
previous studies that probed the interaction between GHS-R1a and growth hormone
releasing peptides (GHRPs), pseudo-peptides and peptidomimetic GHSs. This gives us a
great starting scaffold to do further SAR studies as well as to modify the peptides in the
appropriate way to generate imaging probes73-78.
Rationale of these agonists was based on Feighner et al.77 who utilized site
directed mutagenesis79 and molecular modelling to determine the key residues in GHSR1a that interacted with specific ligands (GHRP-6, MK-0677, and L-692585) (Figure
1.7) 77. The activation of GHS-R1a signalling by these various ligands was measured by
an aequorin bioluminescence assay detecting the changes in intracellular calcium ion
levels.
A homology model based on the helical impression of bacteriorhodopsin and a 2dimensional sequence alignment of repeated motifs across many GPCRs (neurotensin,
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somatostatin-2, angiotensin-2, beta-2-adrenergic, human/swine/rat GHS-Rs) was used to
determine the number of amino acids that are needed to allow for a successful ligand
interaction with GHS-R1a 77. Figure 1.12 below is the 366 amino acid GHS-R1a
discovered by homology modeling, with the indicated mutated residues in red.

Figure 1.12 - The GHS-R1a with mutated sites in red performed by Feighner et al36.
Adapted from 36
It was from here that are larger number of residues in the receptor were identified
as key for the binding and activation by a variety of synthetic ligands. For instance, E124
in transmembrane 3 (TM3) forms a salt bridge with the primary ammonium cation on the
N terminus of a peptide ligand or an amino group that is on a small molecule ligand77.
This interaction was confirmed by site directed mutation from E124 to Q124. Residue
M213 was crucial to the binding of L-692585 (ghrelin small molecule)80, and when
mutated to D213 binding and activity was lost. D99 (TM2) was also key as the functional
activity decreased by half when mutated to N99 (again with L-692585)77. Residue C116
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was also key for the binding, since all activity was lost when mutated to A116 (TM2)
(proven with various ligands listed in Figure 1.7). This Cys116 residue forms a disulfide
interaction with Cys198 that is crucial in the stabilization of the receptor in an active
conformation. Also, residues S123 and Q120 were shown to have a high importance in
the binding of ligands to GHS-R1a. This was confirmed by using [35S]-MK-067781 and
mutating S123 to A123 and Q120 to H120 in TM377.
Several follow up studies utilized computational methods to further investigate
the interaction of GHS-R1a and various ligands. In 2001 Huang et al.78 identified 6 key
pharmacophoric regions in GHS-R1a by using six peptide-based and 4 non-peptide-based
ligands. They first identified the low-energy conformers for each of the ligands and used
a mutated version of GHRP-6 as a negative control ([Val3]GHRP-6). The computer
program that was designed by Huang et al. (DistComp)82 was used to identify the 3dimensional pharmacophore and its functional groups that are required to activate GHSR1a. The key functional groups identified were: two aromatic rings, a proton acceptor, a
protonated amine and a small hydrophobic group. Once this pharmacophore region with
the key residues was identified it was further screened against a larger database of
compounds in order to find potential hit ligands. This resulted in the identification of a hit
ligand agonist benzothiazepin GH secretagogue (Figure 1.13) with an EC50 of 1 nM. This
was a conformation that the computational method developed by Huang et al. was a valid
way to identify hit ligands that target GHS-R1a78.

Figure 1.13 - Benzothiazepin identified to have 1 nM potency when targeting
GHS-R1a
The protonated C-terminal amine (previously identified by Feighner et al.) and
aromatic groups in benzothiazepin was the establishment in the necessary molecular
framework in designing peptide base agonist that targeted GHS-R1a. Hansen et al. also
confirmed through the design of ipamorelin (Figure 1.7) derivatives that there is a need
for C-terminal aromatic groups in order to maintain binding towards GHS-R1a 59.
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Pedretti et al. then conducted a fragment based computational study of GHS-R1a
in order to further study its interaction with various ligands. The 7TM GHS-R1a was
divided into 15 fragments and these fragments were modelled against rhodopsin. The
active core of the ghrelin peptide (Gly-Ser-Ser(n-octanoyl)-Phe-NH2 in Figure 1.11)
along with 35 literature peptidomimetic GHSs was docked against this fragmentationbased model for each of the 15 fragments. Additional sub-pockets in the binding domain
of GHS-R1a were identified. There was the identification of a polar sub-pocket bordered
by TM2 and TM3 and a non-polar/aromatic pocket surrounded by TM5 and TM6. Since
these binding pockets are too far apart for a single ligand to interact at both sites it was
determined that there is a cooperative effect between the various binding modes. The
receptor goes into an active state when GHSs bind to the aromatic sub-pocket by way of a
non-competitive mechanism through partial agonism79.
Martin-Pastor et al. and Jӧrg Groβauer et al. conducted a 1H-NMR study on the
interaction between the ghrelin ligand with/without the octanoyl chain and GHS-R1a.
This was an in vitro NMR study using both human embryonic kidney (HEK293) and
Chinese hamster ovary (CHO) cells stably transfected with GHS-R1a. 2-dimensional total
correlation spectroscopy (2D-TOCSY), chemical shift perturbations (CSP) and slow
conformational exchange (SCE) were used to better understand the interaction between
GHS-R1a and its natural ligand. There were a number of residues affected by the
interaction between the octanoylated version of human ghrelin and GHS-R1a, most
notably the octanoyl chain itself, indicating its importance for binding and activating the
receptor81-82.
More recently Hou et al. investigated the interaction between G7039 (agonists
developed by Genentech in Figure 1.7) and GHS-R1a by means of computational
studies; homology modelling, molecular docking, molecular dynamics simulations, and
binding free energy calculation. This investigation included altering the amino acid
structure of G7039 and its consequences on binding. Glu124 in TM3 was a key residue
identified in agonist binding and activation of GHS-R1a. One of the binding models
within this work indicated that pronated amine on the N-terminus of G7039 forms a salt
bridge with the negatively charged residue Glu124. Other interactions identified was a
cation- π interaction between the charged amine of G7039 and Phe279, a hydrophobic
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interaction between the Phe of G7039 and Phe286 and a π-π interaction between the
aromatic (D2Nal) residue of G7039 and the amide of Asn305. These interactions indicate
that the first 4 positions are highly vulnerable to change and altering them could lead to a
loss in binding. This was showed by the removal of these groups in Hou et al.83
The extensive literature that has been reported on various ligands and their
interaction with GHS-R1a sets the ground work to further optimizing these ghrelin
peptidomimetics in order to chemically convert them into useable imaging agents.
1.10 Radiolabelling Strategy
One final important step in designing an appropriate molecular probe is to
determine if the addition of radionuclide can be done either in a direct or indirect method,
as this can determine the success of the potential imaging agent for industrial production3.
A direct labeling approach is usually favored, as it requires fewer steps allowing for a
more efficient synthesis and a less radiochemical decay. This method is done when the
precursor chemical molecule is synthesized with a designated site for substitution,
elimination, or insertion of the radionuclide of interest (e.g. the chelation of a metal). This
also requires the radionuclide to be non-reactive with other sites on the molecule3. In
contrast, a prosthetic group labeling approach is when a precursor is synthesized that will
first be reacted to the radionuclide, and then can be coupled or reacted to the molecular
probe via a linker on the targeting entity. This method is required when the ligand may
have too many other reactive sites towards the radionuclide that was chosen. Prosthetic
group labelling requires more steps and can be less efficient. However, this approach is
used a lot of the time, as to design a molecular probe for direct labeling requires for the
reactivity of the molecule to be changed for efficient synthesis, and this could cause
changes in binding affinity for the target3. Both labelling approaches can be seen in
Figure 1.14 below. Within the scope of the thesis both a prosthetic group and direct
labelling will be used in order to design the lead imaging candidates.
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Figure 1.14 – Prosthetic group labelling versus direct labelling strategy in
radiochemistry. The orange circle is the leaving group (LG), and the red bar is the
linker
1.11 Development of Heterobivalent and Homobivalent Ligands Targeting the GHSR1a Homo-Oligomer
G-protein-coupled receptors (GPCRs) until very recently were thought of as
monomers that are expressed on the surface of both neuronal and non-neuronal cells.
However, GPCRs have been shown by many to exist as oligomers impacting both their
pharmacology and physiology84. However, GPCR oligomerization in terms of
neurotransmission is more accepted by the scientific community and therefore is more
well studied. This is because neurotransmitter receptors cannot be considered as a single
unit, but a multimolecular subunits of proteins that lie on the plasma membrane. This idea
began in the mid-1970s and was shown with the use of radioligand binding assays that
there was a negative cooperative interaction with the Beta-adrenergic receptor binding
sites84. Initially it was thought that the ligand was binding to two separate monomeric
entities; uncoupled or coupled G protein. Then in the 1980s this was further backed up
with the use of Western blotting and/or coimmunoprecipitation with the Beta-adrenergic
and muscarinic acetylcholine receptors in both transfected cells and tissues samples
isolated from the brain85. Techniques such as fluorescence and bioluminescence
resonance energy transfer (FRET and BRET) have become other accepted methods to
indicate oligomerization of GPCRs in cells. However, FRET and BRET are common
techniques to show receptor homo-oligomerization over hetero-oligomerization. When a
ligand interacts with a GPCR oligomer there can be the occurrence of two independent
binding sites, with different affinities for the ligand85. Franco et al devised a receptoroligomer model that allowed for the quantification of cooperativity and termed this the:
“oligomer cooperativity index”85. This allows for the measurement in the extent of
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binding from one orthosteric center to another in the GPCR oligomer complex. We then
can consider this as a measure of intermolecular cross-talk that occurs in a receptor
oligomer. We often see a biphasic binding curve when measuring the affinity of a ligand
towards a receptor oligomer85. A biphasic curve is due to conformational changes in one
receptor when the ligand binds altering the state of a neighbouring receptor, and this is
considered a cooperative mechanism in receptor oligomerization. Cooperativity can
either be negative or positive during oligomerization of GPCRs86. So far, many have
targeted GPCR hetero-oligomers with two separate ligands. This approach has a major
limitation when it comes to designing a novel drug for a receptor oligomer in terms of
drug dosing and formulation. Knowing that this is a possible mechanism in which a
ligand can bind and change the active state of a GPCR oligomer, one can develop novel
heterobivalent and homobivalent ligands that would modulate the signalling in a
differential fashion when compared to the monomeric receptor86-87. By selectively
connecting two ligands together by a given linker length one can create a signal ligand
that will have the same effect as the two ligands separately. The chemical nature of the
linker can also improve pharmacokinetic and pharmacodynamic properties of a chemical
probe, such as enhancing solubility, metabolic stability and enhanced affinity. There have
been many examples in the literature of successful attempts at designing bivalent-based
ligands88-90. Most recently Lensing and co-workers developed a bivalent ligand that
targeted the human melanocortin-4 receptor oligomer (hMC4R). This led to a biased
signalling stimulating cyclic adenosine monophosphate (cAMP, adenylyl cyclase
pathway) signalling, but minimal activation of b-arrestin signalling88.
GHS-R1a has potential therapeutic application towards a wide range of diseases
such as obesity, diabetes, cancer, etc90-94. GHS-R exists in two isoforms: GHS-R1a and
GHS-R1b. GHS-R1a is activated by its endogenous ligand, ghrelin, to induce growth
hormone release,88 while GHS-R1b is functionally inactive and has no binding affinity
for ghrelin95. Along with numerous other GPCRs, GHS-R1a has been shown to form a
homo-oligomer. In 2005, Holst et al. were the first to propose the homo-oligomerization
of GHS-R1a. In this study it was shown that, in the presence of the endogenous agonist
ghrelin, and co-administration of other agonists (GHRPs) acted as a neutral, positive, or
negative modulators of the GHS-R1a receptor in COS-7 cells transfected with GHS-
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R1a96. Further evidence of GHS-R1a homo-oligomerization was provided by Jiang et al.
using a HEK293 derived cell line co-transfected with GHS-R1a-green fluorescent protein
(GFP) and GHS-R1a-Renilla luciferase (rluc)97. The BRET (bioluminescence resonance
energy transfer) study showed a hyperbolic function of GHS-R1a-GFP/GHS-R1a-rluc
ratio, suggesting oligomerization rather than molecular crowding. Kern et al. observed a
FRET signal when CLIP-GHS-R1a and SNAP-GHS-R1a are overexpressed in HEK293
cell through time-resolved (Tr) FRET measurement, again suggesting the formation of
the GHS-R1a homo-oligomer98. Leung et al., also confirmed homo-oligomeric GHS-R1a
in HEK293 cell using BRET and co-immunoprecipitation99. A visual representation of
the GHS-R1a homo-oligomer docked with the novel homobivalent ligand developed in
Chapter 6 can be seen in Figure 1.15. In addition, evidence suggested that the GHS-R1a
receptor has the ability to not only oligomerize with itself but also with other GPCRs,
including GHS-R1b receptor,100 prostaglandin E2 receptor (EP3-1),101 prostacyclin
receptor (IP),101 thromboxane A2 receptor (TPα),101 Somatostatin receptor 5(SST5),102
dopamine receptors (D1 and D2),99,102 melanocortin 3 receptor (MC3),102-103 and serotonin
2C receptor (5-HT2C)102. The first of these interactions to be observed was with the D1and D2-like dopamine receptors as both of these receptors are coexpressed in a number of
sites (e.g. brain regions that are linked to food intake and reward behaviours). Kern et al.
in 2012 was able to demonstrate that when there is a lack of ghrelin circulation in the
brain, GHS-R1a will oligomerize with D2R leading to anorexigenic effects98. Another
example in which GHS-R1a oligomerizes with another GPCRs and changes the
downstream signalling is with MC3R. Rediger et al. demonstrated that in the arcuate
nuclease GHS-R1a is coexpressed in neurons with MC3R by the use of FRET. Typical
signalling by means of MC3R is the Gαs pathway causing an accumulation of cAMP104.
However, when oligomerization occurs with GHS-R1a cAMP accumulation increases by
2-fold, and GHS-R1a constitutive activity along with ghrelin induced activity cause a
decrease of intracellular calcium by 40%. And when the MC3R receptor is
downregulated, this leads to in an increase in GHS-R1a signalling explaining an increase
in fat mass within a MC3R-/- knockout model104. These are just a few of the examples in
which GHS-R1a can oligomerize with another receptor and change the downstream
signalling events leading to different physiological outcomes.

28
Rational design of a bivalent ligand is further discussed in section 6.2.1. Ligands
that are capable of targeting these receptor oligomers holds great promise as a new class
of therapeutics, but equally important, are a powerful chemical biology tool for
understanding the function, mechanism, and disease significance of GPCR oligomers, for
which there is limited knowledge to date.

Figure 1.15 - Visual representation of the GHS-R1a homo-oligomer docked with the
homobivalent ligand designed in Chapter 6. This is not the actual interface that
occurs between the GHS-R1a homo-oligomer
1.12 Tagging Molecular Probes with Fluorescent Moieties
Fluorescently tagged ligands can help us better understand the physiological and
pathological mechanisms of model cell systems. Cells by their inherent nature are
complex, and without the appropriate molecular probes it is difficult to interrogate the
complex cellular structures and gain a deeper insight into molecular interactions, enzyme
activity, and the many other cellular processes that are occurring every second. The
ability for using labelled peptides with platforms such as fluorescence energy transfer
(FRET), bioluminescence resonance energy transfer (BRET), flow cytometry, and
fluorescent microscopy (in vitro, in vivo, and ex vivo) allows us to probe the key cellular
processes involved in human physiology and disease105.
Fluorophores work by absorbing light in the ultraviolet or visible range and reemit part of their energy as radiation (fluorescence). A longer wavelength is seen within
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the emitted radiation then the excitation light and this is called the Stokes shift. The
emission wavelength depends on the wavelength of the excitation light106. Fluorescence
is highly controlled based on the chemical structure of the fluorophore and many of these
fluorophores are commercially available. For the purpose of this thesis a sulfo-cyanine5
dye is used and is commercially available as a pre-activated N-Hydroxysuccinimide
(NHS) ester in order to couple onto a primary amine of a Lys located on the C-terminal
portion of a ghrelin ligand in Chapter 2.
Conjugating a fluorophore to a peptide is similar to designing a radiolabelled
peptide probe. The location of the fluorophore addition to the biomolecule is carefully
considered as to not affect the binding properties of the peptide towards the target. The
decision to use a certain fluorophore depends on the experimental conditions for the
particular in vitro, in vivo, or ex vivo application. For example, fluorophores within the
visible range have an emission between 400 nm and 700 nm (e.g. 7 amino-4methylcoumarin (AMC), fluorescein isothiocyanate (FITC), and 5carboxytetramethylrhodamine (TAMRA)). These fluorophores are typically seen for uses
in cellular applications such as confocal microscopy experiments. However, in the case of
in vivo applications fluorophores in the emission range of 650 nm to 900 nm (nearinfrared – NIR) are required as they will produce less autofluorescence with body
components such as water and hemoglobin. There are a number of commercially
available dyes in the NIR range such as the Cyanine dyes, Alexa Fluor dyes, and IR dyes
that can be used in vivo. All of these commercially available dyes have been chemically
modified to allow for the conjugation to a target peptide in a variety of ways, including
click chemistry and amide bond formation107.
This is the method to design an imaging agent that is almost identical to the PET
probe (same targeting entity), however it differs by only its imaging modality, providing
a dual-purpose ligand towards the same target.
There are many past examples of using peptides conjugated to fluorophores in
both in vitro and in vivo applications. There has been a series of somatostatin derivatives
that have been conjugated to NIR dyes in order to perform in vivo imaging of mice
bearing cells that overexpress the somatostatin receptor-2 (SSTr-2). One of these
derivatives is the conjugation between octreotate and indotricarbocyanine (ITCC) NIR
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dye that was able to show high levels of fluorescence in the mouse tumours even after 24
hours post intravenous (IV) injection107-108.
Within our own group there has been a recent publication using a NIR inulin
optical probe for measuring the glomerular filtration rate (GFR). Inulin is a
polysaccharide that is considered the clinical gold standard for measuring GFR in order to
assess the filtering capacity of the kidney and renal function helping to indicate the
occurrence of chronic kidney disease (CKD). Inulin was conjugated to a Cyanine-7.5 dye
and used to measure the GFR in a pig model non-invasively109.
Within this current work (Chapter 2) I report the design of a ghrelin analogue
conjugated to a sulfo-cyanine-5 dye that has been shown thus far to image both tissue in
an in vitro and ex vivo scenario. However, since sulfo-cyanine-5 is a NIR dye with an
emission maximum at 669 nm, this probe can be used for optical imaging in an in vivo
scenario.
This imaging tool presented in Chapter 2 has the potential to be used in the clinic
as a marker for GHS-R1a (Figure 1.16). In addition, it could serve as a probe to screen
for ghrelin expression in a broad array of cancer cell lines and tumour tissues, as well as
for quantification using flow cytometry techniques.
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Figure 1.16 - Stabilized fluorescent ghrelin analogue developed in chapter 2
targeting and visualizing GHS-R1a in an in vitro scenario. DAPI stained blue
nucleus, Sulf-Cy5 tagged G(1-20) analogue in red. Cells are OVCAR8 stably
transfected with GHS-R1a
1.13 Stapling Peptides to Enhance Both Stability and Binding Towards a Target of
Interest
Ghrelin is a peptide that is mainly α-helical. This was determined by 2D NMR
indicating Pro-7 to Pro-21 being helical, and molecular dynamics simulations showing
the same helical region from Pro-7 to Gly-13110-111. The α-helicity of ghrelin is stabilized
upon binding to GHS-R1a112. The first five amino acids are essential in binding to GHSR1a, shown by the fact that ghrelin(1-5) still retains its affinity to GHS-R1a. Shorter eight
amino acid ghrelin derivatives have been developed for the purpose of molecular imaging
and were determined to have similar GHS-R1a affinity compared to ghrelin112-113.
Ghrelin is therefore an ideal candidate for modification in designing a molecular imaging
probe113-114.
The use of natural peptides in various in vitro and in vivo assays is difficult
because they tend to have lower stability, as well as a high cost of production (usually a
longer amino acid sequence)115. Shortening a natural peptide is a way to overcome this
particular problem. Stabilizing H-bonds seen within physiological conditions of natural
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peptides is drastically reduced when the peptide becomes truncated, as there is a loss in
alpha helical stabilizing amino acids. These additional physiological interactions also
facilitate complete binding towards a target of interest115-116, as confirmation is vital for
ligand recognition116. Many biological processes rely on a secondary helical
structure112,116. However, there is a high energy cost that is required to generate a
secondary structure limiting the stability of truncated natural peptides116.
A possible way to overcome this high energic barrier is by pre-folding, or stapling
peptides. The truncated peptides are then able to adopt a desired secondary structure to
increase both stability and biological activity112,116. When choosing location for
cyclization it is often by means of the positions at i and either i+4 or i+7 as these are
positioned on the same face of the helical secondary structure. The four common methods
for constraining a peptide to promote α-helix formation include a lactam bridge, a
hydrocarbon bridge, a metal-ion clip, or a hydrogen bond surrogate115-116. These
variations in cyclization can be visualized in Figure 1.17.

Figure 1.17 - 4 common methods of stapling. (A) Lactam bridge, (B) hydrocarbon
bridge, (C) metal ion clip, and (D) hydrogen bond surrogate (permission granted by
author)117
These various stapling strategies described above have successfully produced
cyclic peptides with improved target affinity. However, both the hydrocarbon and lactam
cyclization method show a greater level of in vivo stability115-118. The lactam bridge is a
more appropriate method of cyclization for use in a clinical setting due to its natural
amide bond composition119. This is because when this amide bond becomes cleaved it
reveals two natural amino acid side chains. There must be careful consideration for the
location of the staple as to not block the face of the helix that is important in binding
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towards the target of interest. As well as the amino acids altered to incorporate the staple
can also affect secondary structure and binding of the ligand towards the given target120.
‘Staple scanning’ is the preferred method for identifying a peptide sequence that will
exhibit optimal binding, secondary structure, and stability of the modified ligand121. A
staple scan is performed by modifying each residue not essential for binding and
measuring the peptide’s new affinity and secondary structure121. The staple is moved
along the peptide through the modification of the amino acids in the i and either i+4 or
i+7 positions in order to find its optimal location. This method will allow for the best
staple candidate to be identified and further tested. It has been shown that using a
glutamic acid residue in the i position and a lysine residue in the i+4 or i+7 position
provides peptides with maximum helicity and reversing the placement of these amino
acids decreases helicity122-125 (Figure 1.18). This alteration is thought because reversing
the order could change the dipole direction of the amide bonds with respect to the dipole
direction of the helix.

Figure 1.18 - Synthesis route to forming a lactam bridge with Glu in the i position
and Lys in the i + 4 position
Within Chapter 2 of this thesis a staple scan is reported for ghrelin(1-20)
analogues starting in position four and working the staple all the way to position 19, in
order to identify the optimal location for the staple based on alpha helicity and binding to
GHS-R1a (Figure 1.19). This optimization provided a cyclic ghrelin analogue with
greater binding affinity towards GHS-R1a as well as having improved stability.
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Figure 1.19 - Stabilizing ghrelin(1-20) analogues with a lactam bridge (i,i+4
or i,i+7) in order to improve the secondary alpha-helical structure and maintain
binding towards GHS-R1a
1.14 Scope of this Thesis
GHS-R1a is expressed in many human tissues (most notably the hypothalamus)
and causes an increase in appetite upon activation by its endogenous ligand; ghrelin.
GHS-R1a is differentially expressed in malignant compared to benign tumours (e.g.
prostate). Therefore, there is an interest in developing GHS-R1a-targeted peptides as
novel drugs to modulate signaling (e.g. cancer cachexia and obesity) and image receptor
(e.g. disease diagnosis and progression). The focus of this thesis is the development of
ghrelin analogues that act as agonists when targeting GHS-R1a.
The first of these analogues was the development of a stabilized ghrelin 1 to 20
analogue by means of a lactam bridge (Chapter 2). The lead analogue with a sulfocyanine-5 (Cy5) conjugated to the C-terminal lysine (cyclo-12, 16(HGSXFLSPEHQR[EQQRK]ESKK(Sulfo-Cy5)-NH2)) has an [θ]222/[θ]208 ratio of 0.84,
and an IC50 of 1.0 nM. This probe was highly successful in imaging GHS-R1a by
fluorescent microscopy in both cell lines and tissue samples from different disease states
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(cancer, cardiovascular disease, and stroke) associated with the overexpression of GHSR1a. This probe has the potential to image the receptor in an in vivo scenario due to the
high emission maximum of sulfo-Cy5.
Chapters 3 to 6 focussed on the development of ghrelin peptidomimetic analogues
with applications driven to both therapy and imaging. The initial compound G7039, a
peptidomimetic ghrelin agonist (IC50 5.2 nM/EC50 0.18 nM) underwent structure-activity
relationship (SAR) studies to generate ligands and positron emission tomography (PET)
agents to study/image the GHS-R1a. The first generation peptidomimetic (Chapter 3) [1Nal4,Lys5 (4-fluorobenzoyl-4-FB)]G7039 (IC50 69 nM/EC50 1.1 nM) was radiolabelled
with 18F in a decay-corrected radiochemical yield of 48%, radio purity of ≥ 99%, and
molar activity of ≥ 34 GBq/μmol. Despite its success as a PET imaging agent, its
solubility (cLogP = 8.27) and binding affinity (IC50 = 69 nM) needed improvement.
The second generation peptidomimetic (Chapter 4) [Tyr4,Lys5(2-fluoropropionyl
(2-FP)]G7039 (IC50 0.28 nM/EC50 0.12 nM) had improved binding (IC50 = 0.28 nM) and
lipophilicity (cLogP = 4.36). Labeling of this ligand was low yielding, however two
peptides from this project were identified as partial agonists.
The third generation (Chapter 5) required a modified prosthetic group (2-FP to
ammonium methyltrifluoroborate-AMBF3) in order to radiolabel in higher yields,
resulting in [Tyr4,Lys5(AMBF3)]G7039 (IC50 0.85 nM). This compound was
radiolabelled in a single step, with a decay-corrected radiochemical yield of 28%,
radiopurity of ≥ 99%, and molar activity ≥ 15 GBq/μmol. Currently this lead compound
is ready to be evaluated in an in vivo scenario.
Finally, the fourth generation (Chapter 6), a homobivalent G7039 ligand (IC50high
0.43 nM:IC50low 0.42 pM /EC50 1.8-2.1 nM) was found to bind to the GHS-R1a homooligomer and was designed to study GHS-R1a homo/hetero-oligomerization. This
homobivalent ligand when targeting the GHS-R1a is able to change the downstream
signalling compared to the natural signalling mechanisms seen when activating the
monomeric version of GHS-R1a. Four generations of unique peptidomimetics eliciting
differences in receptor binding and activation have been synthesized with potential
applications towards imaging and therapy (Figure 1.20).
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Overall several ghrelin analogues have been developed in this thesis that have
applications both driven towards imaging and therapy.

Figure 1.20 - The various chemical tools developed within this thesis that all have a
heavy appetite for GHS-R1a
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Chapter 21
Stapled Ghrelin Peptides as Fluorescent Imaging Probes
2.1 Introduction
Ghrelin was first discovered in 1999 by Kojima et al., when it was identified to be
the endogenous ligand of the growth hormone secretagogue receptor type 1a (GHSR1a)1,2. It was originally reported that GHS-R1a was found within the pituitary and
hypothalamus2. GHS-R1a is a seven trans-membrane α-helical G-protein coupled
receptor with an extracellular binding domain, and its activation has been shown to
increase cellular proliferation in prostate cancer through the ERK1/2 MAPK pathway3–6.
The overexpression of GHS-R1a increases the motile phenotype in astrocytomas, in
which increased GHS-R1a expression is correlated with a higher tumour grade 7.
Overexpression of GHS-R1a has more recently been demonstrated in some ovarian
epithelial carcinomas, a disease with poor prognosis due to the late stages in which it is
usually diagnosed8,9.
Human ghrelin is a 28-amino acid peptide that is derived from a 117- amino acid
sequence (preproghrelin) through post-translational modifications, terminating with the
octanoylation of Ser-3 by ghrelin O-acyl transferase (GOAT) to produce the active
form3,10. This is the only known instance of a peptide being post-translationally modified
with a fatty acid, and it is required for its binding to and activating GHS-R1a1,11,12.
Ghrelin is a peptide that is mainly α-helical, with 2D NMR studies showing Pro-7 to Pro21 being helical, and molecular dynamics simulations showing that there is a helical
region from Pro-7 to Gly-1313,14. The α-helicity of ghrelin is stabilized by its natural
environment in addition to its binding to GHS-R1a 15. The first five amino acids have
been shown to be key in binding to GHS-R1a, as ghrelin(1-5) still retains its affinity to
the receptor16. Recently, ghrelin derivatives have been developed for the purpose of
molecular imaging and were determined to have similar GHS-R1a affinity as that of the
endogenous ligand, even when truncated to eight amino acids length16,17. This makes it
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an ideal candidate for modification for the purpose of imaging GHS-R1a using
fluorescence microscopy18,19.
Using natural peptides within in vitro/in vivo assays is challenging due to the
typically low stability of a linear peptide, as well as a high cost of production20. To
increase the stability of ghrelin and attempt to decrease production costs, the amino acid
sequence can be shortened. However, truncated peptides are unlikely to retain their
secondary structure in physiological conditions due to the decrease in stabilizing
hydrogen bonding from the backbone. These interactions also facilitate complete
binding21,22, as conformation is vital for ligand recognition15. Helical structures play an
important role in many biological processes15,22; however, the energy required to generate
this conformation is very high, which limits the structural stability of truncated
peptides23.
Pre-folding, or stapling the peptide assists in overcoming this energy barrier. This
enables the truncated peptides to adopt the desired secondary structure, potentially
increasing its biological activity and reducing susceptibility to hydrolysis15,25. Cyclization
typically occurs at positions i and either i+4 or i+7 as they are positioned on the same
face of a helix 22,24. There are four commonly used methods of constraining a peptide and
promoting α-helix formation: a lactam bridge, a hydrocarbon bridge, a metal-ion clip, or a
hydrogen bond surrogate20,22.
All of these stapling strategies have successfully produced cyclic peptides with
increased target affinity. Peptides constrained with hydrocarbon and lactam bridges
typically having greater stability in vivo21,22. The lactam bridge is predicted to be more
appropriate for use in therapeutics due to its natural amide bond composition25. The
location of a staple is an important consideration in constrained peptides, as improper
choice may block one face of the peptide 23. ‘Staple scanning’ is the preferred method for
identifying a peptide sequence that will exhibit optimal agonist properties21. This is done
by manipulating each residue not essential for binding, and measuring the peptide’s
affinity and secondary structure21. This method will allow for the best staple candidate to
be identified and further tested. The use of a glutamic acid residue in the i position and a
lysine residue in the i+4 or i+7 position appear to give peptides maximum helicity, as
reversing the placement of these amino acids results in a decrease in helicity26.
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The aim of this project was to create an improved fluorescently-tagged ghrelinpeptide as a novel GHS-R1a detection tool, while gaining a better understanding of the
secondary structure of ghrelin as the natural ligand for GHS-R1a. Only the first 20 amino
acids of ghrelin were used in this study, as these amino acids demonstrated α-helical
character based on 2D NMR studies13,14, while the 8 amino acids at the C-terminus of
ghrelin are predicted to be a random coil. In an attempt to recover α-helicity in the
truncated peptide, lactam bridges were created in the i, i+4 and the i, i+7 positions with a
staple scan utilizing amino acids 4 to 19 of ghrelin(1-20) being performed. Each peptide
in this library was analyzed by circular dichroism (CD) spectroscopy and competitive
receptor binding assay in order to determine α-helical character and binding affinity to
GHS-R1a, respectively.
2.2 Results and Discussion
GHS-R1a has been shown to have increased expression in 32% of patient samples
from ovarian cancer tissue27,28. We propose that an improved ghrelin imaging probe, for
fluorescence imaging of ovarian cancer cells or tissue samples through the use of chemistaining or confocal microscopy, can be developed through the creation of stapled ghrelin
analogues. Previous studies have shown that truncated fluorescently labelled ghrelin
analogs, where the fluorescent dye is attached through a Lys19 ε-amine of a modified
ghrelin(1-19), provides a fluorescent probe with comparable GHS-R1a affinity to that of
natural ghrelin(1-28) and was demonstrated to bind to GHS-R1a in cardiac tissues18,19.
This imaging probe was also used to distinguish between prostate cancer and benign
hyperplasia in ex vivo prostate tissue29 and for in vivo biodistribution analysis30. There is
also a report indicating that a DOTA chelator attached to Lys19 can be used to form a
gallium-68 radiolabelled ghrelin analogue for PET imaging31. These previous analogues
have reduced binding affinity towards GHS-R1a.
To establish a baseline and enable measurement of the effect synthetic staples
have on α-helicity and binding to GHS-R1a, the natural ghrelin(1-20) sequence was
synthesized by standard Fmoc solid-phase peptide synthesis (SPPS). In order to
incorporate the unnatural n-octanyl side chain at position three, diaminopropionic acid
was used. This allows for the coupling of octanoic acid via an amide linkage, which
offers increased stability and ease of synthesis over the natural ester linkage (Figure 2.1).
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Figure 2.1 - Depiction of ghrelin(1-20) indicating the region that is predicted to be
coiled or part of an a-helix. X indicates the unnatural amino acid, diaminopropionic
acid, which was used in order to attach the n-octanyl side chain at the third position.
The dashed line shows the region of the sequence in which i, i+4 or i, i+7 staples
were systematically placed
The lactam bridge in the ghrelin(1-20) derivatives was formed utilizing glutamic
acid in position i and lysine in position i+4 or i+7. To synthesize the stapled peptides, the
linear peptide was first synthesized by SPPS, incorporating allylester-protected glutamic
acid and alloxycarbonyl-protected lysine residues in the i and i+4 or i+7 positions
respectively. These protecting groups were used because they can be selectively
deprotected using a palladium (0) catalyst under basic conditions, allowing for lactam
bridge formation without removing any other protecting groups or cleaving the peptide
from the resin. After completing global deprotection and cleaving the peptide from the
resin, the peptides were purified and characterized by LC-MS. Both i, i+4 (Table 2.1)
and i, i+7 (Table 2.2) staple libraries were synthesized to observe any staple-related
differences in helicity and binding when compared to the linear sequence (1).
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Table 2.1 - Sequences of ghrelin(1-20) containing (i, i+4) staples. Mean residue
ellipticity at 222 nm ([θ]222) and ratios of mean residue ellipticities at 222 and 208
nm ([θ]222/[θ]208) at 20°C. Competitive binding affinity data (IC50) was determined
using HEK293 cells expressing GHS-R1a and [125I]ghrelin
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Table 2.2 - Sequences of ghrelin(1-20) containing (i, i+7) staples. Mean residue
ellipticity at 222 nm ([θ]222) and ratios of mean residue ellipticities at 222 and 208
nm ([θ]222/[θ]208) at 20°C are included to demonstrate helicity. Competitive binding
affinity data (IC50) was determined using HEK293 cells expressing GHS-R1a and
[125I]ghrelin

To determine the degree of α-helicity, all compounds were analyzed by CD
spectroscopy in either deionized water or 40% TFE, which is used to stabilize the α-helix
to observe the maximum possible helicity for each peptide32. To analyze the degree of ahelicity induced by these staples, the mean residue ellipticity at 222 nm ([θ]222) and the
ratio of the mean residue ellipticities at 222 and 208 nm ([θ]222/[θ]208) were utilized. The
unstapled peptide (1) has the CD spectra characteristic of a random coil, with a maximum
at 220 nm and a minimum at 190 nm. This was expected due to the lack of stabilizing
factors. When the i, i+4 staples are introduced, the α-helicity increases for all sequences,
with greater helicity (represented by a smaller [θ]222 value and a [θ]222/[θ]208 ratio nearing
1.00) observed in peptides with the staple introduced near the C-terminus. Compounds 7,
9, and 10 exhibited the greatest helicity in both deionized water and 40% TFE. The
observed differences in helicity could be due to differences in amino acid sequence. The
region in between the glutamic acid and the lysine in compounds 9 and 10 is rich in
glutamine, a helix-stabilizing residue, which may decrease the energy barrier for helix
formation33.
The increase in helicity induced by the i, i+7 staples is not as great relative to the
increase generated by the i, i+4 staples. This could be due to the increased distance
between the residues that generate the staple, which could be increasing the strain on the
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cyclic peptide and discouraging helix formation. There is currently little agreement in the
literature about the most effective ring size of the staple, as the effectiveness of stapling is
very case dependent33; it is possible that in this case, the ring size of the i+7 staple is too
great. Regardless, compounds 18, 19 and 22 all show relatively large increases in helicity
in both water and 40% TFE. Notably, compound 16 does not exhibit any appreciable
increase in helicity; the proline residue adjacent to the glutamic acid could cause this.
Proline is a helix destabilizing residue, as it causes more strain within the backbone, and
therefore could have countered the helix-promoting effects of the staple33.
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Figure 2.2 - CD spectra of linear unstapled sequence of ghrelin (1-20) (1) and the (i,
i+4) (10) and (i, i+7) (18) peptides that showed the greatest increase in helicity
The peptides were tested in 25% human serum, to determine if the cyclization
provides improved stability to enzymatic hydrolysis. The linear sequence (1) saw a 40%
degradation of the peptide within the first four hours, while both 10 and 18 were stable
for 24 hours. This indicates that the presence of the staple has improved the stability of
this truncated sequence, which plausibly is due to the increase in helicity.
The unstapled [Dpr3-octanoyl]ghrelin(1-20) (1) peptide was used as a reference in
order to compare how well the introduced staples improved the binding affinity of the
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truncated sequence. To test the affinity of these peptides towards GHS-R1a, a
competitive binding assay was performed with both unstapled and stapled peptides, with
[125I] human ghrelin as the competitor. The IC50 for the i, i+4 and i, i+7 staples can be
seen in Table 2.1 and Table 2.2, respectively. The greatest binding affinity is observed
in peptides with staples close to the C-terminus. In general, binding affinity is lower than
the linear peptide when the staple is within the first 7 amino acids, and greater when in
the 8th position or further. These results correlate to those of the CD spectra, as the
binding improves with increased α-helicity. This relates to earlier findings that have
noted that the first 5-8 amino acids are critical for receptor binding17. Therefore,
modifying these positions to incorporate a lactam bridge would interfere with receptor
recognition.
As with the helicity data, the binding affinities of the i, i+7 staples were lower
than that of the i, i+4 staples and the unstapled ghrelin(1-20) (1), with the exception of 18
and 20. This could be due to the decrease in helicity relative to the i, i+4 staples; it is also
possible that the staple could be blocking the binding surface or forcing the peptide into a
conformation that is incompatible with the receptor binding site.
Based on the helicity data and the IC50 values, one compound from the i, i+4 (10)
and i, i+7 (18) staple libraries was chosen (Table 2.3). These compounds exhibited the
optimal combination of α-helicity and receptor binding.
Table 2.3 - Summary of IC50 (nM) and [θ]222/[θ]208 values (in deionized water) for
the best compounds from the i, i+4 and i, i+7 staple libraries. The values of the
unstapled sequence are included for reference

To identify the effect of staple orientation on the binding of the peptides to GHSR1a, a helical wheel projection was used. This will model the spatial location of the i, i+4
and i, i+7 staples in peptides 10 and 18, and will facilitate comparison by showing the
positioning of amino acid residues, assuming that the ghrelin(8-20) region forms a perfect
helix (Figure 2.3). While it is likely that this region is not perfectly helical, this is the
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portion of natural ghrelin that is predicted to be helical13,14. Both the i, i+4 and i, i+7
staples fall on the same face of the helix, indicating that the positioning of the staple may
be imperative for binding.

Figure 2.3 - Helical wheel projection of ghrelin(8-20). Indicated on the image are the
locations of the staple in compound 10 (i ,i+4) and 18 (i, i+7). This projection
assumes that ghrelin(8-20) forms a perfect helix
2.2.1 Modifying the best cyclic peptides for use in imaging GHS-R1a using confocal
microscopy
The lead peptides identified from the staple scan (10 and 18) were labelled with a
Sulfo-Cyanine 5 dye (Cy5) by forming an amide bond with the side chain of Lys20
(Table 2.4). This allowed for the dye to be as removed as possible from the binding areas
of the peptide, as well as allowing for facile attachment of the dye. Sulfo-Cy5 was chosen
due to its favourable properties such as its high solubility in water and high extinction
coefficient (271000 M-1 cm-1 at 646 nm).
Table 2.4 - Sequences of linear, (i, i+4), and (i, i+7) stapled ghrelin(1-20) peptides
with a sulfo-cyanine5 dye attached to Lys19. Mean residue ellipticity at 222 nm
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([θ]222) and ratios of mean residue ellipticities at 222 and 208 nm ([θ]222/[θ]208) at
20°C are included to demonstrate helicity. Binding affinity data (IC50) is also
included

These labelled peptides were analyzed to determine whether the Cy5 dye had an
effect on secondary structure and ability to bind GHS-R1a. Interestingly, the α-helicity of
the linear peptide with Cy5 (23) was greater than that of 1. This was unexpected, as the
addition of Cy5 to the lead i, i+4 and i, i+7 sequences (24 and 25, respectively), did not
elicit the same increase in helicity (Figure 2.4).
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Figure 2.4 - CD spectra of linear unstapled ghrelin(1-20) (1), the lead (i, i+4) stapled
sequence (10), and the lead (i, i+7) stapled sequence (18) compared to their
respective sequences containing the Sulfo-Cy5 dye (23-25)
However, this increase in helicity of the Cy5-labelled linear peptide did not
correlate with a significant change in binding to GHS-R1a. All labelled sequences had
similar, or slightly improved, binding to GHS-R1a compared to the unlabelled sequences.
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Considering the improved stability data for 10 and 18, this suggests that these probes
have both improved GHS-R1a affinity and stability as compared to linear dye-ghrelin
entities.
These compounds were then tested in a group of selected ovarian cancer cell
lines. These cell lines were previously assessed for their relative GHS-R1a expression
level by confocal microscopy using established linear dye-ghrelin probes (Figure 2.S1).
Two cell lines (HEYA8 and OvCar3) express detectable endogenous GHS-R1a, while
one cell line (OvCar8) had nearly undetectable expression. Thus, OvCar8 cells were
stably transfected to express GFP-tagged GHS-R1a to generate a high expression line.
The OvCar8-GHS-R1a cell line also served as a positive control to verify that these
peptides were specifically binding to GHS-R1a and no other targets at the cell surface.
Compounds 23-25 were incubated with the cells in order to identify if the binding assay
results positively correlated with the ability of the peptides to bind to GHS-R1a in situ
(Figure 2.5).

Figure 2.5 - Confocal microscopy of compounds 23-25 incubated with various
ovarian cancer cell lines expressing GHS-R1a. One cell line (OvCar8) does not
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express GHS-R1a, one cell line (OvCar8-GHS-R1a+/+) was stably transfected with
GHS-R1a, and two cell lines (HEYA8 and OvCar3) have naturally high expression
of GHS-R1a. Cy5 signal can be seen in red and DAPI can be seen in blue
The i, i+4 sequence (24) exhibited increased binding to GHS-R1a in vitro
compared to the linear sequence (23) and the i, i+7 sequence (25). This was expected, as
23 and 25 have a lower IC50 value than 24. This difference is observed with the
endogenous GHS-R1a expression in HEYA8 and OvCar3 cells, but most evident within
the OvCar8 cells-GHS-R1a overexpressing cell line when compared with parental
OvCar8 cells. Also compounds 23, 24, and 25 were co-incubated with a 10x
concentration of compound 1 in each of the cell lines presented in Figure 5. This blocking
study confirmed specificity towards GHS-R1a (Figure 2.S2 and 2.S3).

2.3 Conclusions
A staple scan of ghrelin(1-20) utilizing both i, i+4 and i, i+7 lactam bridge staples
was performed and two peptides (10 and 18) were identified with superior qualities, in
terms of increased helical content and greater binding affinity to GHS-R1a compared to
the linear sequence. Modification of the lead sequences and the linear sequence with a
Sulfo-Cy5 dye was then done in order to identify a better tool for fluorescence imaging of
GHS-R1a. The dye-labelled version of the i, i+4 stapled peptide (24) had greatly
increased affinity for GHS-R1a with similar helical content. Compound 24 was shown to
bind to GHS-R1a in vitro when expressed by ovarian cancer cell lines that are stablytransfected with GHS-R1a, as well as cells with elevated endogenous expression. This
potentially allows 24 to act as a specific and sensitive imaging tool for the identification
and quantification of GHS-R1a among ovarian cancer cell lines, and potentially tumours.
We propose that compound 24 could be further tested as an improved stain to aid in
differentiating between malignant and benign tissue. This imaging tool therefore has the
potential to be used in the clinic as a marker for GHS-R1a, a biomarker of aggressive
malignancy within ovarian, prostate, and other cancer tissues29. In addition, compound 24
could serve as a probe to screen for GHS-R1a expression in a broad array of cancer cell
lines and tumour tissues, as well as quantification using flow cytometry techniques.
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2.5 Materials and Methods
2.5.1 General Information
All reagents were obtained from the commercial suppliers and used without
further purification. Fmoc-protected amino acids, HCTU, HATU, and Rink amide
MBHA resin (4-(2’,4’-dimethoxyphenyl-(9-fluorenylmethoxycarbonyl)-aminomethyl)phenoxy-acetamidonorleucyl-4-methyl benzhydrylamine resin) were obtained from
ChemImpex. Tetrakis(triphenylphosphine)palladium(0), and phenylsilane were obtained
from Sigma-Aldrich. All solvents were obtained from Fischer Thermo-Scientific. SulfoCyanine-5 NHS Ester was obtained from Lumiprobe.
2.5.2 Solid-Phase Peptide Synthesis
Fmoc-based solid-phase synthesis was carried out manually and automatically
using a Biotage® Syro Wave™ automated peptide synthesizer. Synthesis was done on a
0.1 mmol scale with 0.52 mmol/g Fmoc-Rink amide MBHA resin and a 3-fold excess of
the protected amino acids. The resin was allowed to swell in DCM (2.0 mL, 15 min) and
then solvent was removed. The resin was then rinsed with DMF (1.0 mL, 1 min); after
removal of the solvent, Fmoc deprotection was performed by adding a solution of 20%
piperidine/DMF (1.5 mL) to the resin and vortexing for 5 minutes. The resin was then
washed three times with DMF (2.0 mL, vortex 30 sec) and the resin was vortexed for 15
min with 20% piperidine/DMF (1.5 mL). The resin was then washed with DMF six times
to remove any unreacted products (2.0 mL, vortex 30 sec). A Kaiser test was performed
after the Fmoc removal to verify the presence of a free primary amino group. The desired
Fmoc-protected amino acid (0.3 mmol) and the coupling reagent HCTU (0.3 mmol) was
dissolved in DMF (1.5 mL) and added to the resin. The mixture was vortexed for 30
seconds and then DIPEA (0.6 mmol) was added to the mixture and was vortexed for 1
hour. This deprotection/amino acid coupling cycle was repeated until the desired amino
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acid sequence was obtained. After the final amino acid was coupled, the resin was
washed 3 times with DMF (2.0 mL, vortex 30 sec) and then 3 times with DCM (2.0 mL,
vortex 30 sec), dried under vacuum, and stored in the freezer at -20°C. The removal of
the final Fmoc protecting group on the N-terminus was achieved using the previously
described procedure.
To determine if the correct peptide has been synthesized, a microcleave was
performed before full cleavage from the resin. A small amount of resin (<5 mg) was
added to a small peptide vessel and a solution of 95% trifluoroacetic acid/2.5%
triisopropylsilane/2.5% water (500 μL) was added. The mixture was vortexed for 3-4
hours, and the resulting liquid was precipitated with cold tert-butyl methyl ether (TBME)
(2 mL). The precipitate was centrifuged (3000 xg for 10 min), and the mother liquor was
decanted. The pellet was dissolved in water (2 mL), frozen, and lyophilized. If the correct
peptide was synthesized as determined by analytical HPLC/MS, then a full cleave was
performed. The procedure for full cleaves identical to the microcleave procedure: a
solution of 95% trifluoroacetic acid/2.5% triisopropylsilane/2.5% water (3 mL) was
added to the resin and vortexed for 4-6 hours. The solution was drained, precipitated in
TBMe (20 mL) and centrifuged (3000 xg for 10 min). The mother liquor was decanted,
and the pellet was dissolved in water (20 mL) and lyophilized to obtain the crude fully
deprotected peptide.
2.5.3 Kaiser Test
To qualitatively determine if there is free amine present (i.e. after a Fmocdeprotection, amino acid coupling, or alloc/allylester deprotection), a Kaiser test was
performed. A small amount of resin (<5 mg) was placed in a small test tube. To the test
tube, solutions of Phenol:EtOH (8:2 v/v), 0.001M KCN:pyridine (2:98 v/v) and ninhydrin
in EtOH (5% w/v) were added. The test tube was heated to 70°C and the presence of a
free amine was indicated by the resin beads turning blue. The lack of free amine was
indicated by the presence of clear/yellow resin beads.
2.5.4 Deprotection of Allyloxycarbonyl (Alloc) and Allylester (OAll) Protecting Groups
Selective deprotection of the allyloxycarbonyl and the allylester protecting groups
was accomplished by adding DCM (4.5 mL) to the resin-bound peptide and shaking
gently for 10 minutes. After addition of phenylsilane (24 equiv.), the peptide vessel was
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flushed with nitrogen and allowed to react for 5 minutes. Then,
tetrakis(triphenylphosphine) palladium (0) (0.1 equiv.) was added to the mixture and the
peptide vessel was again flushed with nitrogen, and the reaction was allowed to proceed
for 10 minutes. Next, the peptide-resin was washed with DCM four times (1.5 mL),
followed by a series of washings with 1.5 mL of DCM, DMF, MeOH, DMF, and DCM
(30 sec each).
2.5.5 Lactam Bridge Formation
After the resin-bound peptide was selectively alloc- and allylester-deprotected,
HATU (3 equiv.) was dissolved in DMF (1.5 mL) and allowed to vortex for 30 seconds.
DIPEA (6 equiv.) was then added to the peptide vessel in order to form lactam bridge and
the reaction was vortexed for 2 hours. Final washings with DMF and DCM (2.0 mL, 3 x
30 sec each) were performed to remove any residual reactants.
2.5.6 4-Methyltrityl (Mtt) Deprotection
Selective deprotection of the 4-methyltrityl (Mtt) protecting group was
accomplished by swelling the resin in DCM (3 mL) for 15 minutes. The DCM was then
drained and a cocktail of 95% DCM, 4% TIPS, and 1% TFA was added to the resin (2
mL). The resin was then vortexed for 2 minutes followed by a thorough rinse with DCM.
This addition of the cocktail and vortexing was done 10 times, or until the yellow colour
was no longer seen.
2.5.7 Coupling of Octanoic Acid
After the Mtt protecting group has been removed, octanoic acid was coupled to
the modified serine residue in the third position. This was accomplished by adding
octanoic acid (0.3 mmol) and the coupling reagent HATU (0.3 mmol) dissolved in DMF
(1.5 mL) to the resin. This mixture was vortexed for 2 hours, and the resin was then
washed 3 times with DMF (2.0 mL, vortex 30 sec) and 3 times with DCM (2.0 mL,
vortex 30 sec), then dried under vacuum.
2.5.8 Purification of RP-HPLC/ESI-MS
Peptides were analyzed using a reverse-phase analytical HPLC column (Agilent
Zorbax SB-C8 column 4.6 x 150 mm, 3.5 μm). This system was equipped with a Waters
600 136 controller, Waters Prep degasser, and Waters Masslynx software (version 4.1).
Employed mobile phases were 0.1% TFA in deionized water (eluent A) and 0.1% TFA in
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acetonitrile (eluent B). The flow rate was set at 1.5 mLmin-1 over 15 minutes. The
column eluate was monitored using a Waters 2998 Photodiode array detector set at 220
nm, 254 nm and 400 nm. Peptides were purified using a reverse-phase preparative HPLC
column (Agilent Zorbax SB-C18 column 21.2 x 150 mm, 5 μm) on the same system
mentioned above. The detection method and eluents were the same was mentioned above
for the analytical system and the flow rate was set at 20 mLmin-1. The collected fractions
were then lyophilized to a solid and analyzed by ESI-MS. Purity of final products was
determined by analytical RP-HPLC (200-800 nm).
2.5.9 Circular Dichroism (CD) Spectroscopy
CD spectra were obtained on a Jasco J-810 spectropolarimeter and recorded in the
range of 180-260 nm. Peptide solutions were prepared with a 0.1 M phosphate buffer
solution to a concentration of 0.5 mM. The measurements were performed in quartz
cuvettes with a path length of 1 mm and a scanning speed of 10-50 nm/min. Five
individual data points were averaged by the instrument to obtain reported CD spectra.
The measurements were carried out at 20ᴼC. A blank solution of 0.1 M phosphate buffer
solution was run before every measurement in order to correct for any UV interference
from the buffer.
2.5.10 Receptor Ligand Binding Assay
Competitive ligand binding assays were performed in triplicate using
HEK293/GHS-R1a cells and [125I]Ghrelin as the competitive ligand, as previously
described17–19. Receptor binding affinities were calculated as IC50 values as previously
described17–19. In brief HEK293T cells were transiently transfected with GHS-R1a for 48
hours by means of calcium phosphate. Post transfection cells were harvested by
membrane fragmentation at 50, 000 g and stored at -80oC at 2 million cells per vial. The
day of the experiment cells were thawed, and a complete vial was used per binding assay.
2.5.11 Transfection of OvCar8 with GFP-GHS-R1a
The OvCar8 human ovarian cancer cell line (ATCC) was maintained in RPMI
medium (Wisent) supplemented with 10% fetal bovine serum (FBS; Wisent). Cells were
seeded into 6-well tissue culture plates (Sarstedt) at a density of 1.5 x 105 cells per 35mm well. The following day, the culture media were removed and replaced with
OptiMEM (Invitrogen) containing 10% FBS, and cells were transfected with 0.5 µg
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pCMV6-GHS-R1a-EGFP plasmid using LipofectAMINE 3000 (Invitrogen) as per
manufacturer’s instructions. Forty-eight hours later, cells were trypsinized and expanded
into 4 separate 100-mm plates containing RPMI/10% FBS media. Stable clones were
selected in 400 µg/ml G418 (Wisent) and maintained (in the same concentration of G418
for 7 to 10 days). GFP-positive colonies were visualized by indirect fluorescence using a
Leica DMI 4000B inverted microscope, isolated using cloning rings, and transferred to
24-well plates containing RPMI/10% FBS.
2.5.12 Confocal Microscopy
OvCar3, HEYA8, OvCar8 and OvCar8 cells stably transfected with GHS-R1a
(OvCar-GHS-R1a) were trypsinized and seeded onto coverslips at a density of 75000
cells/well. The following day, media were removed and replaced with serum-free RPMI
containing 0.1 µM of compounds 23, 24, and 25 and incubated at 37°C for 1 hour. Cells
were then washed three times with phosphate buffered saline (PBS), fixed with 4%
paraformaldehyde in PBS and mounted onto slides containing Pro-Long Gold Antifade
mounting medium with DAPI. Images were acquired using an Olympus FluoView FV
1000 confocal microscope.
Blocking experiments were conducted using OvCar8-GHS-R1a cells. Cells were
suspended in serum-free RPMI and incubated with 0.1 µM of compounds 23, 24, and 25,
together with a 10-fold excess of compound 1, at 37 °C for one hour. Cells were washed 3
times with PBS, reseeded onto coverslips, cultured in RPMI and allowed to adhere. Cells
were washed with PBS, fixed with 4% formaldehyde in PBS and mounted onto slides.
Images were then acquired as described above.
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Chapter 2 Supplementary Information
Peptide Characterization Tables
Supplementary Table 2.1 - Characterization of synthesized unstapled truncated
Ghrelin(1-20) (Where X is modified serine residue with an octanyl side chain)
Compoun
d

Sequence

1

GSXFLSPEHQRVQQR
KESKK-NH2

[M+3H]3+
Expected
m/z
620.8769

Observed m/z
620.8730

Purit
y
(%)*
>99

Yiel
d
(%)
15

Supplementary Table 2.2 - Characterization of synthesized i, i+4 lactam stapled
truncated Ghrelin 1-20 (Where X is modified serine residue with an octanyl side
chain)
Compoun
d
2
3
4
5
6
7
8
9

[M+3H]3+
Expecte Observe
d m/z
d m/z
H-(cyclo-4, 8)815.170 815.8046
GSX[ELSPK]HQRVQQRKESKK 6
-NH2
H-(cyclo-5, 9)824.826 824.3851
GSXF[ESPEK]QRVQQRKESKK 6
-NH2
H-(cyclo-6, 10)836.511 836.0917
GSXFL[EPEHK]RVQQRKESKK 4
-NH2
H-(cyclo-7, 11)823.823 823.4539
GSXFLS[EEHQK]VQQRKESKK 3
-NH2
H-(cyclo-8, 12)831.178 831.7017
GSXFLSP[EHQRK]QQRKESKK 9
-NH2
H-(cyclo-9, 13)819.833 819.4630
GSXFLSPE[EQRVK]QRKESKK- 3
NH2
H-(cyclo-10, 14)822.833 822.3869
GSXFLSPEH[ERVQK]RKESKK- 3
NH2
H-(cyclo-11, 15)803.149 803.6989
GSXFLSPEHQ[EVQQK]KESKK 6
-NH2
Sequence

Purit
y (%)
>99

Yiel
d
(%)
3

>99

10

>99

5

>99

7

>99

9

>99

12

>99

8

>99

15

69
10
11
12
13

H-(cyclo-12, 16)GSXFLSPEHQR[EQQRK]ESKKNH2
H-(cyclo-13, 17)GSXFLSPEHQRV[EQRKK]SKK
-NH2
H-(cyclo-14, 18)GSXFLSPEHQRVQ[ERKEK]KK
-NH2
H-(cyclo-15, 19)GSXFLSPEHQRVQQ[EKESK]K
-NH2

832.486
6

832.1008 >99

12

822.836
4

822.0571 >99

16

836.511
4

836.0917 >99

10

813.473
3

813.0776 >99

6

Supplementary Table 2.3 - Characterization of synthesized i, i+7 lactam stapled
truncated Ghrelin 1-20 (Where X is modified serine residue with an octanyl side
chain)
Compound Sequence
14
15
16
17
18
19
20
21

H-(cyclo-4, 11)GSX[ELSPEHQK]VQQRKESKKNH2
H-(cyclo-5, 12)GSXF[ESPEHQRK]QQRKESKKNH2
H-(cyclo-6, 13)GSXFL[EPEHQRVK]QRKESKKNH2
H-(cyclo-7, 14)GSXFLS[EEHQRVQK]RKESKKNH2
H-(cyclo-8, 15)GSXFLSP[EHQRVQQK]KESKKNH2
H-(cyclo-9, 16)GSXFLSPE[EQRVQQRK]ESKKNH2
H-(cyclo-10, 17)GSXFLSPEH[ERVQQRKK]SKKNH2
H-(cyclo-11, 18)GSXFLSPEHQ[EVQQRKEK]KKNH2

[M+3H]3+
Expected Observed
m/z
m/z
806.1198 806.6921

Purity Yield
(%)
(%)
>95

7

836.4574 836.9563

>95

10

835.4705 678.2541
>95
4+
([M+4H] )

16

678.3984 678.4536
>95
([M+4H]4+)

6

845.2495 845.6032

>95

9

818.7833 819.2634

>95

5

821.4666 822.1901

>95

7

826.1233 826.7796

>95

10

70
22

H-(cyclo-12, 19)GSXFLSPEHQR[EQQRKESK]KNH2

831.4466 832.1008

>95

13

71
IC50 competition binding curves for compounds 1-22 using HEK 293 cells in a
competitive binding assay with [125I]human ghrelin
Compound 1

% Radioligand Bound

140
120
100
80
60
40

25 nM

20
0
10-12

10-10

10-8

10-6

10-4

Log Concentration (M)

Compound 2

% Radioligand Bound

140
120
100
80
60
40

>1000 nM

20
0
10-12

10-10

10-8

10-6

Log Concentration (M)

10-4
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Compound 3

% Radioligand Bound

140
120
100
80
60
40

984 nM

20
0
10-12

10-10

10-8

10-6

10-4

Log Concentration (M)

Compound 4

% Radioligand Bound

140
120
100
80
60

667 nM

40
20
0
10-12

10-10

10-8

10-6

Log Concentration (M)

10-4
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Compound 5

% Radioligand Bound

140
120
100
80
60
40

>1000 nM

20
0
10-12

10-10

10-8

10-6

10-4

Log Concentration (M)

Compound 6

% Radioligand Bound

100
80
60
40

14.7 nM
20
0
10-12

10-10

10-8

10-6

Log Concentration (M)

10-4
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Compound 7

% Radioligand Bound

140
120
100
80
60

23.4 nM

40
20
0
10-12

10-10

10-8

10-6

10-4

Log Concentration (M)

Compound 8

% Radioligand Bound

140
120
100
80
60

10.6 nM

40
20
0
10-12

10-10

10-8

10-6

Log Concentration (M)

10-4
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Compound 9

% Radioligand Bound

140
120
100
80
60

37.3 nM

40
20
0
10-12

10-10

10-8

10-6

10-4

Log Concentration (M)

Compound 10

% Radioligand Bound

140
120
100
80
60
40

7.85 nM

20
0
10-12

10-10

10-8

10-6

Log Concentration (M)

10-4
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Compound 11

% Radioligand Bound

140
120
100
80
60
40

8.16 nM

20
0
10-12

10-10

10-8

10-6

10-4

Log Concentration (M)

Compound 12

% Radioligand Bound

140
120
100
80
60
40

11.8 nM

20
0
10-12

10-10

10-8

10-6

Log Concentration (M)

10-4
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Compound 13

% Radioligand Bound

140
120
100
80
60
40

10.9 nM

20
0
10-12

10-10

10-8

10-6

10-4

Log Concentration (M)

% Radioligand Bound

Compound 14

100

80

60
10-12

>1000 nM

10-10

10-8

10-6

Log Concentration (M)

10-4
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Compound 15

% Radioligand Bound

140
120
100
80
60
40

>1000 nM

20
0
10-12

10-10

10-8

10-6

10-4

Log Concentration (M)

% Radioligand Bound

Compound 16

100

10-12

>1000 nM

10-10

10-8

10-6

Log Concentration (M)

10-4
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% Radioligand Bound

Compound 17

100

48.3 nM
80

10-12

10-10

10-8

10-6

10-4

Log Concentration (M)

Compound 18

% Radioligand Bound

140
120
100
80
60
40

10.3 nM

20
0
10-12

10-10

10-8

10-6

Log Concentration (M)

10-4
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Compound 19

% Radioligand Bound

140
120
100
80
60
40

106 nM

20
0
10-12

10-10

10-8

10-6

10-4

Log Concentration (M)

Compound 20

% Radioligand Bound

140
120
100
80
60
40
20
0
10-12

7.41 nM

10-10

10-8

10-6

Log Concentration (M)

10-4
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Compound 21

% Radioligand Bound

140
120
100
80
60
40

91.9 nM

20
0
10-12

10-10

10-8

10-6

10-4

Log Concentration (M)

Compound 22

% Radioligand Bound

100
80
60
40

29.0 nM

20
0
10-12

10-10

10-8

10-6

Log Concentration (M)

10-4
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Compound 23

% Radioligand Bound

120
100
80
60
40

11.0 nM

20
0
10-12

10-10

10-8

10-6

10-4

Log Concentration (M)

Compound 24

% Radioligand Bound

140
120
100
80
60

1.0 nM

40
20
0
10-14

10-12

10-10

10-8

Log Concentration (M)

10-6

10-4
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Compound 25

% Radioligand Bound

120
100
80
60
40

6.2 nM

20
0
10-12

10-10

10-8

10-6

Log Concentration (M)

10-4
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HPLC and MS traces for compounds 1-22
Compound 1
LC:
3.9E+07
3.4E+07
2.9E+07

AU

2.4E+07
1.9E+07
1.4E+07
9.0E+06
4.0E+06
-1.0E+06

0

2

4

6
Time (min)

8

10

12

MS:
4.00E+06
3.50E+06
3.00E+06

R.A.

2.50E+06
2.00E+06
1.50E+06

[M+4H]4+
620.8730

1.00E+06
5.00E+05
0.00E+00
-5.00E+05

0

500

1000

1500
m/z

2000

2500
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Compound 2
LC:
6000000
5000000

AU

4000000
3000000
2000000
1000000
0
6

7

8

9

10

11

12

Time (min)

MS:
4.50E+06
4.00E+06

[M+3H]3+
815.8046

3.50E+06

R.A

3.00E+06
2.50E+06
2.00E+06
1.50E+06
1.00E+06
5.00E+05
0.00E+00
0

500

1000

1500
m/z

2000

2500
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Compound 3
LC:
2.0E+07
1.8E+07
1.6E+07
1.4E+07

AU

1.2E+07
9.5E+06
7.5E+06
5.5E+06
3.5E+06
1.5E+06
-5.0E+05
-1

1

3

5

7
Time (min)

9

11

13

15

MS:
2.50E+06

[M+3H]3+
824.3851

2.00E+06

R.A

1.50E+06

1.00E+06

5.00E+05

0.00E+00
0

500

1000

1500
m/z

2000

2500
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Compound 4
LC:
2500000

2000000

AU

1500000

1000000

500000

0
6

7

8

9
Time (min)

10

11

12

MS:
2.00E+06
1.80E+06

[M+3H]3+
836.0917

1.60E+06
1.40E+06

R.A

1.20E+06
1.00E+06
8.00E+05
6.00E+05
4.00E+05
2.00E+05
0.00E+00
0

500

1000

1500
m/z

2000

2500
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Compound 5
LS:
3.9E+06
3.4E+06
2.9E+06

AU

2.4E+06
1.9E+06
1.4E+06
8.5E+05
3.5E+05
-1.5E+05
-1

1

3

5

7
Time (min)

9

11

13

15

MS:
2.50E+06

2.00E+06

[M+3H]3+
823.4539

R.A

1.50E+06

1.00E+06

5.00E+05

0.00E+00
0

500

1000

1500
m/z

2000

2500
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Compound 6
LC:
3.9E+07
3.4E+07
2.9E+07

AU

2.4E+07
1.9E+07
1.4E+07
9.0E+06
4.0E+06
-1.0E+06

0

2

4

6
Time (min)

8

10

12

MS:
4.50E+06
4.00E+06

[M+3H]3+
831.7017

3.50E+06

R.A

3.00E+06
2.50E+06
2.00E+06
1.50E+06
1.00E+06
5.00E+05
0.00E+00
0

500

1000

1500
m/z

2000

2500
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Compound 7
LC:
8000000
7000000
6000000

AU

5000000
4000000
3000000
2000000
1000000
0
6

7

8

9
Time (min)

10

11

MS:
5.00E+06
4.50E+06

[M+3H]3+
819.4630

4.00E+06
3.50E+06
R.A

3.00E+06
2.50E+06
2.00E+06
1.50E+06
1.00E+06
5.00E+05
0.00E+00
0

500

1000

1500
m/z

2000

2500

12
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Compound 8
LC:
12000000
10000000

AU

8000000
6000000
4000000
2000000
0
6

7

8

9

10

11

12

Time (min)

MS:
8.00E+06

[M+3H]3+
822.3869

7.00E+06
6.00E+06

R.A

5.00E+06
4.00E+06
3.00E+06
2.00E+06
1.00E+06
0.00E+00
0

500

1000

1500
m/z

2000

2500
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Compound 9
LC:

2.20E+06

1.70E+06

AU

1.20E+06

7.00E+05

2.00E+05

-3.00E+05
0

2

4

6

8

10

12

Time (min)

MS:
5.00E+06

[M+3H]3+
803.6989

4.50E+06
4.00E+06
3.50E+06
3.00E+06
2.50E+06
2.00E+06
1.50E+06
1.00E+06
5.00E+05
0.00E+00
0

500

1000

1500

2000

2500
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Compound 10
LC:
1.8E+07
1.6E+07
1.4E+07
1.2E+07
AU

9.7E+06
7.7E+06
5.7E+06
3.7E+06
1.7E+06
-3.5E+05
-1

1

3

5

7

9

11

13

15

Time (min)

MS:
7.00E+06
6.00E+06

[M+3H]3+
832.1008

5.00E+06
4.00E+06
3.00E+06
2.00E+06
1.00E+06
0.00E+00
0
-1.00E+06

500

1000

1500

2000

2500
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Compound 11
LC:
8.7E+06
7.7E+06
6.7E+06
5.7E+06
AU

4.7E+06
3.7E+06
2.7E+06
1.7E+06
6.5E+05
-3.5E+05
-1

1

3

5

7
Time (min)

9

11

13

15

MS:
6.00E+06
5.00E+06

[M+3H]3+
822.0571

4.00E+06
3.00E+06
2.00E+06
1.00E+06
0.00E+00
0
-1.00E+06

500

1000

1500

2000

2500
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Compound 12
LC:
10000000
9000000
8000000
7000000
6000000
5000000
4000000
3000000
2000000
1000000
0
-1000000

0

2

4
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Compound 18
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Compound 19
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Compound 25
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Additional Confocal Images

Supplementary Figure 2.1 - (top) Confocal microscopy images incubated with the
Cy5-Ghrelin(1-19) in 5 different ovarian cancer cell lines; (middle) Confocal
microscopy images incubated with the Cy5-Ghrelin(1-19) and blocked with 10x
concentrated Ghrelin(1-19) in 5 different ovarian cancer cell lines; (bottom)
Confocal microscopy images incubated with the scrambled-Cy5-Ghrelin(1-19) in 5
different ovarian cancer cell lines
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Supplementary Figure 2.2 - (a) Confocal microscopy of compound 25 incubated
with compound 1 in the Ovcar8 GHS-R1a+/+ cell line; (b) Confocal microscopy of
compound 24 incubated with compound 1 in the Ovcar8 GHS-R1a+/+ cell line; (c)
Confocal microscopy of compound 23 incubated with compound 1 in the Ovcar8
GHS-R1a+/+ cell line; (d) Confocal microscopy of compound 25 incubated with
compound 1 in the Ovcar8 cell line; (e) Confocal microscopy of compound 24
incubated with compound 1 in the Ovcar8 cell line; (f) Confocal microscopy of
compound 23 incubated with compound 1 in the Ovcar8 cell line
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Supplementary Figure 2.3 - (a) Confocal microscopy of compound 25 incubated
with compound 1 in the Ovcar8 GHS-R1a+/+ cell line; (b) Confocal microscopy of
compound 24 incubated with compound 1 in the Ovcar8 GHS-R1a+/+ cell line; (c)
Confocal microscopy of compound 23 incubated with compound 1 in the Ovcar8
GHS-R1a+/+ cell line; (d) Confocal microscopy of compound 25 incubated with
compound 1 in the Ovcar8 cell line; (e) Confocal microscopy of compound 24
incubated with compound 1 in the Ovcar8 cell line; (f) Confocal microscopy of
compound 23 incubated with compound 1 in the Ovcar8 cell line
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Chapter 32
Peptidomimetic growth hormone secretagogue derivatives for positron emission
tomography imaging of GHS-R1a
3.1 Introduction
Growth hormone secretagogues (GHSs) are a class of compounds that stimulate
the secretion of growth hormone (GH) by acting on the growth hormone secretagogue
receptor type-1a (GHS-R1a)1. This receptor is predominantly found in the hypothalamus
and pituitary gland1 and its secretion occurs through a route disparate from that of growth
hormone-releasing hormone (GHRH)2. The first GHSs to show GH release in vitro were
a series of Met-enkephalin analogues described by Bowers et al in 19803. Further
development of these analogues led to a hexamer that released GH in vivo in a number of
animals4-5, including humans6. This peptide was later termed growth hormone-releasing
peptide-6 (GHRP-6), and a number of GHSs were subsequently synthesised in order to
find alternatives to recombinant human GH therapy. These encompassed peptides (e.g.
GHRP-17, hexarelin8, KP-102 ((later designated GHRP-2)9), peptidomimetics (e.g.
G703910, [1-Nal]4G703911and ipamorelin12) and small-molecules (e.g. L-692,42913and
MK-067714). The amino acid sequences of the peptidic GHSs and the structures of the
peptidomimetic and small-molecule GHSs are shown in Figure 3.1. The endogenous
ligand for GHS-R1a is ghrelin, a 28-mer peptide with an n-octanoyl group on the Ser3
side-chain, which was discovered in 199915 and exhibits a multitude of biological
activities, such as the regulation of food intake and glucose metabolism16-17.

2

Fowkes, M.M.; Lalonde, T.; Yu, L.; Dhanvantari, S.; Kovacs, M.S.; Luyt, L.G.
Peptidomimetic growth hormone secretagogue derivatives for positron emission
tomography imaging of the ghrelin receptor. Eur. J. Med. Chem. 2018, 157, 1500-1511.
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Figure 3.1 - Peptidic, peptidomimetic and small-molecule growth hormone
secretagogues. All amino acids are designated by the standard three-letter code. D2-Nal, D-2-naphthylalanine; Inp,
GHS-R1a is expressed in a number of human malignancies including prostatic
carcinoma cell lines18-19 and tissues20, breast carcinoma tumours and cell lines21, testicular
tumours22, and malignant ovarian cysts and tumours23. In addition, it has an elevated level
of expression in tissues from patients with atherosclerosis24 and in biopsies from those
with chronic heart failure25. GHS-R1a thus represents a potential target for molecular
imaging of carcinoma and cardiovascular disease. Among the imaging modalities most
commonly utilised in the clinic, positron emission tomography (PET) combines a high
spatial resolution with high sensitivity26. A number of recent publications have thus
described the development of PET radiotracers for visualising the GHS-R1a receptor in
disease27-30. For example, Hou and co-workers synthesized the first picomolar
quinazolinone binder of GHS-R1a and successfully radiolabelled two nanomolar
compounds in high radiochemical purity30. In another study on small-molecule
derivatives, in vivo imaging in mice with a [11C]radiotracer revealed a higher specific
uptake in the pancreas compared to other organs28. However, these studies27-29 and
others30-31 have primarily focused on either small-molecule quinazolinones27-31 or ghrelin-
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derived compounds29,30,33. To the best of our knowledge, a growth hormone
secretagogue-based PET probe has not been reported to date. We reasoned that
modification of peptidic and peptidomimetic GHSs should result in a clinically
translatable PET agent with high target specificity, in vivo stability and favourable
pharmacokinetic properties. Fluorine-18 was our preferred choice of radioisotope as it is
a small innocuous unit that can be easily installed in the absence of a chelator using the
[18F]fluorobenzoyl ([18F]FB) prosthetic group. This modification can be initially trialled
with 4-[19F]fluorobenzoic acid ([19F]FBA), in order to determine the optimal location for
the 18F-radioisotope without significantly affecting peptide/peptidomimetic binding to
GHS-R1a.
We describe herein the design, synthesis and biological evaluation of 4fluorobenzoylated derivatives of GHSs with peptidic (GHRP-1, GHRP-2 and GHRP-6)
and peptidomimetic (G7039, [1-Nal4]G7039 and ipamorelin) structures; the
determination of their IC50 values for GHS-R1a; the identification of the lead peptide [1Nal4,Lys5(4-FB)]G7039 with nanomolar IC50 and EC50 values; and the 18F-radiolabelling
of its precursor [1-Nal4]G7039 to furnish the peptidomimetic growth hormone
secretagogue [1-Nal4,Lys5(4-[18F]-FB)]G7039, which could be applied to PET imaging of
carcinoma and cardiovascular disease via targeting of GHS-R1a.
3.2 Results and Discussion
3.2.1 Design strategy for peptidic and peptidomimetic growth hormone secretagogues
Initially, we sought to determine the location for 18F insertion into the peptidic
and peptidomimetic GHSs without significantly affecting receptor binding affinity. A
study of the literature revealed that Huang and co-workers had designed a 3D
pharmacophore for GHS activity using peptidic and non-peptidic compounds without
inclusion of the lysine side-chain34. This led to the synthesis of a benzothiazepin
compound with low nanomolar in vitro efficacy for GHS-R1a34. In addition, we recently
reported a GHS-R1a homology model based on neurotensin and opioid receptors with
docking of the peptidomimetic G703935. The lysine residue was found to be unimportant
for G7039-GHS-R1a binding owing to an unfavourable interaction energy between its
side-chain amino group and polar Glu197/Arg199 residues35. This led us to select the lysine
side-chain for 18F-radioisotope insertion in the peptidic (GHRP-1, GHRP-2 and GHRP-6)
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and peptidomimetic (G7039, [1-Nal4]G7039 and ipamorelin) GHSs using the [18F]FB
prosthetic group via the pre-activated N-succinimidyl-4-[18F]fluorobenzoate ([18F]SFB)36.
This modification was first tested by coupling a non-radioactive [18F]FB mimic
([19F]FBA) to the lysine side-chain of each individual GHS class using the orthogonal
allyloxycarbonyl (Alloc) protecting group by standard Fmoc-solid phase peptide
synthesis (SPPS). Any change in binding affinity for GHS-R1a (expressed in terms of the
IC50) was determined experimentally through a competitive receptor-ligand binding
assay. Each parent growth hormone secretagogue (Figure 3.1) would be modified in turn
until an IC50 < 100 nM was achieved.
3.2.2 Synthesis and characterisation of peptidic and peptidomimetic growth hormone
secretagogues
The peptidic and peptidomimetic GHSs were synthesised through manual or
automated Fmoc-SPPS and purified by reverse-phase (RP)-HPLC. Amino acids
sequences for these GHSs are shown in the supporting information (Table 3.S1), with
characterisation data listed in Table 3.1.
Table 3.1 - HRMS data, purities and yields for synthesised peptides and
peptidomimetics. All amino acids are designated by the standard three-letter code.
4-FB, 4-fluorobenzoyl; AEEA, 2-(2-(2-aminoethoxy)ethoxy)acetic acid; D-2-Nal, D2-naphthylalanine; D-2-Thi, D-2-thienylalanine; Dpr, 2,3-diaminopropionic acid;
Inp, isonipecotic acid. *Characterisation data reported previously35
HRMS
Peptide/Peptidomimetic

HRMS

(calculated) (found)

%

% Yield

Purity

[M + H]+

[M + H]+

Ipamorelin

712.3935

712.3959

> 97

19

[Lys5(4-FB)]ipamorelin

834.4103

834.4133

> 99

15

979.4842

979.4868

> 98

8

840.3667

840.3693

> 98

4

[Inp1, Lys5(4-FB)]ipamorelin

860.4259

860.4284

> 96

6

[Inp1, D-2-Nal4, Lys5(4-

910.4416

910.4400

> 98

10

866.3824

866.3850

> 99

13

5

[Lys (AEEA-4-FB)]ipamorelin
4

5

[D-2-Thi , Lys (4FB)]ipamorelin

FB)]ipamorelin
[Inp1, D-2-Thi4, Lys5(4FB)]ipamorelin
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GHRP-1

955.4943

955.4964

> 99

19

GHRP-2

840.4204

840.4173

> 99

17

[M + Na]+

[M + Na]+

GHRP-6

873.4524

873.4531

> 97

14

[Lys6(4-FB)]GHRP-6

1017.4511

1017.4522

> 96

7

+

+

[M + Na]

[M + Na]

[Dpr ]GHRP-6

831.4055

831.4070

> 99

3

[Dpr6(4-FB)]GHRP-6

953.4223

953.4237

> 98

14

G7039*

798.4343*

798.4339*

> 99*

7*

[Lys5(4-FB)]G7039

920.4511

920.4529

> 97

6

[1-Nal4]G7039

848.4499

848.4501

> 99

23

[1-Nal4, Lys5(4-FB)]G7039

970.4667

970.4693

> 96

9

6

3.2.3 Structure-activity relationships of peptidic and peptidomimetic growth hormone
secretagogues
The IC50 values of the peptidic and peptidomimetic GHSs were determined
through receptor-ligand binding assays utilising human embryonic kidney 293
(HEK293)/GHS-R1a cells and [125I]ghrelin as the competitive radioligand. In order to
ascertain whether overexpression of the receptor in HEK293 cells had been achieved, the
endogenous ligand ghrelin was assayed first. An IC50 value of 7.63 nM was obtained
(Figure 3.S1), indicating a satisfactory level of receptor expression and maintaining
consistency with previously reported values37.
The initial peptidomimetic that was chosen for 19F-fluorobenzoylation was the
pentapeptide ipamorelin (H-Aib-His-D-2-Nal-D-Phe-Lys-NH2, compound 1, Table 3.2).
This is because it displayed a nanomolar binding affinity in previous work using
HEK293/GHS-R1a cells (Ki = 240 nM)38.
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Table 3.2 - IC50 values of ipamorelin and a series of derivatives thereof. The listed
IC50 values were determined in triplicate using HEK293/GHS-R1a cells. For
corresponding displacement curves, the reader is referred to the supporting
information
Compound

Name

IC50, nM

1

Ipamorelin

483

2

[Lys5(4-FB)]ipamorelin

170

3

[Lys5(AEEA-4-FB)]ipamorelin

474

4

[D-2-Thi4, Lys5(4-FB)]ipamorelin

161

1

5

5

[Inp , Lys (4-FB)]ipamorelin

688

6

[Inp1, D-2-Nal4, Lys5(4-FB)]ipamorelin

1920

7

[Inp1, D-2-Thi4, Lys5(4-FB)]ipamorelin

1170

Introduction of a fluorobenzoyl moiety into the lysine side-chain caused the IC50
value of ipamorelin to decrease from 483 nM to 170 nM (compound 2, [Lys5(4FB)]ipamorelin). This could be a consequence of the fluorobenzoyl group strengthening
hydrophobic interactions with aromatic residues (e.g. Phe222 and Phe226) in the nonpolar sub-pocket described in the open GHS-R1a homology model of Pedretti and coworkers39. Ipamorelin also possesses the same three C-terminal residues as G7039 (the
only difference being D-Phe4 as opposed to Phe4, respectively) and thus the additional
fluorobenzene ring could also be interacting with residues in one of the hydrophobic subpockets (e.g. Phe286) detailed by Hou et al35. Extension of the lysine side-chain through
a short mini-PEG linker (2-(2-(2-aminoethoxy)ethoxy)acetic acid, AEEA) prior to 4fluorobenzoyl group coupling furnished [Lys5(AEEA-4-FB)]ipamorelin, compound 3.
This had a higher IC50 value compared to compound 2 (cf. 474 nM for [Lys5(AEEA-4FB)]ipamorelin to 170 nM for [Lys5(4-FB)]ipamorelin). This may result from the
additional flexibility afforded by the mini-PEG linker, which could cause a reduction in
important hydrophobic interactions of the 4-fluorobenzoyl moiety when compared to the
less flexible compound 2. Replacement of the D-Phe residue with D-2-thienylalanine (D2-Thi) was expected to improve binding affinity. This strategy was based on a study by
Hansen and co-workers on dipeptide ipamorelin derivatives, where this alteration caused
the EC50 value to improve by an order of magnitude40. Unfortunately, this modification
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furnished a compound with comparable affinity to the [Lys5(4-FB)]ipamorelin analogue 2
with an IC50 = 161 nM ([D-2-Thi4,Lys5(4-FB)]ipamorelin, compound 4).
The primary amine at the N-terminus of ipamorelin was then exchanged for the
secondary amine isonipecotic acid (Inp) so as to make the subsequent compound
([Inp1,Lys5(4-FB)]ipamorelin, compound 5) similar to the peptidomimetic G7039, known
to have an EC50 = 0.18 nM10. This led to a rise in the IC50 value (cf. [Lys5(4FB)]ipamorelin, IC50 = 170 nM, compound 2 to [Inp1,Lys5(4-FB)]ipamorelin, IC50 = 688
nM, compound 5).
In order to probe the significance of the D-Phe residue in sub-pocket binding, this
residue was replaced with D-2-Nal in [Inp1,Lys5(4-FB)]ipamorelin (5) to give [Inp1,D-2Nal4,Lys5(4-FB)]ipamorelin (IC50 = 1920 nM, compound 6). This caused an
approximately three-fold reduction in binding affinity for GHS-R1a compared to the
parent compound 5. This suggests that D-Phe may be taking part in π-π or hydrophobic
interactions with Phe119 in TM339,41, playing the same role as it does in the active tetrapeptide core of ghrelin42. The synthesis of compound 7 ([Inp1,D-2-Thi4,Lys5(4FB)]ipamorelin) and its corresponding IC50 value (1170 nM) could be seen as an
approximately two-fold reduction in binding affinity for GHS-R1a from switching D-2Thi for D-Phe in compound 5 ([Inp1,Lys5(4-FB)]ipamorelin); or an approximately sevenfold decrease in binding resulting from insertion of an unfavourable secondary amine
(Inp) into compound 4 ([D-2-Thi4,Lys5(4-FB)]ipamorelin). In summary, the various
synthesised derivatives of ipamorelin did not yield the desired IC50 of < 100 nM, despite
some improvements to its initial IC50 value.
Next, our attention turned to the peptidic GHSs (GHRP-1, GHRP-2 and GHRP-6)
due to the low nanomolar Ki values that were obtained for GHRP-2 and GHRP-6 (1.4 nM
and 3.3 nM, respectively) using HEK293/GHS-R1a cells38. The IC50 values of GHRP-1,
GHRP-2 and GHRP-6 are shown in Table 3.3 (compounds 8-10, respectively).
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Table 3.3 - IC50 values of peptidic GHSs and their derivatives. The listed IC50 values
were determined in triplicate using HEK293/GHS-R1a cells. For corresponding
displacement curves, the reader is referred to the supporting information
Compound

Name

IC50, nM

8

GHRP-1

181

9

GHRP-2

449

10

GHRP-6

73

6

11

[Lys (4-FB)]GHRP-6

384

12

[Dpr6]GHRP-6

397

13

[Dpr6(4-FB)]GHRP-6

1060

It was found that GHRP-6, (H-His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) had the
strongest binding to GHS-R1a (IC50 = 73 nM, compound 10) compared to GHRP-1 (IC50
= 181 nM, compound 8) and GHRP-2 (IC50 = 449 nM, compound 9). This peptide was
therefore transformed into the fluorobenzoylated analogue [Lys6(4-FB)]GHRP-6 (IC50 =
384 nM, compound 11). Unfortunately, this alteration was not tolerated by GHS-R1a in
spite of prior success with ipamorelin (cf. compound 11, IC50 = 384 nM to compound 2,
IC50 = 170 nM). One possible explanation for this is that the lysine residue of GHRP-6 is
involved in binding to polar sub-pocket residues (e.g. Arg199)39.
Endeavouring to increase affinity for GHS-R1a, the lysine of GHRP-6 was
replaced with 2,3-diaminopropionic acid (Dpr) to furnish [Dpr6]GHRP-6 (IC50 = 397 nM,
compound 12). This increase in IC50 could be a product of the shorter side-chain of Dpr
which could be decreasing lysine’s charge-transfer interactions with Arg199 in the polar
sub-pocket. This would also explain the greater loss in binding affinity after the
attachment of the 4-fluorobenzoyl group ([Dpr6(4-FB)]GHRP-6, IC50 = 1060 nM,
compound 13). Not only does the lysine side-chain appear to play an important role in
receptor binding for GHRP-6 (a result contrary to that obtained for ipamorelin), but the
length of the alkyl chain also appears to be essential. Further derivatisation of this class of
peptides was not pursued owing to the high initial IC50 values of GHRP-1 (181 nM,
compound 8) and GHRP-2 (449 nM, compound 9) and the assumption that the lysine
residue in these peptides was also important for receptor interaction.
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Finally, two Genentech 5-mers G7039 (H-Inp-D-2-Nal-D-2-Nal-Phe-Lys-NH2)
and [1-Nal4]G7039 (H-Inp-D-2-Nal-D-2-Nal-1-Nal-Lys-NH2) were investigated as a
consequence of their reported low nanomolar in vitro efficacies (EC50 = 0.18 nM for
G703910 and 0.10 nM for [1-Nal4]G703911, respectively) and our recent computational
study on the docking of G7039 to GHS-R1a, which suggested that the lysine residue was
not critical for receptor binding35. The parent compounds G7039 (compound 14) and [1Nal4]G7039 (compound 16) and their fluorobenzoyl congeners (compounds 15 and 17,
respectively) can be viewed in Table 3.4.
Table 3.4 - IC50 values of Genentech peptidomimetics and their derivatives. The
listed IC50 values were determined in triplicate using HEK293/GHS-R1a cells. For
corresponding displacement curves, the reader is referred to the supporting
information. *Literature data35
Compound Name

IC50, nM

14

G7039*

5.2*

15

[Lys5(4-FB)]G7039

242

4

16

[1-Nal ]G7039

28

17

[1-Nal4, Lys5(4-FB)]G7039 69

Attaching G7039 to para-fluorobenzoic acid had the effect of increasing the halfmaximal inhibitory concentration (5.2 nM to 242 nM for [Lys5(4-FB)]G7039, compound
15), whilst a smaller increase in the IC50 value was observed for [1-Nal4]G7039 (28 nM
to 69 nM for [1-Nal4,Lys5(4-FB)]G7039, compound 17). The smaller increase observed
for [1-Nal4]G7039 compared to G7039 indicates that the introduction of an additional
aromatic functionality (fluorobenzene) along with the already present 1-Nal4 residue is
simply strengthening hydrophobic sub-pocket binding, whereas for G7039 this
modification is less favourable; perhaps due to the reduction of salt-bridge interactions
with Glu197 in the polar sub-pocket35. In spite of the increase in IC50 value for [1Nal4,Lys5(4-FB)]G7039, this peptidomimetic represents the first lead compound to be
synthesised with the required nanomolar IC50 value (< 100 nM) making it the most
suitable candidate for further study of physical and biochemical characteristics prior to
[18F]-radiolabelling with [18F]SFB.
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3.2.4 Determination of lipophilicity of peptidic and peptidomimetic growth hormone
secretagogues
The logP value of [1-Nal4,Lys5(4-FB)]G7039 as well as the other peptidic and
peptidomimetic GHSs were computed using ACD/LogP software (Table 3.S2). Inserting
the 4-fluorobenzoyl moiety into any peptidomimetic parent compound resulted in an
increase in hydrophobicity for all derivatives (+ 2.25). Most of the parent compounds
exhibited a favourable logP value in the 1-3 unit range, except for G7039 (5.28 ± 0.82)
and [1-Nal4]G7039 (6.51 ± 0.82). This is virtue of the smaller size of these
peptidomimetics compared to GHRP-1, GHRP-2 and GHRP-6, and the prevalence of
more hydrophobic aromatic residues compared to ipamorelin (D-2-Nal and 1-Nal).
Regrettably, the lead compound [1-Nal4,Lys5(4-FB)]G7039 had a logP value of 8.76 ±
0.88, suggesting a lack of suitability for in vivo PET imaging due to potential solubility
issues. Nevertheless, [1-Nal4,Lys5(4-FB)]G7039 possesses a considerably lower IC50
value compared to the next best compound [D-2-Thi4, Lys5(4-FB)]ipamorelin (cf. 69 nM
to 161 nM) and was thus investigated in further in vitro assays.
3.2.5 Determination of efficacy of lead peptidomimetic [1-Nal4,Lys5(4-FB)]G7039
The EC50 value of [1-Nal4,Lys5(4-FB)]G7039 was calculated in terms of the
release of intracellular calcium ions (Figure 3.2). As expected, the control ligand ghrelin
had a low in vitro potency of 1.6 nM, whilst the EC50 value of [1-Nal4,Lys5(4-FB)]G7039
was determined as 1.1 nM. This low nanomolar efficacy signifies that the final compound
remains a potent GHS-R1a agonist despite blocking of the lysine side-chain with the 4fluorobenzoyl group.
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Figure 3.2 - Dose-response curves for the lead peptidomimetic [1-Nal4,Lys5(4FB)]G7039 (red) and the control ligand ghrelin (blue). The EC50 value for these
compounds was determined in terms of intracellular Ca2+ release. The percentage
activation was normalised to the maximal response (Emax) of the control agonist
ghrelin. Each assay concentration was performed in duplicate
3.2.6 Stability of lead peptidomimetic [1-Nal4,Lys5(4-FB)]G7039 in human serum
The lead peptidomimetic agonist [1-Nal4,Lys5(4-FB)]G7039 was tested for
stability in human serum in order to assess its biological half-life. This serum half-life
was found to be 718 minutes, indicating a good potential time-frame for in vivo PET
imaging in small animal models of carcinoma or cardiovascular disease. The [1Nal4]G7039 lead precursor was thus carried forward for radiolabelling with [18F]SFB.
3.2.7 Synthesis of [18F]SFB and 18F-radiolabelling of the lead precursor [1-Nal4]G7039
The synthesis of the [18F]SFB prosthetic group is shown in scheme 1. Acid
catalysed esterification of the 4-dimethylaminobenzoic acid starting material 18 furnished
the intermediate t-butyl ester 19. Methylation with trifluoromethanesulfonate (MeOTf)
gave the triflate salt 20 in a yield of 38% and ≥ 95% purity by UHPLC. Having
synthesized the precursor salt 20, nucleophilic aromatic substitution with the [18F-] anion
(acquired from the PET cyclotron by irradiation of [18O]H2O) led to the formation of the
radioactive compound 21.

123

O

O
a

OH

O

O

Me 2N

Me 2N

O

OTf

b

Me 3N
20

19

18

O
c

O

O

O
d

O

OH

22

21

O

N
O

18F

18F

18F

e

23

O
NH
f

18F

H-Inp-D-2-Nal-D-2-Nal-1-Nal-Lys-NH 2
24

Scheme 3.1 - Synthesis of the [18F]SFB prosthetic group and subsequent 18Fradiolabelling of [1-Nal4]G7039. Reagents and Conditions: a) i) trifluoroacetic
anhydride, THF, 0°C ii) tBuOH, room temperature, 2 hrs; b) MeOTf, N2, 0 °C, 1
hour; c) 18F-, K2CO3, Kryptofix 2.2.2, DMSO, 120 °C, 10 minutes; d) 6M HCl, 120
°C, 10 minutes; e) NHS, EDC, MeCN, room temperature, 15-20 minutes; f) [1Nal4]G7039, N,N-diisopropylethylamine (DIPEA), MeCN/H2O (1:1 ratio), 65 °C, 1520 minutes
Acid-catalysed de-esterification furnished [18F]FBA (22) with an average d.c.
(decay-corrected) radiochemical yield of 82%. The product was confirmed by coinjection with [19F]FBA (see Figure 3.S3 for representative radiochromatogram).
Compound 22 was then coupled to N-hydroxysuccinimide (NHS) using the coupling
reagent N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide (EDC) which led to the
formation of the [18F]SFB prosthetic group 23. The crude compound was purified by
reverse-phase HPLC to give an average decay-corrected radiochemical yield of 71% and
radiochemical purity ³ 99% (see Figure 3.S4 for representative radiochromatogram). The
pure [18F]SFB was added to the peptide precursor [1-Nal4]G7039 in a mixture of
MeCN/H2O using a small quantity of the hindered base DIPEA. After 15-20 minutes, the
crude [1-Nal4,Lys5(4-[18F]-FB)]G7039 lead compound was obtained and purified by
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semi-preparative HPLC. The final radiolabelled peptide [1-Nal4,Lys5(4-[18F]-FB)]G7039
(24) was obtained in an average decay-corrected radiochemical yield of 81%. For the
entire synthesis, an overall average d.c. radiochemical yield of 48% was achieved (n = 3),
an average molar activity of > 34 GBq/μmol and a radiochemical purity of ≥ 99%. Figure
3 displays a series of stacked chromatograms including the peptidomimetic precursor [1Nal4]G7039 (16), the cold standard [1-Nal4,Lys5(4-FB)]G7039 (17) as well as the
radiolabelled [1-Nal4,Lys5(4-[18F]-FB)]G7039 peptidomimetic (24).

Figure 3.3 - Stacked HPLC Chromatograms for [1-Nal4]G7039, [1-Nal4,Lys5(4FB)]G7039 (both λ = 254 nm) and [1-Nal4, Lys5(4-[18F]-FB)]G7039
The retention times of the cold standard and “hot” peptide are almost identical
([1-Nal4, Lys5(4-FB)]G7039, tR = 6.70 mins compared to tR = 6.65 mins for the “hot”
peptide), indicating that the precursor [1-Nal4]G7039 has been selectively radiolabelled at
the amino group of the lysine side-chain. Further evidence for successful coupling of
[18F]SFB to [1-Nal4]G7039 via the lysine side-chain was provided by a co-injection of a
pre-mixed solution of the cold standard and “hot” peptidomimetic (Figure 3.4).
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Figure 3.4 - Stacked HPLC chromatograms resulting from the co-injection of cold
standard [1-Nal4,Lys5(4-FB)]G7039 (λ = 254 nm) and [1-Nal4,Lys5(4-[18F]FB)]G7039
Once again, this showed very similar retention times between the two
peptidomimetic species ([1-Nal4, Lys5(4-FB)]G7039 tR = 6.26 mins and [1-Nal4,Lys5(4[18F]-FB)]G7039 tR = 6.17 mins) lending further credence to regioselective 18Ffluorobenzoylation at the lysine side-chain.
3.3 Conclusions
In this study, several families of peptidic (GHRP-1, GHRP-2 and GHRP-6) and
peptidomimetic (ipamorelin, G7039, [1-Nal4]G7039) GHS-R1a agonists were derivatised
through 4-fluorobenzoylation of the lysine side-chain. This led to a range of half-maximal
inhibitory concentrations ranging from 69 nM ([1-Nal4, Lys5(4-FB)]G7039) to 1920 nM
([Inp1, D-2-Nal4, Lys5(4-FB)]ipamorelin). The peptidomimetic [1-Nal4]G7039 was
identified as the most suitable candidate for 18F-radiolabelling, as its 19F-congener ([1Nal4,Lys5(4-FB)]G7039, compound 17) had a nanomolar binding affinity (IC50 = 69 nM),
high in vitro potency (EC50 = 1.1 nM) and good serum stability (t1/2 = 718 mins). This is
most likely due to the presence of a core framework of aromatic amino acids that are
involved in strong hydrophobic interactions with hydrophobic pockets of the GHS-R1a.
Prosthetic group radiolabelling of [1-Nal4]G7039 with [18F]SFB delivered the
radiolabelled peptidomimetic in an overall average decay-corrected radiochemical yield
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of 48%, a radio-purity ≥ 99% and an average molar activity of > 34 GBq/μmol. This
compound could potentially be used as a PET probe for the detection of diseases that are
characterised by overexpression of GHS-R1a.
3.4 Materials and Methods
3.4.1 General information
All starting peptide reagents (resin, amino acids, coupling agents, and bases) were
obtained from commercial suppliers and used without further purification. Peptides were
either synthesised manually or through the use of a Biotage SyroWave automated peptide
synthesizer. Peptide vessels were shaken using an IKA Vibrax VXR basic shaker with
centrifugation performed on a Beckman Coulter Allegra X-30R or Fisher GS-6R
centrifuge. In order to aid peptide dissolution, sonication of solutions was accomplished
via a Bransonic 2510R-MTH or Fisher F5-14 ultrasonic cleaner. A Fisher 2052 Isotemp
machine was used to heat test tubes in the Kaiser Test. Peptides were lyophilised using a
Labconco FreeZone Freeze Dry System. Accurate weighing was carried out on a MettlerToledo XP6 microbalance. UV traces were obtained with a Waters 2487 UV/Vis Dual λ
Absorbance Detector (170-900 nm) and low-resolution mass spectra with a Micromass
Quattro micro API mass spectrometer (ESI-LC-MS). Peptide purification was achieved
through HPLC (MeCN + 0.1% TFA, H2O + 0.1% TFA solvent system). All peptides and
small molecules obtained had a purity ≥ 95% as determined by HPLC or UHPLC
analysis. A RP preparative C-18 column (SunFire OBD, 19 x 150 mm or Agilent Zorbax
21.2 x 150 mm) was used for preparative HPLC, whilst a C-18 RP column (SunFire, 4.6
x 150 mm or Agilent Zorbax, 4.6 x 150 mm) was used for analytical HPLC. Accurate
mass spectrometry (HRMS) was carried out on a Finnigan MAT 8400 mass spectrometer
(EI) for small molecules and on a Micromass LCT mass spectrometer (ESI-TOF) for
peptides. 1H NMR and 13C NMR spectroscopy were performed on a Mercury VX 400
machine at 400 and 100 MHz respectively. Chemical shifts are referenced to residual
solvent, reported in ppm on a δ scale and all coupling constants quoted in hertz (Hz).
3.4.2 Manual Fmoc-SPPS
Rink amide MBHA resin (192 mg, 0.1 mmol, 1.0 equiv., 0.52 mmol g-1 loading)
was vortexed in DCM (2.0 ml, 1 min.), allowed to swell (15 mins) and solvent removed.
This was followed by addition of DMF (2.0 ml), vortexing (1 min.) and removal of
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solvent. Deprotection of the Fmoc group was then performed. A solution of 20%
piperidine/DMF (1.5 ml, v/v) was added to the resin and the subsequent mixture vortexed
(2 mins) and solvent removed. This was then repeated a second time with vortexing for
15 minutes. After solvent had been removed, the resin was washed of any unreacted byproducts with DMF six times (2.0 ml, vortex 30 s). The desired amino acid or small
molecule (0.3 mmol, 3.0 equiv.) and coupling reagent (HCTU, 0.12 g, 0.3 mmol, 3.0
equiv.) were then dissolved in DMF (1.5 ml) and added to the deprotected resin. After
vortexing (30 s), DIPEA (111 μl, 0.6 mmol, 6.0 equiv.) was added and the final mixture
vortexed (1-2 hrs). The resin was then washed with DMF (2.0 ml, 30 s vortex) a final
four times. The deprotection/coupling cycle was then repeated unless the final amino acid
in the sequence had been added, in which case the peptide was washed with DCM five
times (2.0 ml, 30 s vortex) after washing with DMF and stored in a refrigerator. Removal
of the N-terminal Fmoc-group was carried out in the same fashion as the deprotection
cycle described previously, with resin washing occurring six times with DMF (2.0 ml, 30
s vortex) and four times with DCM (2.0 ml, 30 s vortex). Successful synthesis of the
desired peptide was then ascertained via a microcleave prior to full cleavage of the
peptide from the solid-support. This was carried out as follows: a solution of 95% TFA:
2.5% (iPr)3SiH: 2.5% H2O (300 μl) was added to a small number of resin beads (< 5 mg)
and the subsequent mixture vortexed (3 hrs). The clear liquid was then evaporated under
a stream of N2. Analytical HPLC was then performed to determine whether the correct
peptide had been synthesised. If the correct peptide had been obtained, a full cleavage
was performed using a mixture of 95% TFA: 2.5% (iPr)3SiH: 2.5% H2O (2.0 ml) for 5-7
hrs. The subsequent solution was cooled in an ice-bath alongside tert-butyl methyl ether
(TBMe, 40 ml). After 10 minutes, TBMe (20 ml) was added to the peptide solution,
leading to the formation of a white precipitate. The precipitate was cooled further (10
mins) and then centrifuged (7 mins). Decanting of the supernatant was followed by
addition of a second aliquot of TBMe (20 ml), vortexing (30 s) and final centrifugation (7
mins). After decanting, a white solid was obtained. This was then freeze-dried (20 mins)
to furnish crude peptide. Preparative HPLC was then used to purify the product peptide.
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3.4.3 Deprotection of the Alloc protecting group
The resin-bound peptide was vortexed in DCM (4.5 ml, 30 s) and allowed to swell
(10 mins). Deprotection was carried out under a blanket of N2. The swollen resin-bound
peptide was stirred (5 mins) before addition of PhSiH3 (296 μl, 2.4 mmol, 24.0 equiv.).
Further stirring (5 mins) ensued prior to treating with Pd(PPh3)4 (12 mg, 0.01 mmol, 0.1
equiv.). After 5 minutes, the solution was vortexed (5 mins), solvent removed and the
brown-coloured resin washed four times with DCM (2.0 ml, 30 s vortex). The procedure
was then repeated ab initio, with final resin washing occurring in the following order:
DCM, DMF, MeOH, DMF and DCM (all 2.0 ml, 30 s vortex).
3.4.4 Kaiser Test
A small number of resin beads (< 5 mg) were taken and treated with phenol:
EtOH (200 μl, 8:2 v/v), 0.001 M KCN(aq.): pyridine (200 μl, 2:98 v/v, 0.001 M aqueous
KCN) and ninhydrin in EtOH (200 μl, 5% w/v), respectively. Tentagel resin (< 5 mg)
was used as a control. Both test tubes were heated to 70 °C. The presence of free amine
was indicated by blue resin beads whilst yellow or clear resin beads indicated the
presence of protected amino groups.
3.4.5 Synthesis of peptidic- and peptidomimetic growth hormone secretagogues
All peptidomimetics were synthesised by the same general procedure described
previously unless otherwise noted.
H-Aib-His-D-2-Nal-D-Phe-Lys-NH2: Ipamorelin (1)
The product was purified by preparative HPLC (5-80% MeCN + 0.1% TFA). This
furnished a white powder (20.5 mg, 19%): 1H-NMR (400 MHz, CD3OD); D-2-Nal, DPhe, His: δ 7.99 (s, 1H, ArH), 7.80-7.76 (m, 1H, ArH), 7.71 (d, J = 8.6 Hz, 2H, ArH),
7.56 (s, 1H, ArH), 7.44-7.37 (m, 2H, ArH), 7.32-7.17 (m, 6H, ArH), 6.92 (s, 1H, His
Hδ), 4.58 (m, 3H, Hα), 3.30-3.21 (m, 1H, D-2-Nal Hβ), 3.15-3.00 (m, 2H, Hβ), 2.962.72 (m, 3H, Hβ), Lys: 4.11 (dd, J = 9.7, 4.2 Hz, 1H, Hα), 2.96-2.72 (m, 2H, Hε), 1.751.64 (m, 1H, Hβ), 1.54-1.40 (m, 3H, Hβ, 2Hδ), 1.05-0.93 (m, 2H, Hγ), Aib: 1.48 (s,
3H, CH3) 1.44 (s, 3H, CH3) ppm. ESI-LC-MS m/z 356.9 [M + 2H]2+; HRMS (ESI-MS)
calcd. for C38H50N9O5 [M + H]+ 712.3935, found 712.3959.

129
H-Aib-His-D-2-Nal-D-Phe-Lys(4-FB)-NH2: [Lys5(4-FB)]ipamorelin (2)
Purification by preparative HPLC (20-70% MeCN + 0.1% TFA) yielded a white
powder (15.4 mg, 15%): 1H-NMR (400 MHz, CD3OD); D-2-Nal, D-Phe, His, 4-FB: δ
7.91 (s, 1H, ArH), 7.85-7.77 (m, 3H, ArH, 2F-ArH), 7.70 (d, J = 7.9 Hz, 2H, ArH),
7.54 (s, 1H, ArH), 7.45-7.40 (m, 2H, ArH), 7.29-7.19 (m, 6H, ArH), 7.14-7.07 (m,
2H, 2F-ArH), 6.93 (s, 1H, His Hδ), 4.65-4.52 (m, 3H, Hα), 3.30-3.27 (m, 1H, Hβ), 3.23
(d, J = 4.0 Hz, 1H, Hβ), 3.10 (dd, J = 13.5, 7.8 Hz, 1H, Hβ), 3.04-2.74 (m, 3H, Hβ),
Lys: 4.12 (dd, J = 9.8, 4.2 Hz, 1H, Hα), 3.04-2.74 (m, 2H, Hε), 1.77-1.67 (m, 1H, Hβ),
1.58-1.42 (m, 3H, Hβ, 2Hδ), 1.14-1.03 (m, 2H, Hγ), Aib: 1.50 (s, 3H, CH3), 1.46 (s,
3H, CH3) ppm. ESI-LC-MS m/z 418.0 [M + 2H]2+; HRMS (ESI-MS) calcd. for
C45H53FN9O6 [M + H]+ 834.4103, found 834.4133.
H-Aib-His-D-2-Nal-D-Phe-Lys(AEEA-4-FB)-NH2:[Lys5(AEEA-4-FB)]ipamorelin (3)
Peptide purification by preparative HPLC (20-60% MeCN + 0.1% TFA)
delivered an off-white powder (9.2 mg, 8%): 1H-NMR (400 MHz, CD3OD); His, D-2Nal, D-Phe, 4-FB: δ 7.93 (s, 1H, ArH), 7.86-7.77 (m, 3H, ArH, 2F-ArH), 7.71 (d, J =
8.0 Hz, 2H, ArH), 7.55 (s, 1H, ArH), 7.46-7.41 (m, 2H, ArH), 7.31-7.18 (m, 6H,
ArH), 7.17-7.10 (m, 2H, F-ArH), 6.94 (s, 1H, His Hδ), 4.65-4.58 (m, 2H, Hα), 4.55 (t,
J = 7.5 Hz, 1H, Hα), 3.16-2.76 (m, 6H, Hβ), Lys: 4.10 (dd, J = 9.7, 4.2 Hz, 1H, Hα),
3.16-2.76 (m, 2H, Hε), 1.72-1.62 (m, 1H, Hβ), 1.52-1.43 (m, 1H, Hβ), 1.41-1.30 (m,
2H, Hδ), 1.07-0.97 (m, 2H, Hγ), AEEA linker: 3.93 (s, 2H, NHCOCH2O), 3.65-3.61
(m, 6H, CH2), 3.53 (t, J = 5.6 Hz, 2H, CH2), Aib: 1.50 (s, 3H, CH3), 1.47 (s, 3H,
CH3) ppm. ESI-LC-MS m/z 490.4 [M + 2H]2+; HRMS (ESI-MS) calcd. for
C51H64FN10O9 [M + H]+ 979.4842, found 979.4868.
H-Aib-His-D-2-Nal-D-2-Thi-Lys(4-FB)-NH2: [D-2-Thi4,Lys5(4-FB)]ipamorelin (4)
The title peptide was synthesized by automated peptide synthesis and purified by
preparative HPLC (20-80% MeCN + 0.1% TFA). This furnished a white solid (4.20 mg,
4%): 1H-NMR (400 MHz, (CD3)2SO); δ 8.83 (s, 1H, ArH), 8.59 (d, J = 8.1 Hz, 1H,
NH), 8.42 (t, J = 5.6 Hz, 1H, NH), 8.29 (d, J = 9.3 Hz, 1H, NH), 8.20 (d, J = 8.2 Hz,
1H, NH), 8.09 (d, J = 8.9 Hz, 1H, NH), 7.99 (s, 2H, NH), 7.86-7.81 (m, 2H, F-ArH),
7.79-7.75 (m, 1H, ArH), 7.72 (dd, J = 8.7, 3.7 Hz, 2H, ArH), 7.65 (s, 1H, ArH), 7.417.37 (m, 2H, ArH), 7.35-7.31 (m, 2H, ArH, NH), 7.26 (dd, J = 4.8, 1.5 Hz, 1H, Thi-
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H), 7.22-7.16 (m, 2H, F-ArH), 7.05 (s, 2H, NH, ArH), 6.88-6.84 (m, 2H, Thi-H),
4.73-4.66 (m, 1H, Hα), 4.62-4.51 (m, 2H, Hα), 4.19-4.12 (m, 1H, Lys-Hα), 3.21-3.12
(m, 4H, 2Hε, 2Hβ), 3.06-2.96 (m, 1H, Hβ), 2.87-2.77 (m, 2H, Hβ), 2.62-2.49 (m, 1H,
Hβ), 1.66-1.56 (m, 1H, Lys-Hβ), 1.50-1.36 (m, 3H, Lys-Hβ, 2Hδ), 1.26 (s, 3H, CH3),
1.20-1.10 (m, 2H, Hγ), 1.16 (s, 3H, CH3), ppm. ESI-LC-MS m/z 420.8 [M + 2H]2+;
HRMS (ESI-MS) calcd. for C43H51FN9O6S [M + H]+ 840.3667 found 840.3693.
H-Inp-His-D-2-Nal-D-Phe-Lys(4-FB)-NH2: [Inp1,Lys5(4-FB)]ipamorelin (5)
The title peptide was synthesized via automated peptide synthesis and purified by
preparative HPLC (20-70% MeCN + 0.1% TFA). The title compound was acquired as a
white solid (6.30 mg, 6%): 1H-NMR (400 MHz, (CD3)2SO); δ 8.79 (s, 1H, His Hε), 8.72
(s, 1H, NH), 8.44 (dd, J = 10.8, 6.4 Hz, 2H, NH), 8.19 (d, J = 7.8 Hz, 1H, NH), 8.178.10 (m, 2H, NH), 7.87-7.81 (m, 2H, F-ArH), 7.80-7.76 (m, 1H, ArH), 7.71 (d, J =
7.9 Hz, 2H, ArH), 7.63 (s, 1H, ArH), 7.42-7.35 (m, 2H, ArH), 7.33-7.29 (m, 2H, NH),
7.22-7.18 (m, 6H, ArH), 7.17-7.11 (m, 2H, F-ArH), 7.06 (s, 1H, NH), 6.96 (s, 1H, His
Hδ), 4.64-4.56 (m, 1H, Hα), 4.55-4.44 (m, 2H, Hα), 4.15-4.07 (m, 1H, Lys-Hα), 3.193.07 (m, 5H, CH2), 2.94 (dd, J = 13.6, 5.9 Hz, 1H, CH2), 2.87-2.67 (m, 5H, CH2),
2.58-2.48 (m, 1H, CH2), 2.38-2.29 (m, 1H, Hα), 1.67-1.34 (m, 8H, CH2), 1.15-1.00
(m, 2H, CH2), ppm. ESI-LC-MS m/z 430.9 [M + 2H]2+; HRMS (ESI-MS) calcd. for
C47H55FN9O6 [M + H]+ 860.4259 found 860.4284.
H-Inp-His-D-2-Nal-D-2-Nal-Lys(4-FB)-NH2: [Inp1,D-2-Nal4,Lys5(4-FB)]ipamorelin
(6)
The title peptide was made by automated peptide synthesis and purified by
preparative HPLC (20-80% MeCN + 0.1% TFA). This delivered a white solid (11.3 mg,
10%): 1H-NMR (400 MHz, (CD3)2SO); δ 8.77 (s, 1H, His Hε), 8.51 (d, J = 7.5 Hz, 2H,
NH), 8.36 (t, J = 5.5 Hz, 1H, NH), 8.19-8.10 (m, 2H, NH), 8.05 (d, J = 8.7 Hz, 1H,
NH), 7.85-7.79 (m, 3H, 2F-ArH, ArH), 7.79-7.74 (m, 3H, ArH), 7.73 (s, 1H, ArH),
7.70 (s, 1H, ArH), 7.68 (d, J = 2.4 Hz, 2H, ArH), 7.59 (s, 1H, ArH), 7.43-7.35 (m,
5H, ArH), 7.31-7.27 (m, 2H, NH), 7.20-7.13 (m, 2H, F-ArH), 7.05 (s, 1H, NH), 6.93
(s, 1H, His Hδ), 4.67-4.60 (m, 2H, Hα), 4.52-4.44 (m, 1H, Hα), 4.16-4.08 (m, 1H, LysHα), 3.17-2.93 (m, 7H, CH2), 2.88-2.66 (m, 4H, CH2), 2.53-2.47 (m, 1H, CH2), 2.342.25 (m, 1H, Hα), 1.63-1.34 (m, 6H, CH2), 1.32-1.23 (m, 2H, CH2), 1.07-0.95 (m, 2H,
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CH2), ppm. ESI-LC-MS m/z 455.9 [M + 2H]2+; HRMS (ESI-MS) calcd. for
C51H57FN9O6 [M + H]+ 910.4416 found 910.4400.
H-Inp-His-D-2-Nal-D-2-Thi-Lys(4-FB)-NH2: [Inp1,D-2-Thi4,Lys5(4-FB)]ipamorelin
(7)
The title peptide was prepared by automated peptide synthesis and purified by
preparative HPLC (20-80% MeCN + 0.1% TFA). This furnished a white powder (14.0
mg, 13%): 1H-NMR (400 MHz, CD3OD); His, D-2-Nal, D-2-Thi, 4-FB: δ 8.23 (s, 1H,
His Hε), 7.86-7.81 (m, 2H, F-ArH), 7.80-7.77 (m, 1H, ArH), 7.73 (dd, J = 8.8, 3.3 Hz,
2H, ArH), 7.59 (s, 1H, ArH), 7.45-7.39 (m, 2H, ArH), 7.27 (dd, J = 8.5, 1.6 Hz, 1H,
ArH), 7.22 (dd, J = 5.0, 1.2 Hz, 1H, Thi-ArH), 7.15-7.08 (m, 2H, F-ArH), 6.92 (s, 1H,
His Hδ), 6.91-6.85 (m, 2H, Thi-ArH), 4.61 (dd, J = 10.3, 4.4 Hz, 1H, Hα), 4.53-4.47
(m, 2H, Hα), 4.22 (dd, J = 9.8, 4.2 Hz, 1H, Lys-Hα), 3.39-3.29 (m, 6H, CH2), 3.263.22 (m, 1H, CH2), 3.01-2.80 (m, 5H, CH2), 2.53-2.44 (m, 1H, Inp-Hα), 1.87-1.50 (m,
8H, CH2), 1.35-1.22 (m, 2H, CH2), ppm. ESI-LC-MS m/z 433.8 [M + 2H]2+; HRMS
(ESI-MS) calcd. for C45H53FN9O6S [M + H]+ 866.3824 found 866.3850.
H-Ala-His-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2: GHRP-1 (8)
The product was purified by preparative HPLC (15-80% MeCN + 0.1% TFA).
This yielded a white powder (26.4 mg, 19%): 1H-NMR (400 MHz, CD3OD); His, D-2Nal, Trp, D-Phe: δ 8.41 (s, 1H, His Hε), 7.81-7.71 (m, 3H, ArH), 7.65 (s, 1H, ArH), 7.49
(d, J = 7.8 Hz, 1H, ArH), 7.46-7.40 (m, 2H, ArH), 7.35 (dd, J = 8.4, 1.7 Hz, 1H, ArH),
7.31 (d, J = 8.1 Hz, 1H, ArH), 7.24-7.13 (m, 3H, ArH), 7.10-7.04 (m, 4H, ArH), 7.00 (t, J
= 7.5 Hz, 1H, ArH), 6.89 (d, J = 0.8 Hz, 1H, His Hδ), 4.67-4.60 (m, 2H, Hα), 4.38 (t, J =
7.4 Hz, 1H, Hα), 4.32 (t, J = 7.7 Hz, 1H, Hα), 3.25-2.68 (m, 8H, Hβ), Ala, Ala: 4.17-4.10
(m, 1H, Hα), 3.94 (q, J = 7.0 Hz, 1H, Hα), 1.35 (d, J = 7.1 Hz, 3H, CH3), 1.10-1.01 (m,
3H, CH3), Lys: 4.17-4.10 (m, 1H, Hα), 3.25-2.68 (m, 2H, Hε), 1.81-1.70 (m, 1H, Hβ),
1.58-1.45 (3H, Hβ, 2Hδ), 1.10-1.01 (m, 2H, Hγ), ppm. ESI-LC-MS m/z 478.5 [M + 2H]2+;
HRMS (ESI-MS) calcd. for C51H63N12O7 [M + H]+ 955.4943 found 955.4964.
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H-D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2: GHRP-2 (9)
Purification by preparative HPLC (25-70% MeCN + 0.1% TFA) delivered the
title peptide as a white powder (19.7 mg, 17%): 1H-NMR (400 MHz, CD3OD); D-2-Nal,
Trp, D-Phe: δ 7.76 (d, J = 9.2 Hz, 2H, ArH), 7.73 (s, 1H, ArH), 7.65 (s, 1H, ArH), 7.517.47 (m, 1H, ArH), 7.44-7.37 (m, 2H, ArH), 7.35 (dd, J = 8.4, 1.7 Hz, 1H, ArH), 7.257.14 (m, 4H, ArH), 7.09-7.01 (m, 4H, ArH), 7.00 (s, 1H, ArH), 4.77 (dd, J = 10.9, 4.6
Hz, 1H, Hα), 4.49 (t, J = 6.8 Hz, 1H, Hα), 4.36 (t, J = 7.6 Hz, 1H, Hα), 3.11 (t, J = 6.7 Hz,
2H, Hβ), 3.07 (d, J = 4.5 Hz, 1H, Hβ), 2.88-2.70 (m, 3H, Hβ), D-Ala, Ala: 4.23 (q, J = 7.1
Hz, 1H, Hα), 3.79 (q, J = 7.0 Hz, 1H, Hα), 1.27 (d, J = 7.2 Hz, 3H, CH3), 1.00 (d, J = 7.1
Hz, 3H, CH3), Lys: 4.16 (dd, J = 10.3, 4.1 Hz, 1H, Hα), 2.88-2.70 (m, 2H, Hε), 1.82-1.72
(m, 1H, Hβ), 1.56-1.43 (m, 3H, Hβ, 2Hδ), 1.07-0.96 (m, 2H, Hγ), ppm. ESI-LC-MS m/z
409.9 [M + 2H]2+; HRMS (ESI-MS) calcd. for C45H55N9O6Na [M + Na]+ 840.4204 found
840.4173.
H-His-D-Trp-Ala-Trp-D-Phe-Lys-NH2: GHRP-6 (10)
Purification by preparative HPLC (15-80% MeCN + 0.1% TFA) gave a white
powder (19.7 mg, 14%): 1H-NMR (400 MHz, CD3OD); His, D-Trp, Trp, D-Phe: δ 8.46
(s, 1H, His Hε), 7.54 (d, J = 7.8 Hz, 1H, ArH), 7.46 (d, J = 7.8 Hz, 1H, ArH), 7.28 (t, J =
7.7 Hz, 2H, ArH), 7.23-7.13 (m, 4H, ArH), 7.12-6.92 (m, 8H, 7ArH, His Hδ), 4.47 (t, J =
7.4 Hz, 2H, Trp Hα), 4.35 (t, J = 6.7 Hz, 1H, Hα), 4.28 (t, J = 7.9 Hz, 1H, Hα), 3.22-3.14
(m, 3H, Hβ), 3.14-3.02 (m, 3H, Hβ), 2.83 (d, J = 8.6 Hz, 2H, Hβ), Lys: 4.03 (dd, J = 10.3,
3.9 Hz, 1H, Hα), 2.75 (t, J = 6.8 Hz, 2H, Hε), 1.76-1.63 (m, 1H, Hβ), 1.51-1.39 (m, 3H,
Hβ, 2Hδ), 0.97-0.88 (m, 2H, Hγ), Ala: 3.91 (q, J = 7.2 Hz, 1H, Hα), 0.86 (d, J = 7.3 Hz,
3H, CH3) ppm. ESI-LC-MS m/z 437.4 [M + 2H]2+; HRMS (ESI-MS) calcd. for
C46H57N12O6 [M + H]+ 873.4524 found 873.4531.
H-His-D-Trp-Ala-Trp-D-Phe-Lys(4-FB)-NH2: [Lys6(4-FB)]GHRP-6 (11)
The product was purified by preparative HPLC (15-80% MeCN + 0.1% TFA).
This yielded a white powder (9.60 mg, 7%): 1H-NMR (400 MHz, CD3OD); His, D-Trp,
Trp, D-Phe, 4-FB: δ 8.50 (s, 1H, His Hε), 7.88-7.80 (m, 2H, F-ArH), 7.57 (d, J = 7.9
Hz, 1H, ArH), 7.49 (d, J = 7.8 Hz, 1H, ArH), 7.30 (t, J = 8.2 Hz, 2H, ArH), 7.26-6.95
(m, 14H, 13ArH, His Hδ), 4.53-4.46 (m, 2H, Hα), 4.37-4.30 (m, 2H, Hα), 3.26-3.04
(m, 6H, Hβ), 2.87 (d, J = 8.0 Hz, 2H, Hβ), Lys: 4.04 (dd, J = 10.2, 4.0 Hz, 1H, Hα),
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3.26-3.04 (m, 2H, Hε), 1.81-1.70 (m, 1H, Hβ), 1.58-1.43 (m, 3H, 2Hδ, Hβ), 1.06-0.97
(m, 2H, Hγ), Ala: 3.94 (q, J = 7.3 Hz, 1H, Hα), 0.87 (d, J = 7.3 Hz, 3H, CH3) ppm.
ESI-LC-MS m/z 498.4 [M + 2H]2+; HRMS (ESI-MS) calcd. for C53H59FN12O7Na [M +
Na]+ 1017.4511 found 1017.4522.
H-His-D-Trp-Ala-Trp-D-Phe-Dpr-NH2: [Dpr6]GHRP-6 (12)
Purification by preparative HPLC (15-80% MeCN + 0.1% TFA) furnished the
title peptide as a white powder (4.7 mg, 3 %): 1H-NMR (400 MHz, CD3OD); 8.49 (s, 1H
His Hε), 7.55 (d, J = 7.9 Hz, 1H, ArH), 7.46 (d, J = 7.9 Hz, 1H, ArH), 7.30 (t, J = 8.6 Hz,
2H, ArH), 7.21-7.12 (m, 3H, ArH), 7.11-7.04 (m, 3H, ArH), 7.02-6.92 (m, 5H, ArH),
6.89 (d, J = 1.0 Hz, 1H, His Hδ), 4.62 (t, J = 6.8 Hz, 1H, Hα), 4.52 (t, J = 7.9 Hz, 1H, Hα),
4.42-4.33 (m, 2H, Hα), 4.28 (t, J = 6.7 Hz, 1H, Dpr-Hα), 4.00 (q, J = 7.3 Hz, 1H, Ala-Hα),
3.24-3.11 (m, 3H, CH2), 3.12-2.92 (m, 5H, CH2), 2.89-2.76 (m, 2H, CH2), 0.94 (d, J = 7.3
Hz, 3H, Ala-CH3), ppm. ESI-LC-MS m/z 831.4 [M + H]+; HRMS (ESI-MS) calcd. for
C43H51N12O6 [M + H]+ 831.4055 found 831.4070.
H-His-D-Trp-Ala-Trp-D-Phe-Dpr(4-FB)-NH2: [Dpr6(4-FB)]GHRP-6 (13)
Preparative HPLC (25-70% MeCN + 0.1% TFA) gave the title compound as a
white solid (19.8 mg, 14%): 1H-NMR (400 MHz, CD3OD); His, D-Trp, Trp, D-Phe, 4FB: δ 8.58 (d, J = 1.3 Hz, 1H, His Hε), 7.82-7.75 (m, 2H, F-ArH), 7.52 (d, J = 7.9 Hz,
1H, ArH), 7.40 (d, J = 7.9 Hz, 1H, ArH), 7.27 (dd, J = 8.6, 1.5 Hz, 2H, ArH), 7.157.07 (m, 5H, ArH), 7.06-6.98 (m, 6H, ArH), 6.97-6.89 (m, 3H, 2ArH, His Hδ), 4.544.45 (m, 1H, Hα), 4.44-4.30 (m, 3H, Hα), 3.22-2.98 (m, 6H, Hβ), 2.93-2.74 (m, 2H,
Hβ), Dpr: 4.54-4.45 (m, 1H, Hα), 3.67 (dd, J = 13.8, 5.6 Hz, 1H, Hβ), 3.54 (dd, J =
13.8, 7.8 Hz, 1H, Hβ), Ala: 3.93 (q, J = 7.3 Hz, 1H, Hα), 0.86 (d, J = 7.3 Hz, 3H, CH3)
ppm. ESI-LC-MS m/z 477.4 [M + 2H]2+; HRMS (ESI-MS) calcd. for C50H54FN12O7 [M
+ H]+ 953.4223 found 953.4237.
H-Inp-D-2-Nal-D-2-Nal-Phe-Lys-NH2: G7039* (14)
Purification of the peptide proceeded through preparative HPLC (25-80% MeCN
+ 0.1% TFA). The title compound was obtained as a white powder (6.70 mg, 7%): 1HNMR (400 MHz, CD3OD); 7.80-7.76 (m, 1H, ArH), 7.74 (dd, J = 6.1, 2.2 Hz, 2H, ArH),
7.70 (dd, J = 8.5, 3.5 Hz, 3H, ArH), 7.56 (s, 1H, ArH), 7.50 (s, 1H, ArH), 7.46-7.35 (m,
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4H, ArH), 7.26 (dd, J = 8.5, 1.5 Hz, 1H, ArH), 7.20-7.10 (m, 6H, ArH), 4.66-4.56 (m,
2H, Hα), 4.50 (dd, J = 9.3, 5.4 Hz, 1H, Hα), 4.30 (dd, J = 9.5, 4.7 Hz, 1H, Lys-Hα), 3.202.80 (m, 10H, CH2), 2.78-2.64 (m, 2H, CH2), 2.33-2.24 (m, 1H, Inp-Hα), 1.92-1.82 (m,
1H, CH2), 1.74-1.65 (m, 1H, CH2), 1.64-1.44 (m, 5H, CH2), 1.44-1.24 (m, 3H, CH2),
ppm. ESI-LC-MS m/z 399.8 [M + 2H]2+; HRMS (ESI-MS) calcd. for C47H56N7O5 [M +
H]+ 798.4343 found 798.4339. HRMS data and yield has been reported previously[35],
whereas the 1H-NMR data has not.
H-Inp-D-2-Nal-D-2-Nal-Phe-Lys(4-FB)-NH2: [Lys5(4-FB)]G7039 (15)
Preparative HPLC (35-80% MeCN + 0.1% TFA) furnished the title compound as
a white solid (5.90 mg, 6%): 1H-NMR (400 MHz, (CD3)2SO); δ 8.50 (d, J = 8.2 Hz, 1H,
NH), 8.45 (t, J = 5.5 Hz, 1H, NH), 8.39 (s, 1H, NH), 8.15-8.09 (m, 2H, NH), 8.04 (d,
J = 8.4 Hz, 1H, NH), 7.86-7.82 (m, 2H, F-ArH), 7.82-7.76 (m, 2H, ArH), 7.75-7.66
(m, 4H, ArH), 7.58 (s, 1H, ArH), 7.48 (s, 1H, ArH), 7.45-7.38 (m, 4H, ArH), 7.31
(dd, J = 8.5, 1.5 Hz, 1H, ArH), 7.28 (s, 1H, ArH), 7.26 (s, 1H, NH), 7.24-7.17 (m, 5H,
ArH), 7.15-7.08 (m, 2H, ArH), 7.04 (s, 1H, NH), 4.66-4.60 (m, 1H, Hα), 4.60-4.53
(m, 2H, Hα), 4.20-4.14 (m, 1H, Lys-Hα), 3.25-3.14 (m, 2H, CH2), 3.13-3.02 (m, 3H,
CH2), 2.98-2.91 (m, 1H, CH2), 2.90-2.83 (m, 1H, CH2), 2.81-2.56 (m, 5H, CH2), 2.302.22 (m, 1H, Inp-Hα), 1.75-1.65 (m, 1H, CH2), 1.62-1.55 (m, 1H, CH2), 1.54-1.43 (m,
6H, CH2), 1.38-1.19 (m, 2H, CH2), ppm. ESI-LC-MS m/z 452.5 [M + 4H - F]2+; HRMS
(ESI-MS) calcd. for C54H59FN7O6 [M + H]+ 920.4511 found 920.4529.
H-Inp-D-2-Nal-D-2-Nal-1-Nal-Lys-NH2: [1-Nal4]G7039 (16)
Peptide purification by preparative HPLC (25-80% MeCN + 0.1% TFA)
delivered a white powder (24.9 mg, 23%): 1H-NMR (400 MHz, CD3OD); δ 8.12 (d, J =
8.4 Hz, 1H, ArH), 7.84 (d, J = 7.8 Hz, 1H, ArH), 7.78-7.72 (m, 2H, ArH), 7.68 (d, J =
8.5 Hz, 3H, ArH), 7.62-7.46 (m, 5H, ArH), 7.43-7.35 (m, 5H, ArH), 7.30 (d, J = 6.4
Hz, 1H, ArH), 7.27-7.21 (m, 2H, ArH), 7.02 (dd, J = 8.4, 1.5 Hz, 1H, ArH), 4.69 (dd,
J = 9.4, 5.4 Hz, 1H, Hα), 4.65-4.55 (m, 2H, Hα), 4.32 (dd, J = 9.4, 4.8 Hz, 1H, LysHα), 3.65 (dd, J = 14.4, 5.4 Hz, 1H, CH2), 3.20-3.10 (m, 2H, CH2), 3.05-2.94 (m, 3H,
CH2), 2.92-2.80 (m, 5H, CH2), 2.76-2.62 (m, 2H, CH2), 2.30-2.23 (m, 1H, Inp-Hα),
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1.92-1.81 (m, 1H, CH2), 1.75-1.29 (m, 9H, CH2), ppm. ESI-LC-MS m/z 424.8 [M +
2H]2+; HRMS (ESI-MS) calcd. for C51H58N7O5 [M + H]+ 848.4499, found 848.4501.
H-Inp-D-2-Nal-D-2-Nal-1-Nal-Lys(4-FB)-NH2: [1-Nal4,Lys5(4-FB)]G7039 (17)
The product was purified by preparative HPLC (25-90% MeCN + 0.1% TFA)
which yielded a white powder (9.80 mg, 9%): 1H-NMR (400 MHz, (CD3)2SO); δ 8.64 (d,
J = 8.3 Hz, 1H, NH), 8.46 (t, J = 5.5 Hz, 1H, NH), 8.33 (s, 1H, NH), 8.25 (d, J = 8.4
Hz, 1H, ArH), 8.13 (d, J = 8.0 Hz, 1H, NH), 8.09 (d, J = 7.5 Hz, 1H, NH), 8.03 (d, J
= 8.5 Hz, 1H, NH), 8.01-7.97 (m, 1H, NH), 7.89 (d, J = 8.2 Hz, 1H, ArH), 7.86-7.80
(m, 2H, F-ArH), 7.79-7.72 (m, 3H, ArH), 7.71-7.66 (m, 2H, ArH), 7.58-7.50 (m, 4H,
ArH), 7.44 (d, J = 6.9 Hz, 1H, ArH), 7.42-7.34 (m, 5H, ArH), 7.31-7.25 (m, 2H,
ArH), 7.21-7.15 (m, 3H, 2F-ArH, ArH), 7.07 (s, 1H, NH), 7.02 (d, J = 8.4 Hz, 1H,
ArH), 4.72-4.65 (m, 1H, Hα), 4.62-4.50 (m, 2H, Hα), 4.19 (dd, J = 13.3, 8.4 Hz, 1H,
Lys-Hα), 3.61 (dd, J = 14.3, 3.9, 1H, CH2), 3.24-3.00 (m, 5H, CH2), 2.97-2.89 (m, 1H,
CH2), 2.82-2.49 (m, 5H, CH2), 2.29-2.19 (m, 1H, Inp-Hα), 1.78-1.66 (m, 1H, CH2),
1.66-1.54 (m, 1H, CH2), 1.53-1.40 (m, 5H, CH2), 1.40-1.16 (m, 2H, CH2), ppm. ESILC-MS m/z 477.4 [M + 4H - F]2+; HRMS (ESI-MS) calcd. for C58H61FN7O6 [M + H]+
970.4667 found 970.4693.
3.4.6 Synthesis of 4-(tert-butoxycarbonyl)-N,N,N-trimethylbenzenammonium triflate
(20)
4-dimethylaminobenzoic acid (1.00 g, 6.05 mmol, 1.0 equiv.) was added to THF
(50 ml) and the resultant mixture stirred and cooled to 0°C. After 15 minutes,
trifluoroacetic anhydride (1.85 ml, 13.3 mmol, 2.2 equiv.) was added dropwise and the
consequent blue solution stirred (35 mins). Addition of tBuOH (11.4 ml, 119 mmol, 19.7
equiv.) was followed by further stirring at room temperature (2 hrs). The solution was
then poured into saturated NaHCO3 (250 ml) and extracted with DCM (3x 100 ml, 3x 50
ml). The combined organic layers were dried (MgSO4), filtered by gravity and residual
solvent removed by rotary evaporation. This delivered a black oil which was eluted
through a silica pad (DCM, 60 ml) and solvent removed by concentration in vacuo. The
final yellow oil (1.12 g, crude) was then re-dissolved in DCM (dry, 30 ml) and cooled to
0°C under a blanket of N2. This was followed by the addition of MeOTf (0.86 ml, 7.61
mmol, 1.5 equiv.) and stirring at 0°C (1 hr). The reaction mixture was then poured into an
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ice-cold solution of Et2O (200 ml) which caused instant precipitation of the product salt
as a white crystalline solid (740 mg, 38%): 1H-NMR (400 MHz, CD3COCD3); δ 8.24
(d, J = 9.3 Hz, 2H), 8.18 (d, J = 9.3 Hz, 2H), 3.91 (s, 9H, NMe3), 1.60 (s, 9H,
OC(CH3)3); 13C-NMR (100 MHz, CD3COCD3); δ 205.5 (CO) 163.6 (ArC), 133.7
(ArC), 131.0 (ArC), 120.9 (ArC), 81.7, 56.9, 27.3 (CH3CO) ppm. ESI-MS m/z 165.1
[C10H13O2]+; HRMS (ESI-MS) calcd for C14H22NO2 [M-CF3O3S]+ 236.1651, found
236.1658.
3.4.7 Receptor-ligand binding assay
Competitive binding assays were carried out using HEK293/GHS-R1a cells with
[125I]ghrelin as the competitive radioligand. A solution of binding buffer (50 ml, pH 7.4)
was made up by adding 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES, 0.3
g, 25 mM), MgCl2 (0.051 g, 5 mM), CaCl2 (7.4 x 10-3 g, 1 mM), EDTA (0.015 g, 2.5
mM) and BSA (0.2 g, 0.4%) to distilled water. pH adjusted with 5 M HCl. The resultant
solution was filtered through a 0.22 μm syringe filter and kept on ice.
An aliquot of frozen cells (HEK293T cells transiently transfected with GHS-R1a
by means of calcium phosphate transfection for 48 hours before being harvested and
fragmented by 50, 000 g centrifugation and frozen to 2 million cells per vial in 10 %
DMSO in FBS) was thawed to room temperature (1.5 x 106 cells/pellet), centrifuged
(3000 rpm, 10 mins, room temperature) and the subsequent cell pellet re-suspended in
binding buffer (2 ml) and placed on ice. A stock solution of peptide/peptidomimetic was
diluted in binding buffer to acquire final concentrations between 10-5 to 10-11 M and
added (30 µl) to these cells (50 µl) in triplicate.
[125I]-ghrelin (10 µl) was added to binding buffer (3 ml) and vortexed. An aliquot
of this [125I]-ghrelin solution (20 µl) was counted on a Cobra II Auto-Gamma gamma
counter and initial volume adjusted to obtain 14000-17000 counts per minute (cpm) per
20 µl aliquot. [125I]-ghrelin (20 µl) was added to each peptide/peptidomimetic-cell
mixture, to give a final volume of 300 µl in binding buffer. Each solution concentration
was vortexed, followed by agitation (550 rpm, 20 mins, 37 °C). After 20 minutes, samples
were spun (13 000 rpm, 5 mins, 4 °C) and placed on ice. The supernatant was removed
and the cell pellet rinsed with ice-cold Tris-HCl (200 µl, 50 mM, pH 7.4). The samples
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were spun again (13,000 rpm, 5 mins, 4 °C), cooled on ice, supernatant removed and cell
pellet counted using a Cobra II Auto-Gamma gamma counter.
All binding assays were performed in triplicate for each concentration of
peptide/peptidomimetic. Binding buffer (300 µl) and [125I]-ghrelin (20 µl) alone were
used as background controls. [125I]-ghrelin (20 µl) and cells (50 µl) in binding buffer (230
µl) were used to calculate the percentage of bound [125I]-ghrelin displaced by each
concentration of peptide/peptidomimetic.
3.4.8 Computation of partition coefficients (LogP) for peptides and peptidomimetics
The n-octanol/water partition coefficients for all peptides and peptidomimetics
were calculated using ACD/LogP prediction software from ACD/ChemSketch
(Freeware) 2017.2.1.
3.4.9 Calcium flux dose-response assay
This assay was used to determine the EC50 value for [1-Nal4,Lys5(4-FB)]G7039 in
terms of intracellular Ca2+ release, with ghrelin used as the control ligand. The
peptidomimetic compound was dissolved in DMSO (1 ml) at a concentration of 250 μM
and solubility tested in Hank’s balanced salt solution (HBSS): 1.26 mM CaCl2, 0.493
mM MgCl2·6H2O, 0.407 mM MgSO4·7H2O, 5.33 mM KCl, 0.441 mM KH2PO4, 4.17
mM NaHCO3, 137.9 mM NaCl, 0.338 mM Na2HPO4, 5.56 mM D-Glucose, 20 mM
HEPES, pH 7.4 with a final concentration of 1.2 % DMSO. Following successful
solubility, human recombinant GHS-R1a calcium-optimised stable cell lines (chem-1
cells) were loaded with a fluorescent calcium dye (Fluo-8 NW from ABD Bioquest
21080) and calcium flux detected in response to the agonist by a Molecular Devices
FLIPRTETRA instrument in a modified HBSS buffer (20 mM HEPES, 2.5 mM Probenecid,
pH 7.4). Fluorescence values underwent baseline correction and the percentage activation
was normalised to the maximum response (Emax) of the control ligand ghrelin. The
agonist assay was performed for a total of 180 seconds and each assay concentration was
performed in duplicate.
3.4.10 Serum stability study
A Waters Oasis HLB plate was used for both collection and extraction. The
peptidomimetic [1-Nal4,Lys5(4-FB)]G7039 was incubated in a solution of 25% human
serum in PBS for 24 hours. Aliquots were removed at 0, 20, 60, 240, 420, and 1440
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minutes, with each time-point performed in triplicate. These aliquots were then mixed
with 4% (v/v) ammonium hydroxide (NH4OH) in water to denature peptidomimeticserum (albumin) interactions. [1-Nal4,Lys5(4-FB)]G7039 was then extracted from human
serum using 20% MeOH/2% HCO2H in water and quantified by UHPLC-MS. The
amount was then expressed as the percentage of the area under the curve (AUC) in the
UV chromatogram relative to time 0, plotted against time (minutes) and data fitted to a
curve of exponential decay to determine the serum half-life (t1/2).
3.4.11 Radiochemistry
General information
All reagents and solvents used for radiosynthesis were purchased from SigmaAldrich unless otherwise specified. 18F-fluoride was produced via the 18O(p,n) 18F
reaction in a GE PETtrace 880 cyclotron (Lawson Health Research Institute, London,
Ontario, Canada). A Biotage V-10 evaporator was used to remove solvent. A Waters
HPLC with a 1525 binary pump system (solvent A = MeCN + 0.1% TFA, solvent B =
H2O + 0.1% TFA) and two detectors (Waters 2487 Dual λ absorbance detector set at 254
nm and a radioactive flow count detector) were utilised for product analysis and
purification. An analytical column (Agilent Eclipse XDB-C18, 4.6 × 150 mm, 5 μm) was
used for determining radiochemical purity and molar activity of [1-Nal4,Lys5(4-[18F]FB)]G7039. A semi-preparative column (Agilent Zorbax SB-C18, 9.4 × 150 mm, 5 μm)
was used for the purification of [18F]SFB and [1-Nal4,Lys5(4-[18F]-FB)]G7039.
Synthesis of [18F]FBA
Scheme 1 shows the synthetic pathway to [18F]FBA. Aqueous [18F]fluoride was
trapped on a Waters Sep-Pak Accell Plus Light (46 mg) QMA Carbonate cartridge preactivated with MilliQ water (10 ml). The initial radioactivity of the cartridge was
measured using a dose calibrator (980-1300 MBq) A solution of acetonitrile/H2O (1 ml,
25:75, v/v) containing potassium carbonate (2.1 mg, 0.015 mmol, 2.6 eq.) and
4,7,13,16,21,24-Hexaoxa-1,10-diazabicyclo[8.8.8]hexacosane (6.0 mg, 0.016 mmol, 2.8
eq.) was used to elute [18F]fluoride into the reaction vial. The solvent was removed
azeotropically under vacuum at 50 °C. [18F]fluoride was then dried a further two times
under the aforementioned conditions by adding anhydrous acetonitrile (1 ml). 4-Tert-
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butoxycarbonyl)-N,N,N-trimethylbenzenammonium triflate (2.0 mg, 0.0057 mmol, 1.0
eq.) in anhydrous DMSO (400 μl) was added to dried [18F]F- and the subsequent solution
heated for 10 mins at 120 °C. Aqueous HCl (1 ml, 6 M) was added and the resultant
mixture heated further (10 mins, 120 °C). Water (2 ml) was added to dilute the reaction
mixture containing crude [18F]FBA. This solution was then trapped on two interconnected Waters Sep-Pak C-18 light cartridges sequentially pre-treated with ethanol (15
ml) and water (15 ml). Elution of product then occurred using anhydrous acetonitrile (800
μl) to deliver the title compound [18F]FBA in an average d.c. radiochemical yield of 82%
(n = 3). This compound was used in the next step without further purification. To confirm
that the correct product had been acquired, a co-injection of 4-[19F]-FBA and [18F]-FBA
in water was performed (20 μl, 30-70% MeCN + 0.1% TFA gradient system, see Figure
4.S3 supporting information).
Synthesis of [18F]SFB
[18F]FBA was trapped onto two inter-connected Waters Sep-Pak C-18 light
cartridges sequentially pre-treated with ethanol (15 ml) and water (15 ml) and eluted with
acetonitrile (800 μl) into a vial charged with NHS (29 mg, 0.25 mmol.) and EDC (71 mg,
0.46 mmol.). The resultant solution was allowed to stand at room temperature for 15-20
minutes before being diluted with water + 0.1% TFA (1.2 ml) and purified by semipreparative HPLC (30-70% MeCN + 0.1% TFA gradient system). After solvent removal
(V-10 evaporator, 36 °C) dry [18F]SFB was obtained in an average d.c. radiochemical
yield of 71% (n = 3) and ³ 99% radiochemical purity.
Synthesis of [1-Nal4, Lys5(4-[18F]-FB)]G7039
A solution of [1-Nal4]G7039 (2.0 mg, 1.86 x 10-3 mmol.) in acetonitrile (100 μl)
and H2O (100 μl) was added to the [18F]SFB, followed by DIPEA (10 μl) and the
resultant solution heated to 65 °C for 15-20 minutes. Crude [1-Nal4, Lys5(4-[18F]FB)]G7039 began to precipitate out of solution as a white solid. The solvent was
subsequently removed and the solid re-dissolved stepwise with DMF (300 μl), H2O (500
μl) and MeCN (200 μl). This solution was purified by preparative HPLC (30-70% MeCN
+ 0.1% TFA gradient system) and delivered the title [18F]radiolabelled peptidomimetic
[1-Nal4,Lys5(4-[18F]-FB)]G7039 in an average d.c. radiochemical yield of 81% (n = 3),
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an overall average d.c. radiochemical yield of 48% (n = 3), a radiochemical purity ≥ 99%
and an average molar activity of 34 GBq/μmol (n = 3).
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Chapter 3 Supplementary Information

Supplementary Table 3.1 - Synthesised peptides and peptidomimetics. 4-FB, 4fluorobenzoyl; AEEA, 2-(2-(2-aminoethoxy)ethoxy)acetic acid; D-2-Nal, D-2naphthylalanine; D-2-Thi, D-2-thienylalanine; Dpr, 2,3-diaminopropionic acid; Inp,
isonipecotic acid
Peptide/Peptidomimetic
Ipamorelin

Amino Acid Sequence
H-Aib-His-D-2-Nal-D-Phe-Lys-NH2

[Lys5(4-FB)]ipamorelin
[Lys5(AEEA-4-FB)]ipamorelin

H-Aib-His-D-2-Nal-D-Phe-Lys(4-FB)-NH2
H-Aib-His-D-2-Nal-D-Phe-Lys(AEEA-4-FB)-NH2

[D-2-Thi4,Lys5(4-FB)]ipamorelin

H-Aib-His-D-2-Nal-D-2-Thi-Lys(4-FB)-NH2

[Inp1,Lys5(4-FB)]ipamorelin

H-Inp-His-D-2-Nal-D-Phe-Lys(4-FB)-NH2

[Inp1,D-2-Nal4,Lys5(4FB)]ipamorelin
[Inp1,D-2-Thi4,Lys5(4FB)]ipamorelin
GHRP-1

H-Inp-His-D-2-Nal-D-2-Nal-Lys(4-FB)-NH2

GHRP-2

H-D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2

GHRP-6

H-His-D-Trp-Ala-Trp-D-Phe-Lys-NH2

[Lys6(4-FB)]GHRP-6
[Dpr6]GHRP-6
[Dpr6(4-FB)]GHRP-6
G7039
[Lys5(4-FB)]G7039
[1-Nal4]G7039
[1-Nal4,Lys5(4-FB)]G7039

H-His-D-Trp-Ala-Trp-D-Phe-Lys(4-FB)-NH2
H-His-D-Trp-Ala-Trp-D-Phe-Dpr-NH2
H-His-D-Trp-Ala-Trp-D-Phe-Dpr(4-FB)-NH2
H-Inp-D-2-Nal-D-2-Nal-Phe-Lys-NH2
H-Inp-D-2-Nal-D-2-Nal-Phe-Lys(4-FB)-NH2
H-Inp-D-2-Nal-D-2-Nal-1-Nal-Lys-NH2
H-Inp-D-2-Nal-D-2-Nal-1-Nal-Lys(4-FB)-NH2

H-Inp-His-D-2-Nal-D-2-Thi-Lys(4-FB)-NH2
H-Ala-His-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2
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Supplementary Figure 3.1 - Displacement curve for the endogenous ligand ghrelin

Supplementary Table 3.2 - LogP values for peptides and peptidomimetics. These
values were computed using ACD/LogP prediction software from ACD/Labs
Peptidomimetic
Ipamorelin
[Lys5(4-FB)]ipamorelin
[Lys5(AEEA-4-FB)]ipamorelin
[D-2-Thi4,Lys5(4-FB)]ipamorelin
[Inp1,Lys5(4-FB)]ipamorelin
[Inp1,D-2-Nal4,Lys5(4-FB)]ipamorelin
[Inp1,D-2-Thi4,Lys5(4-FB)]ipamorelin
GHRP-1
GHRP-2
GHRP-6
[Lys6(4-FB)]GHRP-6
[Dpr6]GHRP-6
[Dpr6(4-FB)]GHRP-6
G7039
[Lys5(4-FB)]G7039
[1-Nal4]G7039
[1-Nal4,Lys5(4-FB)]G7039

LogP
1.72 ± 0.85
3.97 ± 0.89
2.80 ± 0.93
3.65 ± 0.90
3.92 ± 0.89
5.15 ± 0.89
3.60 ± 0.89
2.60 ± 0.90
3.41 ± 0.86
1.51 ± 0.88
3.76 ± 0.92
1.61 ± 0.89
3.86 ± 0.93
5.28 ± 0.82
7.53 ± 0.88
6.51 ± 0.82
8.76 ± 0.88
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Supplementary Figure 3.2 - Decay-curve for the lead peptidomimetic [1-Nal4,Lys5(4FB)]G7039 in human serum. The amount of peptidomimetic is expressed as the
percentage of the area under the curve (AUC) from time = 0 (T0) in the UV
chromatogram. Each time point was performed in triplicate
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Supplementary Figure 3.3 - Radiochromatogram of [19F]FBA and [18F]FBA coinjection
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Supplementary Figure 3.4 - Radiochromatogram of [18F]SFB
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Peptidic and peptidomimetic HPLC chromatograms
Ipamorelin: H-Aib-His-D-2-Nal-D-Phe-Lys-NH2 (1)

[Lys5(4-FB)]ipamorelin: H-Aib-His-D-2-Nal-D-Phe-Lys(4-FB)-NH2 (2)
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[Lys5(AEEA-4-FB)]ipamorelin: H-Aib-His-D-2-Nal-D-Phe-Lys(AEEA-4-FB)-NH2 (3)

[D-2-Thi4,Lys5(4-FB)]ipamorelin: H-Aib-His-D-2-Nal-D-2-Thi-Lys(4-FB)-NH2 (4)
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[Inp1,Lys5(4-FB)]ipamorelin: H-Inp-His-D-2-Nal-D-Phe-Lys(4-FB)-NH2 (5)

[Inp1,D-2-Nal4,Lys5(4-FB)]ipamorelin: H-Inp-His-D-2-Nal-D-2-Nal-Lys(4-FB)-NH2 (6)
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[Inp1,D-2-Thi4,Lys5(4-FB)]ipamorelin: H-Inp-His-D-2-Nal-D-2-Thi-Lys(4-FB)-NH2 (7)

GHRP-1: H-Ala-His-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2 (8)
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GHRP-2: H-D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2 (9)

GHRP-6: H-His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 (10)
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[Lys6(4-FB)]GHRP-6: H-His-D-Trp-Ala-Trp-D-Phe-Lys(4-FB)-NH2 (11)

[Dpr6]GHRP-6: H-His-D-Trp-Ala-Trp-D-Phe-Dpr-NH2 (12)
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[Dpr6(4-FB)]GHRP-6: H-His-D-Trp-Ala-Trp-D-Phe-Dpr(4-FB)-NH2 (13)

G7039: H-Inp-D-2-Nal-D-2-Nal-Phe-Lys-NH2 (14)
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[Lys5(4-FB)]G7039: H-Inp-D-2-Nal-D-2-Nal-Phe-Lys(4-FB)-NH2 (15)

[1-Nal4]G7039: H-Inp-D-2-Nal-D-2-Nal-1-Nal-Lys-NH2 (16)
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[1-Nal4,Lys5(4-FB)]G7039: H-Inp-D-2-Nal-D-2-Nal-1-Nal-Lys(4-FB)-NH2 (17)
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Peptidic- and peptidomimetic 1H-NMR spectra
Ipamorelin: H-Aib-His-D-2-Nal-D-Phe-Lys-NH2 (1)
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[Lys5(4-FB)]ipamorelin: H-Aib-His-D-2-Nal-D-Phe-Lys(4-FB)-NH2 (2)

161
[Lys5(AEEA-4-FB)]ipamorelin: H-Aib-His-D-2-Nal-D-Phe-Lys(AEEA-4-FB)-NH2 (3)
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[D-2-Thi4,Lys5(4-FB)]ipamorelin: H-Aib-His-D-2-Nal-D-2-Thi-Lys(4-FB)-NH2 (4)
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[Inp1,Lys5(4-FB)]ipamorelin: H-Inp-His-D-2-Nal-D-Phe-Lys(4-FB)-NH2 (5)
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[Inp1,D-2-Nal4,Lys5(4-FB)]ipamorelin: H-Inp-His-D-2-Nal-D-2-Nal-Lys(4-FB)-NH2 (6)
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[Inp1,D-2-Thi4,Lys5(4-FB)]ipamorelin: H-Inp-His-D-2-Nal-D-2-Thi-Lys(4-FB)-NH2 (7)
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GHRP-1: H-Ala-His-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2 (8)
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GHRP-2: H-D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2 (9)
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GHRP-6: H-His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 (10)
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[Lys6(4-FB)]GHRP-6: H-His-D-Trp-Ala-Trp-D-Phe-Lys(4-FB)-NH2 (11)
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[Dpr6]GHRP-6: H-His-D-Trp-Ala-Trp-D-Phe-Dpr-NH2 (12)
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[Dpr6(4-FB)]GHRP-6: H-His-D-Trp-Ala-Trp-D-Phe-Dpr(4-FB)-NH2 (13)
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G7039: H-Inp-D-2-Nal-D-2-Nal-Phe-Lys-NH2 (14)
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[Lys5(4-FB)]G7039: H-Inp-D-2-Nal-D-2-Nal-Phe-Lys(4-FB)-NH2 (15)
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[1-Nal4]G7039: H-Inp-D-2-Nal-D-2-Nal-1-Nal-Lys-NH2 (16)
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[1-Nal4,Lys5(4-FB)]G7039: H-Inp-D-2-Nal-D-2-Nal-1-Nal-Lys(4-FB)-NH2 (17)
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Peptidic- and peptidomimetic displacement curves
Ipamorelin (1)

[Lys5(4-FB)]ipamorelin (2)
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[Lys5(AEEA-4-FB)]ipamorelin (3)

[D-2-Thi4,Lys5(4-FB)]ipamorelin (4)
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[Inp1,Lys5(4-FB)]ipamorelin (5)

[Inp1,D-2-Nal4,Lys5(4-FB)]ipamorelin (6)
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[Inp1,D-2-Thi4,Lys5(4-FB)]ipamorelin (7)

GHRP-1 (8)
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GHRP-2 (9)

GHRP-6 (10)
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[Lys6(4-FB)]GHRP-6 (11)

[Dpr6]GHRP-6 (12)
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[Dpr6(4-FB)]GHRP-6 (13)

G7039* (14)

* Please note that this data has already been published1, but is presented here for
completeness.
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[Lys5(4-FB)]G7039 (15)

[1-Nal4]G7039 (16)
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[1-Nal4,Lys5(4-FB)]G7039 (17)
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UHPLC chromatogram of 4-(tert-butoxycarbonyl)-N,N,Ntrimethylbenzenammonium triflate (20)

1

H-NMR spectrum of 4-(tert-butoxycarbonyl)-N,N,N-trimethylbenzenammonium
triflate (20)
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13

C-NMR spectrum of 4-(tert-butoxycarbonyl)-N,N,N-trimethylbenzenammonium
triflate (20)
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Chapter 43
Single Amino Acid Replacement in G7039 Leads to a 70-Fold Increase in Binding
Towards GHS-R1a
4.1 Introduction
Ghrelin is a hormone produced mainly by the stomach that was first discovered in
1999 by Kojima et al1. Ghrelin actions are mediated via activation of the G Protein
Coupled Receptor (GPCR) growth hormone secretagogue receptor type 1a (GHS-R1a)1,2.
It was originally reported that GHS-R1a was found within the pituitary gland and
hypothalamus2 but recent work has revealed a more widespread expression in other
tissues, including other regions of the brain and heart3,4. GHS-R1a is also reported to be
differentially expressed in certain cancer cells. For example, GHS-R1a activation
increases cellular proliferation in prostate cancer through activation of the p44/42 MAPK
signalling pathway5-7. Overexpression of GHS-R1a increases the motile phenotype in
astrocytomas, in which increased GHS-R1a expression is correlated with a higher tumor
grade8. Overexpression of GHS-R1a has more recently been demonstrated in some
ovarian epithelial carcinomas, a disease with poor prognosis due to the late stages in
which this cancer is usually diagnosed9-14.
A number of synthetic peptides acting as GHS-R1a agonists have been described.
In 1977 Bowers et al, while undertaking structure-activity relationship (SAR) on
enkephalin analogues, discovered that some of these derivatives were involved in the
release of growth hormone (GH) from the pituitary gland in the female rats15-17.The
hexamer H-His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 was identified as the first synthetic
peptide to release GH both in vitro and in vivo through the activation of GHS-R1a. From
this point on, researchers began to develop peptides that had the ability to release growth
hormone through the activation of GHS-R1a, generating the class of compounds known
as growth hormone secretagogues (GHSs)18. They are uniquely classified based on their
function of secreting GH from the pituitary by activation of GHS-R1a, instead of the
3

Lalonde, T.; Fowkes, M.; Hou, J.; Thibeault, P.; Milan, M.; Dhanvantari, S.;
Ramachandran, R.; Luyt, L.G. Single Amino Acid Replacement in G-7039 Leads to a 70Fold Increase in Binding Towards GHS-R1a. Chem. Med. Chem, 2019, DOI:
10.1002/cmdc.201900466.
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through secondary release stimulated by the action of GH releasing hormone from the
hypothalamus18-19.
GHSs allow for a more rapid synthesis (5 to 6-mer peptides) compared to the fulllength ghrelin peptide and act as a small molecule when targeting the receptor20. Our
development of these agonists was guided by work from Feighner et al. who utilized site
directed mutagenesis to determine the key residues in GHS-R1a that interacted with the
GHSs (GHRP-6, MK-0677, and L-692,585) they studied20.
The starting peptidomimetic for this project was G7039 (H-Inp-D2Nal-D2Nal1Nal-Lys-NH2 or [1-Nal4]G7039). Previously, we reported on the evaluation of a
fluorine-containing G7039 peptidomimetic ([1-Nal4, Lys5 (4-fluorobenzoyl-4FB)]G7039) as a positron emission tomography (PET) tracer, through addition of a 4fluorobenzoic acid (4-FBA) group on the C-terminal lysine, allowing for radiolabeling
with fluorine-18 (18F) (panel B Figure 4.1)21.
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Figure 4.1 - (A) Starting peptidomimetic ([1-Nal ]G7039) to perform SAR. (B)
Previously reported fluorine-containing G7039 peptidomimetic ([1-Nal4, Lys5 (4FB)]G7039)21. (C) Current peptidomimetics being studied with changes in the
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fourth position to either Ser and/or Phe, and Tyr (indicated by red X), and
modification of prosthetic group from 4-FB to 2-FP (seen in blue)
This led to a compound that had moderate affinity for GHS-R1a (IC50 = 69 nM compared
to ghrelin IC50 = 3 to 5 nM) in addition to high lipophilicity (cLogP of 6.51 ± 0.82)21.
This lead candidate was assessed in a healthy mouse model (C57BL/6) and showed
significant uptake in off target tissues (e.g. liver, spleen, kidneys, and lungs), as expected
due to the high lipohphilicity22. However, it was noted that the first 3 amino acids were
important for binding and activating the receptor, therefore, to improve receptor affinity,
modifications of only the fourth position were proposed, leaving the C-terminal lysine
free for the attachment of a different prosthetic group21. The main goal of this current
work was to evaluate different amino acids in the fourth position in order to reduce the
cLogP and improve the binding affinity towards GHS-R1a. An additional goal was to
switch from the 4-FB group to a 2-fluoropropionyl group (2-FP), appended to the sidechain of the C-terminal lysine. This change in prosthetic group was expected to decrease
the hydrophobicity, but still provide a facile radiolabelling route to the
synthesis of a PET probe23. These proposed structural modifications can be seen in panel
C, Figure 4.1. In total seven G7039 analogues were synthesized and evaluated for GHSR1a affinity by a competitive binding assay (IC50), a β-arrestin-1 and β-arrestin-2
recruitment assay (EC50), and a computational docking study. This led to the discovery of
novel peptides with high affinity and potency that have potential to be used as
therapeutics and/or imaging agents when targeting GHS-R1a.
4.2 Results and Discussion
As an initial step, the previously used prosthetic group 4-FB located off the εamine of the C-terminal lysine, was replaced with the smaller 2-FP group to give
compound 2. This analogue maintained moderate GHS-R1a affinity while maintaining
relatively high cLogP value (Table 4.1). Further structure activity relationship studies
were undertaken to change the fourth position in order to improve both the affinity and
cLogP of this class of peptidomimetics.
Table 4.1 - Peptidomimetics with calculated binding numbers (IC50) and predicted
lipophilicity (cLogP). Only the fourth position was changed and evaluated with the
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exception of compound 3 and 4. The 2-fluoropropionic acid group was added to Lys
5 in all cases except compounds 1 and 7
Compound
Number

Peptide Sequence

IC50
(nM)

cLogP
(ACD/Labs)

1

H-Inp-D2Nal-D2Nal-Phe-Lys-NH2

5.2

5.28 ± 0.82

2

H-Inp-D2Nal-D2Nal-Phe-Lys(2-FP)-NH2

19

4.34 ± 0.90

3

H-Inp-D2Nal-D2Nal-Ser-Phe-Lys(2-FP)-NH2

62.9

4.33 ± 0.90

4

H-Inp-D2Nal-D2Nal-Phe-Ser-Lys(2-FP)-NH2

4.35

4.33 ± 0.90

5

H-Inp-D2Nal-D2Nal-Tyr-Lys(2-FP)-NH2

0.28

2.77 ± 0.87

6

H-Inp-D2Nal-D2Nal-Ser-Lys(2-FP)-NH2

60.3

2.77 ± 0.87

7

H-Inp-D2Nal-D2Nal-Tyr-Lys-NH2

0.70

2.69 ± 0.89

All peptides in Table 4.1 were synthesized using Fmoc solid-phase peptide chemistry,
purified using reverse-phase high performance liquid chromatography (RP-HPLC) and
analyzed by ESI-MS. To allow the addition of the fluorine-containing entity, peptides
required an orthogonal Alloc protecting group on the C-terminal lysine to allow for
selective deprotection and coupling to the 2-fluoropropionic acid (2-FPA) prosthetic
group. Purity for each peptide was greater than 98% as determined by UHPLC (Table
4.S1).
To test the affinity of these peptides towards GHS-R1a, a competitive binding
assay was performed with [125I] human ghrelin as the competitor (Table 4.1). When a
non-aromatic amino acid was present in the fourth position, affinity towards GHS-R1a is
diminished. Compound 3 and 6, with Ser in position 4, have IC50 values of 62.9 nM and
60.3 nM respectively. If an aromatic group is in the fourth position, as per Phe for
compound 4, the affinity improves to 4.35 nM. Moreover, when incorporating Tyr in the
fourth position the binding substantially improves to 0.28 nM (compound 5). The 2-FP
group was removed from compound 5 in order to confirm that the increase in binding was
due to the Tyr in the 4th position. With no 2-FP prosthetic group compound 7 was found
to maintain this sub-nanomolar affinity with an IC50 of 0.70 nM.
As modifications were made to the C-terminal amino acids of the peptidomimetic,
it was noted that when Phe remains in either the fourth or fifth position (compound 4 and
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3 respectively in Table 4.1) the cLogP remains above 4. However, when the fourth
position is a Tyr or Ser, cLogP drops below 3. This lowered cLogP is desirable and could
help with improving pharmacokinetic behavior in vivo. Tyrosine in the fourth position
was the optimal amino acid change, dramatically decreasing the cLogP (comparing
compounds 1-4 vs. compound 5 and 7). The addition or absence of the 2-FP prosthetic
group doesn’t drastically change the cLogP values (compound 5 vs. 7).
Next, we wanted to assess the potency of the peptides through monitoring the
recruitment of β-arrestin-1 and β-arrestin-2 to GHS-R1a to obtain EC50 values for the
peptides. Both of these intracellular proteins are normally recruited by the activation of
GHS-R1a leading to its internalization and recyclization. In all cases, compounds 1
through 7 were agonists for the receptor, with EC50 values in the sub-picomolar range.
Based on the concentration-effect curves (Figure 4.2), some compounds were more
potent and efficacious than others. From Table 4.2 the most potent peptide is compound
2 (EC50 of 15.8 pM and 72.8 pM for β-arrestin-1 and β-arrestin-2, respectively), while
compounds 3 (EC50 of 202.4 pM and 178.1 pM for β-Arrestin-1 and β-Arrestin-2
respectively) and 7 (EC50 of 178.7 pM and 262.5 pM for β-Arrestin-1 and β-Arrestin-2
respectively) were the least potent. The Emax for compound 3 is 0.0780 and 0.1106 for βArrestin-1 and β-Arrestin-2 respectively and the Emax for compound 6 is 0.0740 and
0.1295 for β-Arrestin-1 and β-Arrestin-2 respectively. Compound 3 and 6 have a 1.5 – 2x
reduction in Emax compared to the other peptides in this series. This indicates that
compounds 3 and 6 are acting as a partial agonist when binding to GHS-R1a.
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Figure 4.2 - β-Arrestin-1 and β-Arrestin-2 recruitment concentration curves
measuring the EC50 of the 7 peptides in HEK293T cells co-transfected with GHSR1a-eYFP and GHS-R1a-Rluc constructs. Data are shown as net BRET (eYFP/rluc)
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Table 4.2 - Potency measured by the recruitment of β-Arrestin-1 and β-Arrestin-2
upon binding of an agonist to GHS-R1a
Compound

Peptide Sequence

Number

b-Arr-

b-Arr-

b-Arr-

b-Arr-

1

2

1

2

EC50

EC50

Emax

Emax

(pM)

(pM)

(Net

(Net

BRET

BRET

Ratio)

Ratio)

1

H-Inp-D2Nal-D2Nal-Phe-Lys-NH2

59.9

61.7

0.1159

0.1889

2

H-Inp-D2Nal-D2Nal-Phe-Lys(2-FP)-NH2

15.8

72.8

0.1072

0.1819

3

H-Inp-D2Nal-D2Nal-Ser-Phe-Lys(2-FP)-NH2

202.4

178.1

0.0780

0.1106

4

H-Inp-D2Nal-D2Nal-Phe-Ser-Lys(2-FP)-NH2

90.9

81.7

0.1307

0.1748

5

H-Inp-D2Nal-D2Nal-Tyr-Lys(2-FP)-NH2

125.7

121.1

0.1194

0.1616

6

H-Inp-D2Nal-D2Nal-Ser-Lys(2-FP)-NH2

135.6

207.8

0.0740

0.1295

7

H-Inp-D2Nal-D2Nal-Tyr-Lys-NH2

178.7

262.5

0.1176

0.1687

To understand the molecular basis for the experimental observation that Tyr
incorporation in the fourth position improves the binding affinity for this series, a
molecular docking study was performed on compound 7 using a homology model for
GHS-R1a recently developed by our lab23. Our previous molecular dynamics (MD)
simulation revealed that the N-terminal end of compound 1 (G7039) is situated at the
bottom of the orthosteric site engaging in a salt bridge interaction with Glu124, and the
2nd and 3rd residue D2Nal binds to the other two hydrophobic sub-pockets (Figure
4.3A)23. The molecular docking study on compound 7 suggested a very similar binding
pattern except that the fourth residue Tyr is H-bonding with Arg283 (Figure 4.3B). Our
previous model also showed that the 4th residue Phe of G-7039 is surrounded by
hydrophobic residues suggesting switching it to a hydrophilic residue Ser would reduce
the binding affinity, which is consistent with the experimental data (compound 2 vs 6) .
The computational studies showed that the aromatic ring of the Tyr retains the interaction
with the surrounding hydrophobic residues such as Phe 286 in the receptor (Figure 4.3),
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and the additional H-bonding interaction with Arg 283 contributes to the improved
binding affinity.

Figure 4.3 - The structure of compound 1 (G7039) in complex with GHS-R1a
obtained from our previous computational study24. Compound 1 is situated at the
bottom of orthosteric site engaging a salt bridge interaction with Glu124, and the 2nd
and 3rd residues D2Nal binds to the other two hydrophobic sub-pockets. (B) The
structure of compound 7 in complex with GHS-R1a from molecular docking study
suggested a very similar binding pattern except that the 4th residue Tyr is Hbonding with Arg283
4.3 Conclusion
The goal of the current work was to improve the binding affinity and decrease
lipophilicity of a previously reported GHS-R1a targeting peptidomimetic21. Changes
were made to both the fourth position and prosthetic group conjugated from the Cterminal Lys of ([1-Nal4, Lys5 (4-FB)]G7039), followed by assessing the binding affinity,
cLogP, potency, and molecular docking to confirm the outcomes of the amino acid
changes. In total, seven novel ghrelin agonists were synthesized and assessed for their
binding affinity and potency towards GHS-R1a. Compound 5 showed the greatest
binding affinity (IC50 = 0.28 nM) with Tyr in the fourth position and it was noted that an
aromatic amino acid is required in the fourth position in order to retain binding affinity
towards the receptor. Compound 3 and 6 were identified as partial agonists and this class
of molecule can be useful in terms of regulating the GHS-R1a signalling in a differential
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fashion. Molecular docking confirmed an additional H-bond interaction with Tyr in
compound 5 explaining the increase in binding. Compound 5 could be used as an
imaging agent since there is an available fluorine atom (the 2-FP moiety on Lys five) that
can be replaced by fluorine-18 through established prosthetic radiochemistry methods24.
Compound 5 is currently the most potent fluorine-containing peptidomimetic reported for
GHS-R1a (based upon β-arrestin recruitment) and uniquely has the potential to be used as
an imaging agent for the diagnosis of human diseases associated with GHS-R1a.
4.4 Materials and Methods
4.4.1 General Information
All reagents were obtained from the commercial suppliers and used without any
further purification. All Fmoc-protected amino acids were obtained from ChemImpex.
HCTU, HATU, and Rink Amide MBHA Resin (4-(2’,4’-dimethoxyphenyl-(9fluorenylmethoxycarbonyl)-aminomethyl)-phenoxy-acetamidonorleucyl-4-methyl
benzhydrylamine resin) were obtained from ChemImpex.
Tetrakis(triphenylphosphine)palladium(0), and phenylsilane. All other solvents were
obtained from Fischer Thermo-Scientific.
4.4.2 Solid-Phase Peptide Synthesis
Automated Fmoc-based solid-phase synthesis was carried out using a Biotage®
Syro Wave™ automated peptide synthesizer. Synthesis was done on a 0.1 mmol scale
with 0.52 mmol/g Fmoc-Rink amide MBHA resin and a 3-fold excess of the protected
amino acids. The resin was allowed to swell in DCM (2.0 mL, 15 min) and then solvent
was removed. The resin was then rinsed with DMF (1.0 mL, 1min), and after removal of
the solvent, deprotection of the Fmoc group was performed by adding a solution of 20%
piperidine/DMF (1.5 mL) to the resin and was allowed to vortex for 5 minutes. The resin
was then washed three times with DMF (2.0 mL, vortex 30 sec) and then the resin was
vortexed for 15 min with 20% piperidine/DMF (1.5 mL). The resin was then washed with
DMF six times to remove any unreacted products (2.0 m, vortex 30 sec). A Kaiser test
was performed after the Fmoc removal to verify the presence of a free primary amino
group. The desired Fmoc-protected amino acid (0.3 mmol) and the coupling reagent
HCTU (0.3 mmol) was dissolved in DMF (1.5 mL) and added to the resin. The mixture
was allowed to vortex for 30 seconds and then DIPEA (0.6 mmol) was added to the
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mixture and was allowed to vortex for 1 hour. This deprotection/amino acid coupling
cycle was repeated until the desired amino acid sequence was obtained. After the final
amino acid was coupled, the resin was washed 3 times with DMF (2.0 mL, vortex 30 sec)
and then 3 times with DCM (2.0 mL, vortex 30 sec) and then dried under vacuum and
stored in the freezer. The removal of the final Fmoc protecting group on the N-terminus
is achieved using the same procedure for the other deprotections as previously described.
To determine if the correct peptide has been synthesized, a microcleave was performed
before full cleavage off the resin. A small amount of resin (<5 mg) is added to a small
peptide vessel and 95% trifluoroacetic acid/2.5% triisopropylsilane/2.5% water (500 μL)
was added. The mixture was allowed to vortex for 3-4 hours, and the resulting liquid was
precipitated with cold tert-butyl methyl ether (TBMe) (2 mL). The precipitate was
centrifuged, the mother liquor was decanted off, the pellet was dissolved in water (2 mL),
frozen and then lyophilized. If the correct peptide was synthesized as determined by
analytical UHPLC/ESI-MS, then a full cleavage of all of the resin was performed. The
procedure for full cleaves is the same as a microcleave, a solution of 95% trifluoroacetic
acid/2.5% triisopropylsilane/2.5% water (3 mL) was added to the resin and vortexed for
4-6 hours. The solution is drained, precipitated in TBMe (20 mL) and centrifuged. The
mother liquor is decanted, the pellet is dissolved in water (20 mL) and lyophilized to
obtain the crude fully deprotected peptide.
4.4.3 Kiaser Test
To qualitatively test if there is presence of a free amine present (after a Fmocdeprotection, amino acid coupling, or alloc deprotection), a Kaiser test is performed. A
small amount of resin (<5 mg) is taken and placed in a small test tube. To the test tube,
solutions of: Phenol:EtOH (8:2 v/v), 0.001M KCN: pyridine (2:98 v/v) and ninhydrin in
EtOH (5% w/v) were added. The test tube was heated to 70°C and the presence of a free
amine was indicated by the resin beads turning blue. The indication of no free amine was
determined by the presence of clear/yellow resin beads.
4.4.4 Deprotection of Allyloxycarbonyl (Alloc)
Selective deprotection of the allyloxycarbonyl protecting group was accomplished
by adding DCM (4.5 mL) to the resin-bound peptide and shaking gently for 10 minutes.
After addition of phenylsilane (24 equiv.), the peptide vessel was flushed with nitrogen
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and allowed to react for 5 minutes. Then, tetrakis(triphenylphosphine) palladium (0) (0.1
equiv.) was added to the mixture and the peptide vessel was again flushed with nitrogen,
and the reaction was allowed to proceed for 10 minutes. Next, the peptide-resin was
washed with DCM (4 x 30 s), followed by a series of washings with DCM, DMF, MeOH,
DMF, DCM (30 s each).
4.4.5 Coupling of 2-Fluoropropionic Acid Group
Following removal of Alloc, 2-fluoropropionic acid (2-FPA) is coupled onto Lys
adding 2-FP (0.3 mmol) and the coupling reagent HATU (0.3 mmol) dissolved in DMF
(1.5 mL) and then added to the resin. This mixture was allowed to vortex for 2 hours, and
the resin was then washed 3 times with DMF (2.0 mL, vortex 30 sec) and then 3 times
with DCM (2.0 mL, vortex 30 sec) and then dried under vacuum.
4.4.6 Purification of RP-HPLC/ESI-MS
Peptides were analyzed using a reverse-phase analytical HPLC column (Agilent
Zorbax SB-C8 column 4.6 x 150 mm, 3.5 μm). This system was equipped with a Waters
600 136 controller, Waters Prep degasser, and Waters Masslynx software (version 4.1).
Employed mobile phases were 0.1% TFA in deionized water (eluent A) and 0.1% TFA in
acetonitrile (eluent B). The flow rate was set at 1.5mLmin-1 over 15 minutes. The column
eluate was monitored using a Waters 2998 Photodiode array detector set at 220 nm, 254
nm and 400 nm. Peptides were purified using a reverse-phase preparative HPLC column
(Agilent Zorbax SB-C18 column 21.2 x 150 mm, 5 μm) on the same system mentioned
above. The detection method and eluents were the same was mentioned above for the
analytical system and the flow rate was set at 20 mLmin-1. The collected fractions were
then lyophilized to a solid. For analytical UHPLC-MS, studies were performed on a
Waters, Inc. Acquity UHPLC H-Class system, combined with a Xevo QTof mass
spectrometer (ESI+, cone voltage = 30 V). A Waters Acquity UHPLC BEH C18 2.1 x 50
mm, 1.7 μm column was used with a gradient solvent system consisting of 0.1% formic
acid in acetonitrile and 0.1% formic acid in water.
4.4.7 Receptor Ligand Binding Assay
Competitive ligand binding assays were performed in triplicate using
HEK293/GHS-R1a cells and [125I]Ghrelin as the competitive ligand, as previously
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described21. Receptor binding affinities were calculated as IC50 values as previously
described21.
4.4.8 Molecular cloning and constructs
YFP tagged human GHS-R1a from Addgene (hGHS-R1a) was made by replacing
PAR4 in the previously published PAR4-YFP (Ramachandran et al., 2017) construct25
with GHS-R1a using restriction enzymes digestion with EcoRI and Xhol and ligation.
Constructs was verified by direct sequencing (University of Western Ontario, Robarts
DNA sequencing facility).
4.4.9 b-Arrestin Recruitment Assay
Bioluminescent resonance energy transfer was measured between c-terminally
YFP tagged GHS-R1a and Renilla Luciferase (Rluc) tagged b-arrestin 1 (b-Arr-1) or barrestin 2 (b-Arr-2), following 20 minutes of receptor activation in the presence of
agonist compounds in HEK293 cells. HEK293 cells are maintained in Dulbecco’s
Modified Eagle’s medium (DMEM) from Sigma-Aldrich (D5796) with added 5% sodium
pyruvate, 5% penicillin streptomycin, and 10% fetal bovine serum (FBS) at 37°C with
5% CO2. Cells were cultured in a T-75 flask to 95% confluency then lifted by trypsinETDA (0.25%). Once cells were counted and spun down at 1000 rpm they were
resuspended and then re-plated in 10 cm culture dishes at 1 million cells per plate.
Seeding was then accomplished for 24 hrs at 37°C with 5% CO2. GHS-R1a-YFP (2 μg)
and b-arrestin-1-rluc/ -2-luc (0.2 µg; a kind gift from Dr. Michel Bouvier) were
transiently transfected for 24 hours. At 24 hours transfection, cells were re-plated into
white 96-well culture plates (Brand Tech.) and cultured for an additional 24 hours.
Interactions between GHS-R1a and b-arrestin-1/2 were detected by measuring BRET
ratios (eYFP/rluc) at 20 min of agonist stimulation, following the addition of 5 μM
coelenterazine (Nanolight Technology, Pinetop, AZ) 10 min prior to quantification on a
Mithras fluorescence plate reader (Berthold) using the appropriate filters. All drugs being
tested were dissolved in Hanks’ Balanced Salt Solution (HBSS) with 0.1% DMSO. The
highest drug concentration of 10-5 M was first prepared, and each full log concertation
was prepared by serial dilution thereafter. The control well contained just HBSS with
0.1% DMSO. The serum media was removed from the plate before then addition of the
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drug at varying concentrations (10-5 M to 10-17 M). Data are shown as net BRET ratios
(eYFP/rluc – baseline ratio in no agonist control). Concentration effect curves were
calculated using 3 parameter non-linear regression curve fitting, as this was most
appropriate based on the R squared value (Prism 7).
4.4.10 Molecular docking studies
The homology model of GHS-R1a previously developed by our lab was used to
study the interactions between compound 7 and GHS-R1a26. The structure of compound 7
was generated from modification of compound 1, thus both compound 1 and 7 have
identical conformation. To investigate the effort of Tyr replacement in the fourth position
on the binding pattern, the residues of GHS-R1a (Phe289, Arg283, Phe279) surrounding
the Tyr in the fourth position were set to be flexible while the conformation of the
compound 7 remains unchanged during the docking calculation. Docking studies were
performed using the AUTODOCK 4.2 program26. The dimensions of the active site box
were chosen to be large enough to encompass the entire orthosteric site in the receptor.
Docking calculations were carried out using the Local Search Algorithm. The docking
experiment was consisted of 200 independent runs. Default values were used for other
parameters. All the calculations were performed on high-performance computing (HPC)
facilities within the Compute Canada network27. The graphics were generated using DS
Visualizer (BIOVIA).
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Chapter 4 Supplementary Information
Half-Maximal Inhibitory Concentration (IC50) Curves
*Compound 1 previously published in reference 21*
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UHPLC-MS Traces
Supplementary Table 4.1 – Analytical Data for Compounds 1 to 7

Compound Number
1
2
3
4
5
6
7

Compound 1

Calculated Mass
([M+H]+)
872.4521
798.4243
399.7016 ([M+2H]2+)
812.4136
959.4831
959.4831
888.4460
814.4292
407.7284 ([M+2H]2+)

Found Mass
([M+H]+)
872.4536
798.4266
399.6943 ([M+2H]2+)
812.4056
959.4967
959.4967
888.4614
814.4487
407.7061 ([M+2H]2+)

Purity (%)
>96
>98
>98
>98
>96
>98
>98
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Chapter 5
Trifluoroborate Containing Peptidomimetic GHS-R1a Agonist for PET Imaging of
Prostate Cancer
5.1 Introduction
Growth hormone secretagogues (GHSs) are a class of peptides and small
molecules that stimulate the secretion of growth hormone (GH) by acting on the growth
hormone secretagogue receptor type-1a (GHS-R1a)1. This receptor is predominantly
expressed in the hypothalamus and pituitary gland1. When GHS-R1a is activated it causes
the release of GH by a route that is different the normal route, the growth hormonereleasing hormone (GHRH)2. Bowers and co-workers were the first to develop a series of
GHSs based on the natural ligands Met-enkephalin and Leu-enkephalin and performed in
vitro analysis to prove that these analogues could still cause GH release3. Most of these
ligands had the initial purpose to treat patients who have GH abnormalities4-6. Examples
of some of these compounds include the growth hormone-releasing peptide-6 (GHRP-6),
GHRP-17, hexarelin8, GHRP-29, peptidomimetics (e.g. G703910, [1-Nal]4G703911and
ipamorelin12) and small-molecules (e.g. L-692,42913and MK-067714). These various
GHSs can be visualized in Figure 5.1. Human ghrelin is the natural ligand for GHS-R1a
first identified by Kojima et al. in 199915. Ghrelin is a 28-amino acid peptide with an
octanoylation on Ser-3. This octanoylation is performed by ghrelin O-acyl transferase
(GOAT) to produce the active form of the ligand. The activation of GHS-R1a has a
multitude of biological activities, such as the regulation of food intake, glucose
metabolism, cardiovascular and neuroprotective effects15-17.
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Figure 5.1 - Peptidic, peptidomimetic and small-molecule growth hormone
secretagogues that have been designed to target GHS-R1a leading to its activation.
All amino acids are designated by the standard three-letter code (D2Nal, D2naphthylalanine; Inp, isonipecotic acid; D-Trp(2-Me); D-2-methyltryptophan)
The GHS-R1a is over expressed and dysregulated in a number of human
malignancies, including prostate cancer18-19, breast cancer21, testicular cancer22, ovarian
and lung cancer23. The expression of this receptor continues to appear in several other
cancers as more examples become apparent in the literature and cBioPortal. It also has
been shown to be upregulated in a number of other human diseases such as protective
effects in atherosclerosis and chronic heart failure24-25. This makes GHS-R1a a highly
favourable target in terms of designing novel imaging agents in order to perform
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diagnosis and monitor the variety of human diseases in which it is overexpressed. The
imaging modality within this work that was chosen is positron emission tomography
(PET). This is because PET combines a relatively high spatial resolution (5 to 7 mm)
with high sensitivity (in the femtomolar range) and is among the widely used imaging
modalities in the clinic today26. A number of recent publications describe PET
radiotracers to monitor GHS-R1a in human disease27-30. Hou et al. synthesized
radiolabelled quinazolinone derivatives as a small molecule capable of targeting GHSR1a30. Also, a [11C]radiotracer revealed a higher specific uptake in the pancreas
compared to other organs in a mouse model were the tumour cells over expressed GHSR1a28. However, these studies27-29 and others30-31 have primarily focused on either smallmolecule quinazolinones27-31 or ghrelin-derived compounds29,30,31. Peptidic and
peptidomimetic GHSs would result in a clinically translatable PET agent because of their
high target specificity, in vivo stability and favourable pharmacokinetic properties.
Fluorine-18 (18F) was our preferred choice of radioisotope as it is a small innocuous unit
that can be easily installed in the absence of a bulky chelator that potentially can reduce
the affinity towards a given target. Also, 18F can be easily installed to the desired ligand
in a direct labelling manor.
Perrin and co-workers synthesized a novel prosthetic group for 18F chemistry that
is able to directly label a peptide in one step with no HPLC purification, based upon the
precursor alkyne containing ammonium methyltrifluoroborate (AMBF3 – seen in blue in
Figure 5.2). This prosthetic group can easily be installed onto a lysine azide of a desired
peptide by copper catalyzed click chemistry in high purity and yields. Once on the
peptide, direct labelling is accomplished in buffered conditions (aqueous) with high
radiochemical purity (>98%), highly specific molar activity (40 – 111 GBq/µmol), and
high radiochemical yields (20 to 35%). This is data that has been collected over 20
trials32. This particular prosthetic group has been proven to be a beneficial and efficient
way to label biologically relevant peptides in the past such as a bombesin derivative for
prostate cancer imaging and a Des-Ar(10)]Kallidin derivative for imaging Bradykinin B1
receptor expression33. In the cases of imaging gastrin-releasing peptide receptor (GRPR)expressing pancreatic and PC-3 prostate cancer tumours in xenograft models with the
radiofluorinated bombesin derivative there was excellent tumour visualization and low
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background uptake in other organs. This exact same result was seen when visualizing the
Bradykinin B1 receptor expression in a xenograft model33-34.
The peptidomimetic G7039 (Figure 5.1) has undergone substantial structureactivity relationship (SAR) studies in order to both improve binding towards the receptor,
as well as enhance the hydrophilicity35. Fowkes and co-workers made several changes
with respect to the prosthetic group as well as changes to the fourth position of the
peptide. The first three amino acids (piperidine-4-carboxylic acid (Inp), D-2napthylalanine (D2Nal), and D-1-napthylalanine (D1Nal)) are highly vulnerable to
change and have been shown necessary to bind and activate GHS-R1a35. A follow up
study by Lalonde and co-workers (Chapter 4) determined that Tyr in the fourth position
caused an 18-fold increase in binding towards GHS-R1a compared to the parent G7039
molecule (5.2 nM versus 0.70 nM measure by a competitive radioligand assay (half
maximal inhibitory concentration-IC50)). This increase in binding is believed to be due to
an additional H-bond interaction with Arg 283 in the binding pocket of the GHS-R1a
homology model (determined by docking analysis). The addition of a 2-fluoropropionic
acid (2-FPA) group to the C-terminal lysine of ([Tyr4, Lys5(2-fluoropropionyl-2FP)]G7039) caused a slight improvement in binding to 0.28 nM and provided a potential
site to radiolabel the peptide with 18F in order to have the respective PET imaging probe.
However, the 2-FP group proved to be a lengthy four-step labelling with very low yields.
This is because the exchange of a leaving group on the two position of 2-FP for 18F
caused an elimination product over the desired substitution product.
By conjugating AMBF3 to a lysine azide group of ([Tyr4, Lys5(N3)]G7039) the
peptidomimetic ([Tyr4, Lys5(AMBF3)]G7039) was synthesized. This peptide still
maintained binding towards the receptor but can now be labelled in a single step by
isotopic exchange (IEX) of 19F for 18F. This work provides a method to prepare a subnanomolar PET agent for the GHS-R1a with rapid and high yielding radiochemistry in
order to image the receptor by PET.
5.2 Results and Discussion
The azide peptide ([Tyr4, Lys5(N3)]G7039) was synthesized using
fluorenylmethyloxycarbonyl (Fmoc) solid-phase peptide chemistry, purified using
reverse-phase high performance liquid chromatography (RP-HPLC) and analyzed by
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electronspray ionization-mass spectrometry (ESI-MS). In a single step, AMBF3 was
conjugated onto the lysine azide utilizing copper click chemistry in an 89% chemical
yield to furnish ([Tyr4, Lys5(AMBF3)]G7039) (Scheme 5.1), followed by purification by
RP-HPLC and analysis by ESI-MS.
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Scheme 5.1 - Chemical synthesis ([Tyr4, Lys5(AMBF3)]G7039) using copper click
chemistry. The Tyr in position four is highlighted in pink and is a significant
contributor to improved GHS-R1a affinity. AMBF3 is highlighted in blue and is the
prosthetic group required for IEX
Previously the peptide ([1-Nal4, Lys5(4-fluorobenzoyl - 4-FB)]G7039) determined to
have an IC50 of 69 nM and a cLogP of 8.76 ± 0.8835. The lower binding affinity and high
cLogP of the peptide led to poorer in vivo PET images in a cancer mouse model35. In
Chapter 4 Lalonde and co-workers improved on both the binding affinity (IC50 of 0.28
nM) and cLogP (2.77 ± 0.87) by altering the Tyr in the fourth position and the 4-FB
prosthetic group to 2-FP ([Tyr4, Lys5(2-FP)]G7039). This prosthetic group proved to be
low yielding during radiosynthesis with 18F. Finally, in this current work the prosthetic
group was changed one additional time to AMBF3. The addition of the AMBF3 caused no
drastic change in binding affinity with a determined IC50 value of 0.85 nM (Figure 5.2).
This was done by a competitive radioligand assay with [125I]-human ghrelin as the
competitor. It can also be noted that the cLogP of this compound was calculated to be
2.54 ± 0.85, which in terms of hydrophobicity is in an acceptable range to have good
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pharmacokinetics. This lead compound has improved on both the binding and cLogP
from the first generation35.

Figure 5.2 - IC50 curve for ([Tyr4, Lys5(AMBF3)]G7039) as determined by
competitive radioligand assay
([Tyr4, Lys5(AMBF3)]G7039 was then radiolabelled with 18F by isotopic
exchange (IEX) with 19F. This was done in a pyridazine-HCL buffer followed by
purification with a C-18 Sep-Pak. Over the course of four trials a decay corrected
radiochemical yield was between 17 and 35%, a radiochemical purity >99%, and a molar
activity of 12 to 15 GBq/μmol. The retention times of the cold standard and “hot” peptide
are almost identical ([Tyr4, Lys5(AMB19F3)], tR = 5.50 mins compared to tR = 5.48 mins
for the “hot” peptide ([Tyr4, Lys5(AMB18F3)]), indicating that the precursor ([Tyr4,
Lys5(AMB19F3)] has been selectively radiolabelled by IEX (Figure 5.3). In terms of the
radiolabelling performed with ([1-Nal4, Lys5(4-FB)]G7039) this is a drastic improvement
in the number of steps to the final product (four versus one step). Radiosynthetic data is
similar in terms of purity, yield, and molar activity35.
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Figure 5.3 - (A) Synthesis scheme for 18F labelling; (B) Overlaid HPLC
chromatograms for ([Tyr4, Lys5(AMB18F3)] and ([Tyr4, Lys5(AMB19F3)] (both λ =
254 nm); (C) Radiochemical yields, purity and molar activity
To demonstrate that ([Tyr4, Lys5(AMB18F3)] was still able to bind to GHS-R1a
after being radiolabelled, a radioligand cellular assay was performed with LNCaP cells
that stably express GHS-R1a. As a control, blocking the radioligand signal coming from
Tyr4, Lys5(AMB18F3) was performed with a 10 mM concentration of Tyr4,
Lys5(AMB19F3). There was on average 10% cellular uptake of the PET agent, which was
significantly different than the blocking study (< 1% uptake). This demonstrates that the
imaging agent is targeting the receptor specifically when using the ([Tyr4,
Lys5(AMB18F3)] PET probe (Figure 5.4).
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Figure 5.4 – Cellular uptake of ([Tyr4, Lys5(AMB18F3)] in LNCaP cells stably
expressing GHS-R1a blocked with a 10 times conc of ([Tyr4, Lys5(AMB19F3)]
5.3 Conclusion
This work has highlighted the development of a sub-nanomolar PET probe with
excellent radiochemical data that specifically targets GHS-R1a. The ([Tyr4,
Lys5(AMB18F3)] analogue of G7039 in terms of the changes made to the fourth position
(Phe to Tyr) and the addition of the AMBF3 improved both binding affinity (0.85 nM)
and cLogP (2.54 ± 0.85). The new prosthetic group allowed for a single step
radiosynthesis route with no HPLC purification. Cellular uptake was demonstrated (10 to
12%), compared to almost none when blocked with ([Tyr4, Lys5(AMB19F3)]. Over the
course of four trials a decay corrected radiochemical yield was between 17 and 35%, a
radiochemical purity >99%, and a radiochemical molar activity of 12 to 15 GBq/μmol.
This demonstrates consistency in radiolabelling with 18F and will facilitate the use of this
PET agent for in vivo imaging experiments. This tracer has the advantage of being
labelled in only one step with no HPLC purification required (32 min to end of synthesis)
making it very attractive to be driven towards a clinical setting.
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5.4 Materials and Methods
5.4.1 General Information
All reagents were obtained from commercial suppliers and used without further
purification. Peptides were either synthesised manually or through the use of a
Biotage SyroWave automated peptide synthesizer. Peptide vessels were shaken using an
IKA Vibrax VXR basic shaker with centrifugation performed on a Beckman Coulter
Allegra X-30R or Fisher GS-6R centrifuge. In order to aid peptide dissolution, sonication
of solutions was accomplished via a Bransonic 2510R-MTH or Fisher F5-14 ultrasonic
cleaner. A Fisher 2052 Isotemp machine was used to heat test tubes in the Kaiser Test.
Peptides were lyophilised using a Labconco FreeZone Freeze Dry System. Accurate
weighing was carried out on a Mettler-Toledo XP6 microbalance. UV traces were
obtained with a Waters 2487 UV/Vis Dual λ Absorbance Detector (170-900 nm) and
low-resolution mass spectra with a Micromass Quattro micro API mass spectrometer
(ESI-LC-MS). Peptide purification was achieved through HPLC (MeCN + 0.1% TFA,
H2O + 0.1% TFA solvent system). All peptides obtained had a purity ≥ 95% as
determined by HPLC or UHPLC analysis. A RP preparative C-18 column (SunFire OBD,
19 x 150 mm or Agilent Zorbax 21.2 x 150 mm) was used for preparative HPLC, whilst a
C-18 RP column (SunFire, 4.6 x 150 mm or Agilent Zorbax, 4.6 x 150 mm) was used for
analytical HPLC.
5.4.2 Solid-Phase Peptide Synthesis
Fmoc-based solid-phase synthesis was carried out manually and automatically
using a Biotage® Syro Wave™ automated peptide synthesizer. Synthesis was done on a
0.1 mmol scale with 0.52 mmol/g Fmoc-Rink amide MBHA resin and a 3-fold excess of
the protected amino acids. The resin was allowed to swell in DCM (2.0 mL, 15 min) and
then solvent was removed. The resin was then rinsed with DMF (1.0 mL, 1 min); after
removal of the solvent, Fmoc deprotection was performed by adding a solution of 20%
piperidine/DMF (1.5 mL) to the resin and vortexing for 5 minutes. The resin was then
washed with three times with DMF (2.0 mL, vortex 30 sec) and the resin was vortexed
for 15 min with 20% piperidine/DMF (1.5 mL). The resin was then washed with DMF
six times to remove any unreacted products (2.0 mL, vortex 30 sec). A Kaiser test was
performed after the Fmoc removal to verify the presence of a free primary amino group.
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The desired Fmoc-protected amino acid (0.3 mmol) and the coupling reagent HCTU (0.3
mmol) was dissolved in DMF (1.5 mL) and added to the resin. The mixture was vortexed
for 30 seconds and then DIPEA (0.6 mmol) was added to the mixture and was vortexed
for 1 hour. This deprotection/amino acid coupling cycle was repeated until the desired
amino acid sequence was obtained. After the final amino acid was coupled, the resin was
washed 3 times with DMF (2.0 mL, vortex 30 sec) and then 3 times with DCM (2.0 mL,
vortex 30 sec), dried under vacuum, and stored in the freezer at -20°C. The removal of
the final Fmoc protecting group on the N-terminus was achieved using the previously
described procedure.
To determine if the correct peptide has been synthesized, a microcleave was
performed before full cleavage from the resin. A small amount of resin (<5 mg) was
added to a small peptide vessel and a solution of 95% trifluoroacetic acid/2.5%
triisopropylsilane/2.5% water (500 μL) was added. The mixture was vortexed for 3-4
hours, and the resulting liquid was precipitated with cold tert-butyl methyl ether (TBME)
(2 mL). The precipitate was centrifuged (3000 xg for 10 min), the mother liquor was
decanted. The pellet was dissolved in water (2 mL), frozen, and lyophilized. If the correct
peptide was synthesized as determined by analytical HPLC/MS, then a full cleave was
performed. The procedure for full cleaves identical to the microcleave procedure: a
solution of 95% trifluoroacetic acid/2.5% triisopropylsilane/2.5% water (3 mL) was
added to the resin and vortexed for 4-6 hours. The solution was drained, precipitated in
TBMe (20 mL) and centrifuged (3000 xg for 10 min). The mother liquor was decanted,
and the pellet was dissolved in water (20 mL) and lyophilized to obtain the crude fully
deprotected peptide.
5.4.3 Synthesis of ([Tyr4, Lys5(AMB19F3)]
AMBF3 was conjugated to the C-terminal lysine of the peptide by copper click
chemistry as previously described32.
5.4.4 General Radiochemistry Information
All reagents and solvents used for radiosynthesis were purchased from SigmaAldrich unless otherwise specified. 18F-fluoride was produced via the 18O(p,n) 18F
reaction in a GE PETtrace 880 cyclotron (Lawson Health Research Institute, London,
Ontario, Canada). A Biotage V-10 evaporator was used to remove solvent. A Waters
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HPLC with a 1525 binary pump system (solvent A = MeCN + 0.1% TFA, solvent B =
H2O + 0.1% TFA) and two detectors (Waters 2487 Dual λ absorbance detector set at 254
nm and a radioactive flow count detector) were utilised for product analysis and
purification. An analytical column (Agilent Eclipse XDB-C18, 4.6 × 150 mm, 5 μm) was
used for determining radiochemical purity and molar activity of ([Tyr4, Lys5(AMB18F3)].
5.4.5 Radiosynthesis of ([Tyr4, Lys5(AMB18F3)]
The micro QMA (a gift from Dr. Neil Vasdev) cartridge and reaction vessel setup
was the same as previously described36. However, the cartridge was preconditioned with
6 mL of 1 M HCl, 6 mL of brine, and finally 6 mL of milli-Q water. Once the fluoride-18
was trapped on the micro QMA it was eluted into the plastic vessel (a 15 mL falcon tube
cut at the 4 mL mark capped with a rubber septum) with 20 uL of pyridazine-HCl buffer
(pH=2) and then azeotropically dried under nitrogen for 10 min at 110OC with an ascarite
filled syringe as the vent needle. The peptide ([Tyr4, Lys5(AMB19F3)] was then added
directly to the vessel at a 10 mM concentration in 10 uL of pyridazine-HCl buffer
(pH=2). The vent ascarite filled syringe (a 5 mL syringe fitted with a 20-gauge needle
with the plunger removed and packed with glass wool then filled to the 4 mL with
ascarite) was removed and the reaction proceeded for 8 min at 110OC. After the reaction
was complete it was quenched with 1 mL of 5% (v/v) NH4OH and directly loaded onto a
C-18 light Sep-Pak cartridge precondition with 10 mL of EtOH and 10 mL of water. The
cartridge was washed with 4 mL of water (2X), followed by elution of the final product
with 1 mL of 1:1 ethanol: water solution. A 20:80 water:acetonitrile HPLC gradient was
used to determine radiochemical purity and molar activity. Over the course of four trials
the decay corrected radiochemical yield was between 17 and 35%, a radiochemical purity
>99% for each trial, and a radiochemical molar activity of 12 to 15 GBq/μmol. The
retention times of the cold standard and “hot” peptide are almost identical ([Tyr4,
Lys5(AMB19F3)], tR = 5.50 mins compared to tR = 5.48 mins for the “hot” peptide ([Tyr4,
Lys5(AMB18F3)]), indicating that the precursor ([Tyr4, Lys5(AMB19F3)] has been
selectively radiolabelled by IEX.
5.4.6 Purification of RP-HPLC/ESI-MS
([Tyr4, Lys5(AMB19F3)] and ([Tyr4, Lys5(N3)] was analyzed using a reverse-phase
analytical HPLC column (Agilent Zorbax SB-C8 column 4.6 x 150 mm, 3.5 μm). This
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system was equipped with a Waters 600 136 controller, Waters Prep degasser, and
Waters Masslynx software (version 4.1). Employed mobile phases were 0.1% TFA in
deionized water (eluent A) and 0.1% TFA in acetonitrile (eluent B). The flow rate was set
at 1.5 mLmin-1 over 15 minutes. The column eluate was monitored using a Waters 2998
Photodiode array detector set at 220 nm, 254 nm and 400 nm. Peptides were purified
using a reverse-phase preparative HPLC column (Agilent Zorbax SB-C18 column 21.2 x
150 mm, 5 μm) on the same system mentioned above. The detection method and eluents
were the same as mentioned above for the analytical system and the flow rate was set at
20 mLmin-1. The collected fractions were then lyophilized to a solid and analyzed by
ESI-MS. Purity of final products was determined by analytical RP-HPLC (200-800 nm).
5.4.7 Receptor Ligand Binding Assay
Competitive ligand binding assays were performed in triplicate using
HEK293/GHS-R1a cells and [125I]Ghrelin as the competitive ligand, as previously
described29,30,35. Receptor binding affinities were calculated as IC50 values as previously
described29,30,35.
5.4.8 Molecular cloning and constructs
YFP tagged human GHS-R1a from Addgene (hGHS-R1a) was made by replacing
PAR4 in the previously published PAR4-YFP (Ramachandran et al., 2017) construct36
with GHS-R1a using restriction enzymes digestion with EcoRI and Xhol and ligation.
Constructs was verified by direct sequencing (University of Western Ontario, Robarts
DNA sequencing facility).
5.4.9 Stable Transfection of LNCaP with GHS-R1a
The LNCaP (metastatic prostate cancer derived from left supraclavicular lymph
node) cell line (ATCC) was maintained in RPMI medium (Wisent) supplemented with
10% fetal bovine serum (FBS; Wisent). Cells were plated at a density of 1 million cells in
a 10 cm dish for 24 hrs. After 24 hrs 6 µg pcDNA-GHS-R1a-eYFP was added along with
Fugene-6 (Promega) in a 1:3 ratio as per the protocol provided by Promega. After 48
hours cells were rinsed with PBS (3x) and replaced with media containing 300 µg/mL of
G418 (Wisent). Cells were then kept under selective pressure for 7 to 10 days. Cells were
then sorted (by FLOW cytometry identify the YFP tagged GHS-R1a) for single cell
populations at the London Regional Flow Cytometry Facility (LRFCF) by manager Dr.
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Kristin Chadwick. A single cell population was collected and re-sorted by the same
method mentioned above. This single cell clonal population was confirmed by confocal
microscopy identifying the tagged GHS-R1a in yellow. Confocal microscopy confirmed
90-95% of cells were expressing GHS-R1a with high cellular membrane expression
(Figure 5.S1).
5.4.10 Cellular Uptake
LNCaP cells stably transfected with GHS-R1a were plated at 150,000 cells per
well in a 6 well plate for 48 hours. Post 48 hours the cells were first rinsed (3X) and then
mechanically lifted in 1x HBSS and treated with 0.1 MBq of ([Tyr4, Lys5(AMB18F3)] per
well for 20 min at 37OC and 5% CO2. After the incubation the cells were transferred to
1.5 mL Eppendorf tubes and spun down at 13,000 G for 5 min. The supernatant was
removed from cell pellet and collected in an additional 1.5 mL Eppendorf tubes. The cell
pellet was washed with 1x HBSS and spun again at 13 000 Gs for 5 min. The
supernatants were combined. The rinse fluid and cell pellet were counted on a gamma
counter to measure a percent uptake value (counts in rinse versus counts in pellets). The
same procedure was performed for blocking with 10 x concentration of ([Tyr4,
Lys5(AMB19F3)]. This whole experiment was performed in triplicate.
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Chapter 5 Supplementary Information
HPLC-MS Traces
[Tyr4, Lys5(N3)] (Found - [M+H]+ - 841.18, Calculated - [M+H]+ - 841.17)
Default file
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[Tyr4, Lys5(AMB19F3)] (Found - [M+H]+ - 1006.30, Calculated - [M+H]+ - 1006.31)
Default file
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Supplementary Figure 5.1 - Confocal microscopy images of stable transfect LNCaP
with GHS-R1a-eYFP indicating the receptor is highly expressed and localized to the
cell membrane
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Chapter 6
Targeting the GHS-R1a Homo-Oligomer: Bivalent Ligands with Exceptional
Binding Affinity and Potency
6.1 Introduction
The growth hormone secretagogue receptor type 1a (GHS-R1a) is a G-protein
coupled receptor (GPCR) that belongs to the rhodopsin-like family of GPCRs (Class A)1.
It is primarily expressed in the pituitary gland and hypothalamus but has also shown
expression in a wide range of other tissues such as the heart, lungs, and brain2. The
natural ligand for this receptor, ghrelin, is a 28-amino acid peptide with an octanoylation
on Ser-3, and this hydrocarbon tail is needed in order to bind the GHS-R1a causing an
activation. Activation of this receptor has been identified in controlling a large number of
human physiological functions including glucose metabolism, insulin release, gut
motility, and many more2. However, its activation has been shown to be problematic in
human disease such as causing an increase of cellular proliferation in prostate cancer
through the p44/42 mitogen -activated protein kinase (MAPK) pathway3–6. The
overexpression of GHS-R1a increases the motile phenotype in astrocytomas, in which
increased GHS-R1a expression is correlated with a higher tumour grade7. Overexpression
of GHS-R1a has more recently been demonstrated in some ovarian epithelial carcinomas,
a disease with poor prognosis due to the late stages in which it is usually diagnosed8-12.
Interestingly, activating this receptor with potent agonists (i.e. anamorelin) has also been
identified to be beneficial in human disease, as is the case of cancer cachexia13. This
makes GHS-R1a an attractive target in the development of ligands that can control its
dysregulation within human diseases.
GPCRs constitute the largest group of membrane receptors in eukaryotes and play
a role in an incredible number of diversified functions in the human body. Significant
progress has been made in understanding GPCR structures and modes of function. Recent
years have seen an explosion in the number of studies showing that GPCRs not only exist
as isolated entities but also may interact with themselves and/or other membrane protein
to form homo-oligomers and hetero-oligomers respectively14-16. Most evidence indicates
that oligomers may be a predominant species, with the potential for formation of higherorder oligomers. GPCR oligomerization represents functional importance such as
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enabling cross-talk, inducing activation of alternative signalling pathways, influencing
pharmacology, influencing receptor internalization and is critical for receptor trafficking
and function14,15,17,18. Therefore, GPCR oligomers offer attractive potential therapeutic
targets for drug development.
GHS-R exists in two distinct isoforms: GHS-R1a and GHS-R1b. GHS-R1a as
mentioned previously is activated by ghrelin, to induce growth hormone release, 17
however GHS-R1b is functionally inactive and does not bind ghrelin24-25. GHS-R1a has
potential therapeutic application towards a range of diseases such as obesity, diabetes,
and cancer19-23. Along with numerous other GPCRs, GHS-R1a has been proven to form a
homo-oligomer. The first example of GHS-R1a homo-oligomerization was described in
2005 by Holst et al. Holst and co-workers used transfected COS-7 cells with GHS-R1a
and in the presence of the endogenous agonist ghrelin, along with the co-administration
of other agonists (small molecules L 692,429 and MK-0677, as well as the peptide
growth hormone releasing peptide-6 (GHRP-6)) there was a neutral, positive, or negative
modulation in signalling26. Jiang and co-workers confirmed this oligomerization in a
human embryonic kidney (HEK293) derived cell line co-transfected with GHS-R1agreen fluorescent protein (GFP) and GHS-R1a-Renilla luciferase (rluc)26. Upon
stimulation with human ghrelin a fluorescence resonance energy transfer (FRET) signal
was observed. A time-resolved (Tr) FRET measurement was also observed by Kern et al.
using a CLIP-GHS-R1a and SNAP-GHS-R1a HEK293 derived cell line28. The GHS-R1a
homo-oligomerization was also observed by Leung et al. using bioluminescence
resonance energy transfer (BRET) and co-immunoprecipitation28.
GHS-R1a has the ability to not only oligomerize with itself but also with other
GPCRs, including GHS-R1b receptor,27 prostaglandin E2 receptor (EP3-1),29 prostacyclin
receptor (IP),29 thromboxane A2 receptor (TPα),29 Somatostatin receptor 5(SST5),30
dopamine receptors (D1 and D2),27,31 melanocortin 3 receptor (MC3),32 and serotonin 2C
receptor (5-HT2C)33. Kern et al. was one of the first to describe the oligomerization
between the D1- and D2-like dopamine receptors and GHS-R1a. These receptors are
coexpressed in a number of brain regions linked to food intake and reward behaviours.
They demonstrated when there was a lack of ghrelin circulation in the brain the
oligomerization between D1- and D2-like dopamine receptors and GHS-R1a leads to
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anorexigenic effects. Rediger et al. demonstrated an additional example for the
oligomerization between GHS-R1a and MC3R32. GHS-R1a and MC3R are coexpressed
in the arcuate nuclease of neurons as observed by FRET. The stimulation of MC3R leads
to the accumulation of cAMP by means of Gas33. cAMP increases by 2-fold when MC3R
is stimulated and coupled with GHS-R1a, however GHS-R1a constitutive activity along
with ghrelin induced activity decreases intracellular calcium by 40%. However, when the
MC3R receptor is antagonized, there is an increase in GHS-R1a signalling underlying an
increase in fat mass within a MC3R-/- knockout mouse model33. These are examples in
which GHS-R1a hetero-oligomerization change the downstream signalling events leading
to different physiological outcomes.
The existence of multiple GHS-R1a oligomerization states significantly increases
the pharmacological diversity of the GHS-R1a receptor, which is expected to result in
enhanced specificity of GHS-R1a-targeted drugs34. On the other hand, GHS-R1a has a
broad spectrum of functions and is associated with a wide range of diseases. Therefore,
targeting the GHS-R1a monomer may suffer from low specificity as it will not only affect
the biological function of interest, but will also affect the other systems where the
receptor is involved. The ability to target the specific GHS-R1a homo- or hetero-oligomer
is more desirable as it is likely to lead to a more selective pharmacotherapy35.
Jiang et al. showed that the co-administration of human ghrelin and dopamine
caused a 4-fold increase in cAMP signalling enhancing positive physiological outcomes
associated with mood, learning and memory. This was only seen in the presence D1R and
GHS-R1a oligomerization36. More recently Schellekens et al. demonstrated the positive
effects of the oligomerization between the 5-hydroxytryptamine receptor 2C (5-HT2C –
serotonin receptor). Oligomerization between GHS-R1a and 5-HT2C blocks ghrelin’s
orexigenic effects as well as attenuation of ghrelin-induced food intake after the
administration of human ghrelin and/or Lorcaserin (treatment for obesity)37. Both of these
studies indicate how a combined treatment plan could be necessary to combat human
diseases such as obesity, mood, memory, and learning.
A powerful approach to pharmacologically targeting GPCR oligomers is the use
of bivalent ligands consisting of two pharmacophores linked by a spacer with appropriate
length38-40. Bivalent ligands are capable of binding to both receptors in the oligomer
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simultaneously, resulting in dramatically enhanced binding affinity due to the total
binding energy of two pharmacophores38-40. However negative cooperativity can lead to
reduction in binding and efficacy when targeting GPCR oligomers. A number of bivalent
ligands have been recently developed targeting other GPCR homo- and hetero-oligomers,
but none has been developed for GHS-R1a38-40. In the present study, we reported the
design, synthesis, binding affinity and signalling responses from bivalent ligands
targeting GHS-R1a. Through a rational structure-based design approach, we discovered a
bivalent ligand based on peptidomimetic G7039 that possesses exceptionally high
binding affinity and is able to bind to oligomeric GHS-R1a in HEK293 cells. Compound
6 not only displayed exceptional binding, but also caused an increase in b-arrestin
recruitment thus changing the signalling of p44/42 MAPK pathway. However, signalling
mechanism changes were evident when studies were conducted using G protein (Gq,
Gq/11, Gi/o, and G12/13) signaling couple gene reporter assays. The molecular basis for
cellular distribution of, and more importantly, the functional relevance in disease of the
GHS-R1a homo-oligomer formation have been elusive. The bivalent ligand developed
herein presents a powerful tool to enlighten how the homo-oligomer functions and has the
potential to advance a promising novel therapeutic approach for homo-oligomer related
pathological condition through fine-tuning GHS-R1a receptor-mediated activity.
6.2 Results and Discussion
6.2.1 Rationalizing the Design of our Bivalent Ligand
Bivalent ligands intended to simultaneously bind to both receptors in the oligomer
consist of two recognition elements linked by a spacer with optimal length. A number of
studies have described that bivalent can be rationally designed if some important aspects
such as suitable pharmacophore, spacer length, and attachment point are considered38-40.
The peptidomimetic G7039, discovered by Genentech Inc from extensive medicinal
chemistry studies on GHRP-6 and G-7502,41-42 was used as the pharmacophore due to it
high binding affinity (IC50 = 5.2 nM as determined in our lab) and being readily
synthesized via solid phase synthesis (Figure 6.1A).
Theoretically, bivalent ligands successfully bridging two binding sites within the
homo-oligomer should exhibit extremely high binding affinity as the result of the total
binding free energy of two pharmacophores. Indeed, a number of bivalent ligands with

233
improved binding affinities as compared to their parent compounds have been reported43.
Notably, the bivalent ligands mentioned in the literature are small molecule-based
pharmacophores with spacer lengths ranging from about 6 to 20 atoms. It has been
proposed that bivalent ligands with short spacer lengths are not able to extend sufficiently
out of the transmembrane domain to enable the binding to its neighboring receptor44. It is
more likely that these ligands bind to different sites (i.e., orthosteric site and allosteric
site) on a single receptor as suggested by molecular modelling (therefore have been
coined the name bitopic ligands)45. Moreover, Vagner et al. proposed that the enhanced
binding affinities of bivalent ligands with short linkers (<20Å) relative to monomers was
mainly due to the ‘statistical binding effect’, that is, the binding of one pharmacophore of
a bivalent ligand to one receptor leads to an increased local concentration of the ligand,
resulting in the increased statistical probability of binding the other receptor within the
oligomer46-47. The ‘statistical binding effect’ suggests a ‘dual-acting phenotype’, rather
than a true bivalent binding48. The crystal structure of GPCR oligomers as well as
modeling studies estimated the distance between two adjacent binding sites to be in a
drastically wide range ranging from 25 to 100Å, in the case of loosely packed receptors48.

Figure 6.1 - Structure-based approach for the design of bivalent ligands. (A)
Structure of G7039 and the (B) G7039-GHS-R1a complex model previously
developed in our lab indicated that the (C) C-terminus is the suitable attachment
point
With the previous literature in mind, we set out to design a bivalent ligand with
the appropriate linker length in order to target the GHS-R1a homo-oligomer. In order to
better guide our attempt at the appropriate linker length we generated a homo-oligomer
model based on the G7039-GHS-R1a complex model previously developed in our lab49
and the crystal structure of the beta-1 adrenergic receptor oligomer (PDBID: 4GPO50).
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Beta-1-adrenergic and GHS-R1a share a relatively high sequence similarity of about
38%. Our homo-oligomer model of GHS-R1a in complex with G7039 showed a
minimum distance of 50Å between the C-terminus attachment points of G7039 (Figure
6.1C). However, the model indicated that a longer spacer length should be required to
enable a bivalent ligand interaction with the oligomer for a number of reasons. First, the
amides on the C-terminus are not facing straight towards each other due to the binding
pattern of the ligand in the orthosteric site of the receptor. Second, the ligand is buried in
the binding pocket to some extent and an additional spacer length will be needed to
extend the ligand to the extracellular side. A third reason supporting the need for a longer
linker is because the receptor binding pocket is partially blocked by the N-terminus of
GHS-R1a. An estimation of the distance allowing the ligand to be accessible from
extracellular side and at the same time get away with the N-terminus suggested a spacer
length between 50-74Å is required to crosslink both receptors. We next considered the
location to attach the linker between the two G7039 peptides. The G7039-GHS-R1a
complex model shows that the positively charged N-terminus serves as an anchor point
for binding via a charge-charge interaction with Glu124 on the GHS-R1a, while the Cterminus is accessible from the extracellular side. Based on the model, the C-terminus is
determined to be the suitable attachment points for linking two pharmacophores with a
spacer (Figure 6.1B).
Furthermore, the composition of the spacer regarding hydrophilicity, flexibility,
and the ease of synthesis was also considered. We decided to use PEG (polyethylene
glycol) units as this would avoid cumulative increase in hydrophobicity51. The FmocAEEA (Fmoc-8-amino-3,6-dioxaoctanoic acid) was selected as it can be treated as an
amino acid that is readily added on to the peptide via solid phase synthesis. Each of the
AEEA unit consists of 9 atoms and is about 10Å. We concluded that 5-7 AEEA units
will be necessary to enable a bivalent-binding mode, while a ligand containing a spacer
shorter than that should not be able to bridge two binding sites. The ligands bearing 1-4
AEEA units were synthesized as control agents to investigate more thoroughly how the
spacer length affects the binding affinity. Additionally, the ligand with 8 AEEA units was
also synthesized.
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6.2.2 Synthesis
The bivalent ligands based on G7039 were synthesized using standard Fmoc
peptide chemistry on a solid support. They were synthesized with amino acids bearing
standard protecting groups, with the exception of the C-teminus Lys, that contained the
orthogonal protecting group allyloxycarbonyl (Alloc). The first G7039 unit with
additional Alloc protected Lys at the C-terminus was synthesized on solid support using
automated peptide synthesis. The selective deprotection of the lysine Alloc protecting
group was carried out and the resulting free amine at the Lys side chain allows for the
ligation of individual spacer (Fmoc-AEEA) with different lengths.
The second G7039 pharmacophore was then coupled with the deprotected AEEA
using automated peptide synthesis. After both G7039 pharmacophores were added to the
solid support, all protecting groups were cleaved from resin (Scheme 6.1).

Scheme 6.1 - Solid phase synthesis of peptidomimetics. a: Fmoc-Lys(Alloc)-OH; b:
(1) piperidine/DMF, (2)Fmoc-amino acid; c: TPP palladium; d:Fmoc-AEEA; e:
piperidine/DMF; f: Fmoc-amino acid; e: total deprotection from the resin using
95% TFA, 2.5% TIPS, and 2.5% H2O
6.2.3 Radioligand binding evaluation
The bivalent ligands with a spacer length ranging from 13-76 atoms (17-92 Å)
were synthesized. Their binding profiles (IC50) were determined by competitive
radioligand ([125I]-ghrelin) binding assay using GHS-R1a transfected HEK293 cells as
receptor source (Table 6.1, Figure 2). Compound 1 with the shortest spacer showed
slightly increased binding affinity (1.6 nM) as compared to that of the parent ligand
G7039 (5.2 nM). When the spacer length was increased to 22 atoms (28 Å), the binding
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affinity increased to 0.55 nM (Compound 2). Further elongation of the spacer to 31atoms
(38 Å) resulted in a slightly increased binding affinity for bivalent compound 3 (0.32
nM). After this point, further extension of the spacer to 49 atoms (60 Å) resulted in
comparable affinities for compounds 3, 4 and 5. All the binding displayed monophasic
curves. However, the binding characteristics changed dramatically by the extension of the
spacer to 58 atoms (70 Å) for compound 6, a biphasic competition curve with two
individual values for IC50high and IC50low differing by about 2 orders of magnitude was
observed indicating two binding states (Figure 6.2F). The high-affinity binding was
determined to be 0.43 nM with a high-affinity population of 45%, while the affinity for
the low-affinity binding was determined to be 0.00042 nM. The biphasic competition
curve can be explained by the coexistence of different receptor subpopulations, which has
been observed looking at other GPCRs52-54. Our data suggests that GHS-R1 also exists as
two different receptor subpopulations, that is monomer and homo-oligomer. The lowaffinity binding corresponded to a monovalent-binding mode to the receptor, while the
high-affinity binding represented to a bivalent receptor bridging mode of compound 6 to
the GHS-R1 homo-oligomer. Interestingly, the ligands (compound 7, compound 8) with
longer spacer length showed comparable binding affinities (0.31 nM and 0.22 nM,
respectively) but displayed monophasic binding curves rather than biphasic ones,
suggesting that ligands bearing a spacer that is too long (> 67atoms/82 Å) are not
effective at bridging two receptors in the homo-oligomer. To factor out possible
contributions of the spacer to binding affinity, monovalent ligand compound 10
containing a spacer with 58 atoms (70 Å) was synthesized as control. The IC50 was
determined to be 1.09 nM, suggesting that the spacer does not have appreciable
contribution to the binding affinity (Table 6.2). This was also proven by a monophasic
binding curve indicating that compound 10 does not target the homo-oligomer.
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Table 6.1 - Binding affinities for bivalent ligands determined by [125I]-ghrelin
displacement
Bivalent ligands

Compound n
Number

Spacer Length

Spacer Length

(atoms)

(Å)

IC50 (mean ± SE)

Curve shapes

1

1

13

17

1.60 ± 0.57 nM

Monophasic

2

2

22

28

0.55 ± 0.28 nM

Monophasic

3

3

31

38

0.32 ± 0.01 nM

Monophasic

4

4

40

49

0.30 ± 0.14 nM

Monophasic

5

5

49

60

0.23 ± 0.02 nM

Monophasic

6

6

58

70

IC50low =0.43 ± 0.30
nM
IC50high =0.42 ± 0.53

Biphasic

pM
7

7

67

82

0.31 ± 0.04 nM

Monophasic

8

8

76

92

0.22 ± 0.13 nM

Monophasic
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Table 6.2 - Binding affinities for monovalent ligands determined by [125I]-ghrelin
displacement
Monovalent ligands

Ligands n
(Compound

Spacer Length Spacer Length IC50 (mean ± SE)
(atoms)

Curve shapes

(Å)

Number)
G7039 (9)
(10)

6

58

70

3.10 ± 2.97 nM

Monophasic

1.09 ± 0.04 nM

Monophasic
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Figure 6.2 - Radioligand binding curves for all bivalent ligands and monovalent
ligand
Vagner et al. noted that bivalent ligands with shorter spacer (<20Å) exhibited
dual acting binding mode rather than bivalent binding mode due to the ‘statistical
effect’47,51. We suggest that the bivalent ligands compound 1, compound 2, compound 3,
compound 4, and compound 5 engage GHS-R1a receptor in a dual acting mode and the
enhanced binding affinities of these bivalent ligands is due to the ‘statistical effect’.
Among these ligands, the effect became more significant when the spacer is long enough
to extend the second pharmacophore to the extracellular site and enable an increase in
local concentration. With an optimal spacer length of 58 atoms/70 Å, the bivalent ligand
compound 6 is capable of bridging two receptors in the oligomer, leading to a markedly
boosted binding affinity (IC50high). However, due to the coexistence of monomer
subpopulation in the cells, a monovalent binding mode is inevitable, leading to a higher
binding affinity (IC50low). With an even longer spacer, the bivalent ligand is not able to
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bridge both receptors in the oligomer due to the entropy cost, associated with restricting
the second pharmacophore to the second binding site, being too great.

Figure 6.3 - b-Arrestin 1 and 2 recruitment measuring the potency of the ligands
(EC50) values. (A) b-Arrestin 1 recruitment indicating an entire log shift in potency
increase for the bivalent ligand. (B) b-Arrestin 2 recruitment indicating an entire log
shift in potency increase for the bivalent ligand. The bivalent ligand has an increase
in net BRET ratio compared to the other ligands indicating that the bivalent ligand
is more of a full agonist. (C) Measured EC50 values with the bivalent ligand being the
most potent in the series (n=3 for both b-Arrestin 1 and 2 recruitment). *P<0.05
compared to G7039
From this point forward, four ligands were evaluated in terms of differences seen
in downstream signalling with the GHS-R1a homo-oligomer versus the GHS-R1a
monomeric receptor. The lead bivalent ligand (6) was compared to the controls consisting
of human ghrelin, G7039 (9) and G7039-L (10). We used a bioluminescence resonance
energy transfer (BRET) assay to monitor b-arrestin recruitment to GHS-R1a. This was
accomplished by transiently transfecting HEK293 cells with an eYFP tagged GHS-R1a
(GHSR-1a-eYFP) and a Renilla luciferase (rluc) tagged b-arrestin1 (b-Arrestin 1-rluc) or
b-arrestin 2 (b-Arrestin 1-rluc) construct in a 10 to 1 ratio, respectively. Upon addition of
the various ligands (Figure 6.3 panel C) at a concentration range from 1x10-5 M to 1x1013

M a net BRET ratio was measured to assess agonist stimulated arrestin recruitment to

GHS-R1a. Previously it has been shown that when GHS-R1a is activated by an agonist
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such as human ghrelin it causes the recruitment of both b-arrestin-1 and b-arrestin-255-57.
It has been demonstrated that GHS-R1a forms a transient complex with b-arrestin-2 on
the cell membrane provided by the stabilization of phosphate acceptor sites from the tail
of the receptor. This was proven to be destabilized by mutagenesis experiments with the
conserved residues (Pro 148, Ala 144 and Leu 149) seen within this region. This
interaction with b-arrestin-2 is crucial in the induction of Ras Homolog Family Member
A (RhoA) signalling and the remodelling of actin filaments58. We show that the bivalent
ligand (6) has greater potency than ghrelin for activation of b-arrestin-1 and b-arrestin-2
recruitment with EC50 values in the low nanomolar range (EC50 = 1.07 nM for β-Arr-1
and EC50 = 3.09 nM for β-Arr-2). G7039-L (10), and the natural ligand for the receptor,
ghrelin, have 2-80x fold reduction in the recruitment of b-arrestin-1 and b-arrestin-2
(Figure 6.3). This increase in potency is possibly due to the activation of a homooigomer receptor compared to a monomer. The homo-oligomeric complex is causing an
increase in the localization of b-arrestin-1 and b-arrestin-2 to GHS-R1a at the membrane
due GPCR oligomerization when targeting with bivalent based ligands47-48. It can also be
noted that compound 9 has a significant increase in potency (pM) for b-arrestin-1 and barrestin-2 recruitment compared to all other compounds. This is an interesting
observation seen as this compound is only targeting the monomeric GHS-R1a.
To further assess whether or not this bivalent ligand (6) was targeting a homooligomer, an assay was designed using transiently transfected cells with the BRET pair
GHS-R1a-eYFP (2 μg) and GHS-R1a-rluc (2 μg). This particular assay has been used in
the past to show GHS-R1a homo-oligomerization26-28. 48-hour post transfection cells
were treated with the various ligands from a 1x10-5 M to 1x10-15 M concentration range
and the net BRET signal monitored receptor oligomerization.
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Figure 6.4 – Homo-oligomer assay indicating that the bivalent ligand is able to
induce a homo-oligomer formation with GHS-R1a causing a net increase in BRET
signal that is 3x greater compared to the control ligands. (A) Net BRET ratio
measured over a concentration range. (B) Net BRET ratio a given high and low
concentration. The control ligands have little to no increase in net BRET signal at
both a high and low concentration (n=3)
The data in Figure 6.4 panel A indicates that the bivalent ligand (6) targets the
GHS-R1a homo-oligomr as there is an increasing net BRET signal, with a 4-log shift
lower concentration (1x10-10M vs. 1x10-6M) compared to the control ligands. This
bivalent ligang may also be involved in stabilizing the GHS-R1a oligomers. An increase
in net BRET signal is only seen when higher concentrations (1x10-6M to 1x10-5M) of the
control ligands are used and may be indicative of a signaling dependent clustering of the
receptors in membrane microdomains or vesicles. Panel B in Figure 6.4 is an additional
representation of a given high (1x10-6M) and low (1x10-11M) concentration again
showing the bivalent ligand (6) is able to target the GHS-R1a oligomer. This assay
indicated that 6 is able to target the receptor homo-oligomer, and possible stabilize its
formation. The control ligands are only able to bind the monomer receptor as they do not
show an increase in the net BRET signal at the wide range of concentrations assessed.
Changes in intracellular calcium were then measured using LNCaP cells stably
expressing GHS-R1a-eYFP. A leftward shift in the concentration effect curve was
observed with compound 6 compared to ghrelin indicating that compound 6 is more
potent then ghrelin (EC50 of 12 nM versus 121 nM). The Emax is comparable between both
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ghrelin and compound 6, reaching 30% of the maximum calcium signal obtained with
calcium ionophore (A23187) treatment (Figure 6.5).
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Figure 6.5 - Changes in intracellular calcium measured in LNCaP cells stably
transfected with GHS-R1a. This is a percent calcium signal obtained with the
treatment of calcium ionophore (n=3)
A series of experiments were designed to investigate whether activation of GHSR1a homo-oligomer causes differential downstream signalling compared to when
activating the GHS-R1a monomer. The downstream signals measured were the
phosphorylation of extracellular signal–regulated kinases-1 and -2 (ERK-1/-2; a.k.a.
p44/42), and gene reporters nuclear factor kappa-light-chain-enhancer of activated B cells
(NF-kB), serum response element (SRE), serum response factor (SRF), nuclear factor of
activated T-cells (NFAT), and cyclic AMP response element (CRE). GHS-R1a mediated
phosphorylation of ERK-1/-2 (p-p44/42) involves both the interaction with b-arrestin and
G protein components. GHS-R1a activation signalling occurs through a series of Gprotein components including Gq, Gq/11, Gi/o, and G12/1359-63.

Figure 6.6 - (A) pERK/tERK ratio when treated with ghrelin and bivalent ligand
from 0 to 30 min. (B) Representative blot from total data graphed in A. Ghrelin
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induced a higher level of phosphorylation of ERK 1 and 2 compared to the bivalent
at 10- and 20-min incubation. This was done in HEK293T cells that transiently
expressed GHS-R1a-eYFP (eYFP used as loading control – data not shown) (n=3,
p<0.05 for 10- and 20-min time points)
The bivalent ligand (6) caused less phosphorylation at 10- and 20-min. incubation
periods compared to ghrelin. The signal intensity for the pERK/tERK ratio steadily
increases to a maximum at 20 min followed by a steady decrease till 30 min (P<0.05).
These results are the first indication that GHS-R1a homo-oligomer modulates
downstream signalling differently compared to when it is activated as a monomer. Even
though there was a greater increase in b-arrestin recruitment, it was believed that the
activation of the oligomer would have caused an increase in ERK-1/-2 phosphorylation.
However, since compound 6 is more involved in b-arrestin recruitment we expect a
decrease in G-protein recruitment leading to a decrease in ERK phosphorylation (Figure
6.6). Additional ERK phosphorylation was followed up by assessing the other ligands at
various concentrations for a 20 min incubation period (Figure 6.7).

Figure 6.7 - pERK/tERK ratio measured for all 4 ligands from a 1 to 100 nM
concentration for a 20 min incubation period. Background (0 nM) was removed. (B)
Representative western blot indicating there is an increase in pERK/tERK for
ghrelin compared to compound 6. 0 nM concentration is vehicle control with HBSS
and 0.1% DMSO. Only significance for the 100 nM concentration was seen
(indicated by *) (n=3, P<0.05 for 100 nM concentration)
At a concentration of 100 nM there was significantly less phosphorylation (2x to
3x less) of ERK 1 and 2 with the bivalent ligand (6) compared to the other three
monovalent ligands (P<0.05). No significance was seen with the lower concentrations. It
must be noted that for all western blots eYFP was probed for, to ensure equivalent
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receptor expression levels in cells from which lysates were obtained. Data does not
change when the ratio of (pERK/tERK)/(eYFP) is assessed (data not shown).
Next, we investigated the source of ERK activation downstream of GHS-R1a
activation to further investigate our finding that the bivalent ligand (6) activated ERK to
lesser magnitude than that found with ghrelin. ERK activation can occur downstream of
both Gq/11 and b-arrestin signalling pathways64. Pre-incubation with with Gq/11 specific
inhibitor, YM254890 (100 nM), was sufficiently able to inhibit ERK activation at 20
minutes following ghrelin stimulation (100 nM; Figure 6.8). Thus, ERK activation
occurs downstream of Gq/11 activation following GHS-R1a agonism with ghrelin.

Figure 6.8 - (A) Stimulation of ERK (p-p44/42) phosphorylation with or without
pre-incubation with Gq/11 inhibitor YM254890 (100 nM) and stimulation with
ghrelin (100 nM). Data are shown as ratio of pERK/tERK. (B) Representative
western blot indicating pERK is completely inhibited in the presence of YM254890.
Significance was only observed between unstimulated and ghrelin treated vehicle
control (indicated by *) (n=3, p<0.05)
Finally, gene reporters were assessed to test the hypothesis that the GHS-R1a
homo-oligomer leads to differential downstream signalling. The gene reporters that were
studied have known upstream G-protein partners. SRE leads to mitogen activated protein
kinase (MAPK) response and is downstream of Gq/11, Gs, and Gi. SRF is downstream of
Gq/11, and G12/13. CRE is downstream of Gs. NFAT is downstream of Gq/11. Finally, NFkB is downstream of many pathways (Figure 6.9). The intention with using these gene
reporters was to better understand how the GHS-R1a homo-oligomer modulates Gprotein partners when activated.
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Figure 6.9 - Gene reporters assessed at a 100 nM concentration for ghrelin and the
bivalent ligand. CRE and NFAT did not show any signal for all treatments. HBSS
with 0.1% DMSO and Serum are control conditions. No significance was seen
between Ghrelin vs. the Bivalent only trends were observed; (n=3)
The bivalent ligand (6) showed differential signalling compared to the other three
ligands, with 6 causing the greatest activation with SRF and SRE. Ghrelin was least
potent in activating SRF and SRE. This was an expected result as the activation of GHSR1a is known to come from both Gq/11 and G12/13. However, receptor oligomerization led
to an increase in the activation of these G-proteins when targeted with this highly potent
homobivalent agonist. This was reversed for NF-kB, as the bivalent ligand (6) began to
slow this signalling pathway, where ghrelin caused an activation of NF-kB. CRE and
NFAT did not showing any activation with any of the four ligands. The lack of CRE
activation is downstream of Gs and this data is not unexpected since GHS-R1a is not
reported to couple to this G protein. The lack of NFAT activation was however somewhat
unexpected since GHS-R1a coupling to Gaq/11 has been reported and NFAT gene
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reported activity occurs downstream of Gaq/11. This discrepancy could stem from the
time after agonist treatment at which these assays were done and represent a limitation of
using gene reporters to probe signaling pathways. 1x HBSS was used as the negative
control and showed no activation of any of the gene reporters. DMEM media containing
10% FBS was used as a positive control causing an upregulation of SRF, SRE, and NFkB as these are serum response genes. The reduction in NF-kB is highly beneficial in
terms of being able to agonize GHS-R1a in diseases such as cancer cachexia, without
upregulating other pathways involved in inflammation13. This is the first known instant of
targeting the GHS-R1a homo-oligomer with a homobivalent agonist resulting in changes
in downstream signalling events.
6.3 Conclusions
We report herein the development and characterization of a novel ligand targeting
the GHS-R1a homo-oligomer. The ligand that was chosen was the established ghrelin
peptidomimetic G7039, as the initial goal was to determine the spacer length between the
two linked G7039 molecules in order to target the oligomerized GHS-R1a with high
affinity and potency. An optimal spacer length of 58 atoms was determined in order for
compound 6 to target the GHS-R1a homo-oligomer. The discovery of the spacer length
sets the ground work to synthesize additional ghrelin ligands such as heterobivalent
ligands (e.g. agonist linked to antagonist) and other homobivalent ligands (e.g. antagonist
linked to antagonist). Also, based on the previous design of imaging agents derived from
G7039, this high affinity probe can easily be converted into a PET imaging probe54. The
linker region of compound 6 is also a potential sight to conjugate various fluorescent dyes
and imaging moieties for various modalities such as PET, SPECT and confocal
microscopy.
The second major outcome of this paper is when you target and activate the GHSR1a homo-oligomer using compound 6 there is the presence of differential downstream
signalling. The bivalent ligand (6) caused 2 to 80-fold increase (versus human ghrelin and
G7039-L) in b-arrestin-1 and b-arrestin-2 recruitment. This correlates to a large increase
(versus human ghrelin and G7039) in binding (2000 to 11,000-fold increase) when 6
targets the GHS-R1a homo-oligomer. Interestingly G7039 is 50-fold more potent in barrestin-1 and b-arrestin-2 recruitment when targeting the GHS-R1a monomer. However,
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even though compound 6 has the greatest affinity and potency, it caused a decrease in the
phosphorylation of ERK-1/-2 compared to when ghrelin bound the monomeric GHS-R1a.
GHS-R1a oligomerization is an explanation for this decrease in phosphorylation of ERK
1 and 2 as well as the increase observed in b-arrestin recruitment when targeting the
homo-oligomer with 6.
b-arrestin commonly performs the role of desensitizing activated GPCRs leading
to the cessation of G-protein signalling. This hypothesis is supported by the observation
of inhibited ERK phosphorylation in the presence of Gq/11 inhibitor and stimulation with
ghrelin. Thus, increasing b-arrestin recruitment may be contributing to increased
desentization of Gq/11 signalling and the downstream ERK activation pathway.
Compound 6 also caused an increase in SRF and SRE gene reporters compared to
ghrelin. Interestingly this pattern was reversed for NF-kB as ghrelin caused a greater
increase in NF-kB compared to compound 6. NF-kB is an inflammation biomarker,
therefore 6 has the potential to treat diseases associated with lower levels of GHS-R1a
activation (cancer cachexia) but not cause a drastic increase in inflammatory markers
leading to further side effects13, 38-40.
This is the first ever demonstration of the development and assessment of a
ghrelin homobivalent peptide ligand that targets the GHS-R1a homo-oligomer with the
greatest known affinity for a peptide targeting this receptor. It was also discovered that
the receptor homo-oligomer displays differential signalling mechanisms when looking at
specific downstream genes and proteins.
6.4 Materials and Methods
6.4.1 General Information
All reagents were obtained from Sigma-Aldrich, Fisher Scientific, Ark Pharm Inc
or Oakwood Chemicals. The purity of the compounds was analyzed using analytical
UHPLC. These results are summarized in Table S2 and Figure S4, with all compounds
determined to have ≥95% purity. Acquity UHPLC H-Class system (Waters, Inc.)
combined with a Xevo QTof mass spectrometer was used for analytical UHPLC-MS
work. Waters Acquity UHPLC BEH C18 column (2.1 x 50 mm, 1.7 μm) was used. High
resolution mass spectra were obtained on a Thermo Scientific DFS (Double Focusing
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Sector) mass spectrometer. [125I]-Ghrelin for binding assay was purchased from Perkin
Elmer
6.4.2 General Fmoc Synthesis of bivalent ligands
Automated peptide synthesis was carried out using Fmoc-based solid-phase
peptide chemistry. Peptides were synthesized at a 0.1 mmol scale on Rink Amide MBHA
resin (0.52 mmol/g) using a glass peptide reaction vessel. The resin was initially swelled
with N,N-dimethylformamide (DMF), followed by Fmoc deprotection using 2 mL of
20% piperidine in N,N-dimethylformamide (DMF) for two cycles (10 minutes, 5
minutes). Amino acids were preactivated by combining 3 eq. of Fmoc-protected amino
acid, 3 eq. of O-(6-chlorobenzotriazol-1-yl)-N,N,N’,N’-tetramethyluronium
hexafluorophosphate (HCTU) and 6 eq. of N,N-diisopropylethylamine (DIPEA) in 2 mL
of DMF. The mixture was added to the resin and vortexed for 60 minutes. These cycles
were repeated until all N-terminal amino acids were coupled to the resin.
Allyloxycarbonyl deprotection of diaminopropionic acid was performed under inert
atmospheric N2 conditions. DCM was dried over sieves for 24 hours before adding 1 mL
to the resin. Two equivalents of phenylsilane in 1 mL dry DCM was then added to the
peptide resin followed by 0.045 eq. of tetrakis(triphenylphosphine) palladium (0) in 1 mL
dry DCM. The peptide vessel was removed from inert conditions and allowed to react for
30 minutes. 4 eq. of HCTU and 6 eq. of DIPEA in DMF were used. The reaction mixture
was left to couple overnight. Full deprotection of the synthesized peptide was performed
by adding a 2 mL mixture of 95% trifluoroacetic acid (TFA), 2.5% triisopropylsilane
(TIS) and 2.5% water to the resin and allowed it to mix for 5 hours. The cleaved peptide
was precipitated from solution using ice-cold tert-butyl methyl ether (TBME) and
centrifuged (3000 rpm, 10 minutes) resulting in a crude peptide pellet. The supernatant
was decanted and the resulting peptide pellet was dissolved in 20% acetonitrile in water,
frozen at -78 °C and lyophilized to a white crude powder. Purification was performed
using preparative HPLC-MS and purity of the resulting peptides were analyzed using
analytical UHPLC. These results are summarized in Table 4, with all compounds
determined to have ≥95% purity.
Table 6.3 - Analytical data of bivalent and monovalent ligands
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Compds.

Calculated Mass
M+2

M+3

Found Mass
M+4

M+2

M+3

Purity
M+4

(%)

1

927.0071 618.3407 464.0075 927.1216 618.0745 463.7966

98%

2

999.5441 666.6987 500.2760 999.6514 666.4235 500.0591

98%

3

1072.0810 715.0566 536.5444 1072.1301 715.0840 536.3059

97%

4

1144.6180 763.4146 572.8129 1145.3213 763.1813 572.6222

96%

5

1217.1549 811.7725 609.0814 1217.0791 811.7061 608.7670

99%

6

1289.6919 860.1305 645.3499 1289.6057 860.0715 645.0356

98%

7

1362.2288 908.4885 681.6183 1361.8447 908.2506 681.4270

99%

8

1434.7658 956.8464 717.8868 1434.9236 956.6053 717.6960

99%

10

898.9902 599.6628

99%

899.2583 599.4990

6.4.3 Kaiser Test
To qualitatively determine if there is free amine present (i.e. after a Fmocdeprotection, amino acid coupling, or alloc deprotection), a Kaiser test was performed. A
small amount of resin (<5 mg) was placed in a small test tube. To the test tube, solutions
of Phenol:EtOH (8:2 v/v), 0.001M KCN:pyridine (2:98 v/v) and ninhydrin in EtOH (5%
w/v) were added. The test tube was heated to 70°C and the presence of a free amine was
indicated by the resin beads turning blue. The lack of free amine was indicated by the
presence of clear/yellow resin beads.
6.4.4 Deprotection of Allyloxycarbonyl (Alloc) Proctecting Group
Selective deprotection of the allyloxycarbonyl protecting group was accomplished
by adding DCM (4.5 mL) to the resin-bound peptide and shaking gently for 10 minutes.
After addition of phenylsilane (24 equiv.), the peptide vessel was flushed with nitrogen
and allowed to react for 5 minutes. Then, tetrakis(triphenylphosphine) palladium (0) (0.1
equiv.) was added to the mixture and the peptide vessel was again flushed with nitrogen,
and the reaction was allowed to proceed for 10 minutes. Next, the peptide-resin was
washed with DCM four times (1.5 mL), followed by a series of washings with 1.5 mL of
DCM, DMF, MeOH, DMF, and DCM (30 sec each).
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6.4.5 Purification of RP-HPLC/ESI-MS
Peptides were analyzed using a reverse-phase analytical HPLC column (Agilent
Zorbax SB-C8 column 4.6 x 150 mm, 3.5 μm). This system was equipped with a Waters
600 136 controller, Waters Prep degasser, and Waters Masslynx software (version 4.1).
Employed mobile phases were 0.1% TFA in deionized water (eluent A) and 0.1% TFA in
acetonitrile (eluent B). The flow rate was set at 1.5mLmin-1 over 15 minutes. The column
eluate was monitored using a Waters 2998 Photodiode array detector set at 220 nm, 254
nm and 400 nm. Peptides were purified using a reverse-phase preparative HPLC column
(Agilent Zorbax SB-C18 column 21.2 x 150 mm, 5 μm) on the same system mentioned
above. The detection method and eluents were the same was mentioned above for the
analytical system and the flow rate was set at 20 mLmin-1. The collected fractions were
then lyophilized to a solid. For analytical UHPLC-MS, studies were performed on a
Waters, Inc. Acquity UHPLC H-Class system, combined with a Xevo QTof mass
spectrometer (ESI+, cone voltage = 30 V). A Waters Acquity UHPLC BEH C18 2.1 x 50
mm, 1.7 μm column was used with a gradient solvent system consisting of 0.1% formic
acid in acetonitrile and 0.1% formic acid in water.
6.4.6 Coupling of Fmoc AEEA Linker
After the Alloc protecting group has been removed, Fmoc-AEEA (1 to 8 linkers
added) was coupled to additional C-terminal Lys residue of G7039. This was
accomplished by adding Fmoc-AEEA (0.3 mmol) and the coupling reagent HATU (0.3
mmol) dissolved in DMF (1.5 mL) to the resin. This mixture was vortexed for 2 hours,
and the resin was then washed 3 times with DMF (2.0 mL, vortex 30 sec) and 3 times
with DCM (2.0 mL, vortex 30 sec), then dried under vacuum.
6.4.7 Competitive Binding Assay (IC50)
The affinity for GHS-R1a was determined using a radioligand competitive
binding assay. Assays were performed using GHS-R1a transfected HEK293 cells as
receptor source and human [125I]-ghrelin(1-28) (Abcam) as the radioligand. Human
ghrelin(1-28) was used as reference to ensure the validity of the results. A suspension of
membrane from HEK293/GHS-R1a cells (50,000 cells per assay tube) were incubated
with ghrelin(1-8) peptide analogues (at concentrations of 10-5 M, 10-6 M, 10-7 M, 10-8 M,
10-9 M, 10-10 M and 10-11 M) and [125I]-ghrelin (15 pM per assay tube) in binding buffer
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(25 mM HEPES, 5 mM magnesium chloride, 1 mM calcium chloride, 2.5 mM EDTA,
and 0.4% BSA, pH 7.4). The resulting suspension was incubated for 20 minutes under
shaking (550 rpm) at 37 °C. Unbound [125I]-ghrelin was removed and the amount of
[125I]-ghrelin bound to the membranes was measured by gamma counter. IC50 values were
determined by nonlinear regression analysis. All binding assays were performed in
duplicate or triplicate.
6.4.8 Molecular cloning and constructs
YFP tagged human GHS-R1a from Addgene (hGHS-R1a) was made by replacing
PAR4 in the previously published PAR4-YFP (Ramachandran et al., 2017) construct65
with GHS-R1a using restriction enzymes digestion with EcoRI and Xhol and ligation.
Constructs was verified by direct sequencing (University of Western Ontario, Robarts
DNA sequencing facility).
6.4.9 Bioluminescence Resonance Energy Transfer (BRET): β-Arrestin 1/2
Recruitment Assay
HEK293T cells were transfected with BRET pair GHS-R1a-eYFP (2 μg) and βarrestin-1-rluc or β-arrestin-2-rluc (0.2 μg) using calcium phosphate in tissue culture
treated white 96-well plates. 48 hours after transfection, cells were treated with the
agonists being tested, Renilla luciferase substrate (h-coelenterazine) was added to each
well (5 μM final) and incubated (37 °C, 20 min), before measuring BRET ratios on a
Berthold Mithras LB 940. Responses are expressed as net emission of eYFP/rluc
(calculated by subtracting HBSS baseline eYFP/rluc ratio from agonist eYFP/rluc ratio)
and normalized to a positive control. Experiments were performed in triplicate with 3
separate cultures of cells and data was fitted with a non-linear regression analysis fourparameter dose-response curve using GraphPad Prism 6 to determine EC50 values, as this
fitting provided the greatest R squared value.
6.4.10 Homodimer Assay
HEK293T cells were transfected with BRET pair GHS-R1a-eYFP (2 μg) and
GHS-R1a-rluc (2 μg) using calcium phosphate in tissue culture treated white 96-well
plates. 48 hours after transfection, cells were treated with the agonists being tested,
Renilla luciferase substrate (h-coelenterazine) was added to each well (5 μM final) and
incubated (37 °C, 20 min), before measuring BRET ratios on a Berthold Mithras LB 940.
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Increase in a net BRET signal indicated that each of the differentially tagged receptors
were in close proximity.
6.4.11 Gene Reporter Assay
HEK293T cells are maintained in Dulbecco’s Modified Eagle’s medium (DMEM)
from Sigma-Aldrich (D5796) with added 5% sodium pyruvate, 5% penicillin
streptomycin, and 10% fetal bovine serum (FBS) at 37°C with 5% CO2. Cells were
cultured in a T-75 flask to 95% confluency then lifted by trypsin-ETDA (0.25%). Once
cells were counted and spun down at 1000 rpm they were resuspended and then re-plated
in 10 cm culture dishes at 1 million cells per plate. Seeding was then accomplished for 24
hrs at 37°C with 5% CO2. After 24 hrs cells were transiently transfected with 2 ug of
GHS-R1a-eYFP and 2 ug of either NFAT/SRE/SRF/NF- kB/CRE-nluc by calcium
phosphate transfection method for 24 hrs at 37°C with 5% CO2. Following the 24 hr
transfection cells were rinsed 3x with PBS and then 11 mL of serum containing media
was added. Plates were then allowed to sit at 37°C with 5% CO2 for 4 hrs before being
lifted by pipette and re-plated in a 96-well white wall and white bottom plate. Cells then
were maintained at 37°C with 5% CO2 for an additional 24 hrs before reporter assay was
performed. All drugs being tested were dissolved in Hanks’ Balanced Salt Solution
(HBSS) with 0.1% DMSO. The highest drug concentration of 10-5 M was first prepared,
and each full log concertation was prepared by serial dilution thereafter. The control well
contained just HBSS with 0.1% DMSO. The serum media was removed from the plate
before then addition of the drug at varying concentrations (10-5 M to 10-17 M). The drugs
were then incubated in the plate for 4 hrs at 37°C with 5% CO2. After 4 hours Nano-Glo
luciferase (Promega) substrate is added to have a final concentration of 10-8 M and then
placed at 37°C with 5% CO2 for 10 mins. The plate is then read by a Berthold Mithras
LB 940 plater reader at a λ max of 460 nm. The HBSS control is then removed as the
background to all other signals and a dose response plot is used to quantify the signal
from the genes being up or down regulated. The entire experiment described above was
completed in triplicates for each drug and gene being studied.
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6.4.12 Western Blotting
HEK293T cells are maintained in Dulbecco’s Modified Eagle’s medium (DMEM)
from Sigma-Aldrich (D5796) with added 5% sodium pyruvate, 5% penicillin
streptomycin, and 10% fetal bovine serum (FBS) at 37°C with 5% CO2. Cells were
cultured in a T-75 flask to 95% confluency then lifted by trypsin-ETDA (0.25%). Once
cells were counted and spun down at 1000 rpm they were resuspended and then re-plated
in 6-well culture dishes at 500 000 cells per well. Seeding was then accomplished for 24
hrs at 37°C with 5% CO2. After 24 hrs cells were transiently transfected with 0.33 ug of
GHS-R1a-eYFP per well. Following 48 hours of transfection cells were rinsed 3x with
PBS and 1 mL of serum free media was added to each well. The ligands were then added
to have final concentrations of 1 nM, 10 nM, 100 nM, and no ligand as for the control.
Plates were incubated at 37°C with 5% CO2 for 0 min, 5 min, 10 min, 20 min, and 30
min. After the incubation period media was removed and cells were lysed and spun down
at 17 G to collect total protein. SDS gel electrophoresis was ran in a 4 to 12% gradient gel
for 1 hour, followed by transferring to the PVDF membrane for 90 min. pERK was
measured with a specific primary antibody for 24 hours at 4°C, followed by stripping the
blot and measuring tERK with an additional specific antibody for 24 hours at 4°C. Then
the blot was stripped a third time and a specific primary antibody for eYFP was incubated
for 24 hours at 4°C. The ratio of pERK to tERK was calculated and graphed to show
difference in phosphorylation. All antibodies were purchased from Cell Signalling. GHSR1a stimulated ERK signalling in HEK-293 -/+ YM254890: Cells were cultured and
prepared as described above. Either YM254890 (100 nM; FUJIFILM Wako Pure
Chemical Corporation) or DMSO vehicle control (0.001%) were added to wells for 30
minutes prior to agonist stimulation (ghrelin, 100 nM). Cells were incubated with ghrelin
for 20 minutes. Lysates were prepared, processed and quantified as described above.
6.4.13 Stable Transfection of LNCaP cells with GHS-R1a-eYFP.
The LNCaP (metastatic prostate cancer derived from left supraclavicular lymph
node) cell line (ATCC) was maintained in RPMI medium (Wisent) supplemented with
10% fetal bovine serum (FBS; Wisent). Cells were plated at a density of 1 million cells in
a 10 cm dish for 24 hrs. After 24 hrs 6 µg pcDNA-GHS-R1a-eYFP was added along with
Fugene-6 (Promega) in a 1:3 ratio as per the protocol provided by Promega. After 48

255
hours cells were rinsed with PBS (3x) and replaced with serum media containing 300
µg/mL of G418 (Wisent). Cells were then kept under selective pressure for 7 to 10 days.
Cells were then sorted (by FLOW cytometry identify the YFP tagged GHS-R1a) for
single cell populations at the London Regional Flow Cytometry Facility (LRFCF) by
manager Dr. Kristin Chadwick. A single cell population was collected and re-sorted by
the same method mentioned above. This single cell clonal population was confirmed by
confocal microscopy identifying the tagged GHS-R1a in yellow. Confocal microscopy
confirmed 90-95% of cells were expressing GHS-R1a with high cellular membrane
expression
6.4.14 Calcium Assay
LNCaP cells stably transfected with GHS-R1a-eYFP (maintained in RPMI with
10% FBS, 1% Pen-Strep, and 300 µg/mL G418 – Wisent) were grown to 75 to 85%
confluency in a T-75 flask. Cells are lifted from the T-75 flask using 5ml of 1 mM EDTA
in PBS (Wisent). Cell-PBS-EDTA suspension is spun at 1.0 x 103 rpm to pellet cells and
PBS-EDTA is removed. Cells are then suspended in 500μl Fluo-4 NW (no wash, NW)
dye solution and assay buffer (1x HBSS, 20mM HEPES) and incubated (r.t., 30 min.) on
rocking platform. Fluo-4 NW cell suspension is then increased to volume required for
assay with HBSS containing calcium chloride and magnesium chloride. Cells are aliquot
into cuvettes (2ml/cuvette) containing a magnetic stir-bar to keep cells in suspension for
assay. Individual cuvettes are loaded into a Photon Technologies Institute (PTI)
spectrophotometer. Time-based assay parameters are assigned through PTI software as
follows: excitation 480nm, emission 530nm with 8nm capture window, and 5000 secs
duration. Individual cuvettes emission is collected for approximately 10 secs to obtain
baseline emission. Agonist is pipette into cuvette and cellular response is measured. As a
control 3-5 untreated cuvettes are treated with 3μM ionomycin calcium salt in DMSO to
give the maximum response. Each agonist concentration is expressed as a percentage of
average maximum response.
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Chapter 6 Supplementary Information
UPLC and ESI-MS tracers
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3: Diode Array
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Compound 3
JQ-5-21-2-c7-20170202-05-95

3: Diode Array
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Compound 4
JQ-5-21-1-C6-20170207-05-95

3: Diode Array
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Compound 5
JQ-5-19-2-c10-20170123-05-95-2

3: Diode Array
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Compound 6
JQ-5-19-1-c9-20170123-05-95-1

3: Diode Array
Range: 9.248e+1

1.46

8.0e+1

6.0e+1

AU

4.0e+1

0.31

2.0e+1

0.0
-0.00
0.20
JQ-5-19-1-c9-20170123-05-95-1

0.40

0.60

0.80

1.00

1.20

1.40

1.60

1.80

2.00

2.20

2.40

2.60

1.49

JQ-5-19-1-c9-20170123-05-95-1 1051 (1.492) Cm (1030:1113)

2.80

1: TOF

645.0356

100

3.00
1: TOF MS ES+
TIC
MS ES+
1.03e4

5.84e3

1.49

1.50
%

1.51

%

1.53

645.5347
0
101.0653
-0.00

0.20

0.40

0.60

645.7924
1.20

0.80

609.0328

110.0152

860.0715

1.00

1.40

686.0669

1.60

860.7407

1.80

2.00

2.20

2.40

2.60

2.80

3.00

Time

1289.6057

0

200

400

600

800

1000

1200

1400

m/z
1600

267
Compound 7
JQ-5-27-1-F10-20170303-05-95

3: Diode Array
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Compound 8
JQ-5-27-2-F11-20170303-05-95

3: Diode Array
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Compound 10
JQ-5-27-4-F11-20170307-05-95

3: Diode Array
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Supplementary Figure 6.1 - pERK and tERK blots at 0, 5, 10, 20, and 30 min
intervals with the treatment of Ghrelin versus Compound 6 (n=3)

Supplementary Figure 6.2 - pERK and tERK blots for various concentrations of
Compound 6, Compound 9, Compound 10, and Ghrelin for a 20 min incubation
(n=3)

271

Supplementary Figure 6.3 - pERK and tERK blots with either DMSO vehicle
control or YM254890 with/without ghrelin stimulation for 20 min incubation (n=3)
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Supplementary Figure 6.4 - Confocal microscopy images of stable transfect LNCaP
with GHS-R1a-eYFP indicating the receptor is highly expressed and localized to the
cell membrane
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Chapter 7
7.1 Conclusion
The focus of this work was the development of chemical tools, both fluorescent
and PET probes, that target the growth hormone secretagogue receptor-1a (GHSR1a). All of these chemical tools acted as agonists when targeting GHS-R1a leading
to an activation in signalling. This receptor is an attractive GPCR target because of its
wide range of physiological functions in the human body (e.g. metabolism, cardiac
output, depression, neuroprotection)1-2. GHS-R1a is also highly dysregulated within
certain disease states. It is over and differentially expressed in malignant prostate
cancer versus benign, as well as upregulated in a variety of other cancers such as
ovarian, lung, uterine3-4. GHS-R1a is also highly promiscuous, as it heterooligomerizes with many other GPCRs such as the dopamine and melanocortin
receptors. More recently, some have shown how GHS-R1a homo-oligomerizes with
itself. However, within the scope of this work, the development of a ghrelin
homobivalent ligand was used to target the GHS-R1a oligomer to elucidate the
changes in the signaling cascade as a result of the oligomer. When GHS-R1a
oligomerizes with itself or other GPCRs there are changes to the downstream
signalling (e.g. changes in G-protein activation) leading to different physiological
outcomes5-8.
The natural ligand for the GHS-R1a is ghrelin, a 28-amino acid peptide that is
derived from a 117- amino acid sequence (preproghrelin), through post-translational
modifications, terminating with the octanoylation of Ser-3 by ghrelin O-acyl
transferase (GOAT) producing the active form of the ligand3. This is the only known
instance of a peptide being post-translationally modified with a fatty acid, and this
modification is required for its binding to, and activation of GHS-R1a1-2. However,
the natural ligand is highly susceptible to degradation by enzymes, due to its natural
amide backbone and the 28 natural amino acids that make up the structure of the
peptide. Also, the ester linkage for the attachment of the octanoyl chain to Ser in
position three is susceptible to esterase hydrolysis. Therefore, this is changed to an
amide linkage to improve stability but still maintain binding to GHS-R1a. There is a
need to develop GHS-R1a targeting probes that have a structure with a greater level
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of stability but still maintain binding towards the receptor. There is a greater interest
in developing imaging-based probes to monitor the changes in GHS-Rla receptor
expression in the presence or absence of diseases such as cancer, cardiovascular, and
metabolic imbalance. The design of chemical probes driven towards therapy is also a
consideration, as down regulation of this receptor is seen in diseases such as cancer
cachexia (muscle wilting after chemotherapy)4.
There are many styles of chemical probes that can be developed (e.g. small
molecules, proteins, antibodies), however, peptides have several advantages. Peptides
are easily synthesized by Fmoc solid phase peptide synthesis, and because of the ease
of this synthesis technique they can be chemically changed without difficulty (e.g. Damino acids, amidated C-terminus, backbone stabilization). Peptides also have a
greater affinity towards their target of interest, since most known targets only have
one natural peptide ligand that binds to them and changes its state of activation.
Peptides have a natural structure, their degradation by proteases can be readily
determined, therefore this structure can be altered to improve their stability and
efficacy as drug molecules.
The first Chapter of this thesis focused on the development of a stabilized ghrelin
fluorescent probe that was able to bind to the receptor with nanomolar affinity. With a
lactam bridge stabilization in the backbone of a ghrelin 1 to 20 analogue (as
determined by a staple scan), the peptide probe was fully stable over a 24-hour period
when incubated with 25% human serum. This probe was demonstrated in an in vitro
situation identifying receptor mediated binding in cells that artificially had over
expression of the receptor, as well as in cells that had endogenous levels of GHS-R1a.
This peptide probe was also able to detect changes in GHS-R1a expression in a
mouse model of stroke by immunofluorescent imaging (ghrelin expression
upregulated after stroke due to its neuroprotective effects). This work is not part of
the immediate thesis but is an ongoing collaboration with Dr. Rithwik Ramachandran
from the Department of Physiology and Pharmacology at Western University. By
evaluating this probe in a mouse model of stroke, we can further validate the probe in
a more realistic scenario of detecting the GHS-R1a dysregulated expression in an ex
vivo situation. This chemical tool will be highly effective as an imaging probe in both
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an in vitro and ex vivo situation as most known antibodies for this receptor have
proven to have inadequate specificity.
The second section of this thesis, encompassing Chapters 3-5, was a “roller
coaster” in terms of probe synthesis and design (structure activity relationship studies
– SAR studies) due to many challenges associated with receptor affinity,
radiochemistry, and lipophilicity. This second section consists of three individual
chapters and was driven towards applications in an in vivo imaging scenario. This
research focussed on modifying a G7039 peptidomimetic first developed by
Genentech. This peptide was originally developed to be used as a growth hormone
drug, however due to its relatively small size (mimicking a small molecule class of
drug) the conversion into an imaging agent was highly feasible. Prior work
highlighted in Chapter 3 looked at the simple addition of 4-fluorobenzoic acid group
onto the C-terminal portion and a fourth position changed from a Phe to a 1naphthylalanine (1-Nal). This proved to be ineffective when it came to imaging by
PET (compound 17 in Chapter 3). It had a substantially lower affinity, a higher
cLogP, and a lengthy radiosynthesis route. However, this project included an
extensive SAR study that indicated which positions of this short 5-mer peptide could
be altered without negatively affecting the binding towards GHS-R1a. This allowed
for a follow up project that would focus on only altering the fourth position of the 5mer peptide, as well as changing the prosthetic group to improve lipophilicity,
binding, and the radiosynthetic route.
These findings led into the second part of the project (Chapter 4) that had the
goals of reducing the cLogP of the compound, increasing the binding affinity to GHSR1a, and improving the radiosynthesis route. Converting the fluoride-19 (19F) group
to a fluoride-18 (18F) group on the 4-fluorobenzoic acid prosthetic group in Chapter 3
was too lengthy of a radiosynthetic route. In the end, two of these tasks were
accomplished, and further opportunities for subsequent structural modifications
(further changes to the radiosynthetic prosthetic group) were considered. The fourth
position of G7039 was modified from a Phe to a Tyr, and the prosthetic group chosen
was a 2-fluoropropanoic acid group on the C-terminal lysine. These changes resulted
in a compound with an affinity that was sub-nanomolar and a reduced cLogP was
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observed. This was thought to be the compound that would be labelled and provide
decent PET images in an in vivo scenario. This was not the case as the 2fluoropropioic acid labelling with 18F proved to be low yielding and thus had a similar
issue to that found when using the 4-fluorobenzoic acid prosthetic group. However,
this new peptidomimetic proved to have low nanomolar affinity and picomolar
activity as measured by b-arrestin recruitment. This is believed to be due to the Tyr in
the fourth position forming a new H-bond interaction with Arg 283 in the binding
pocket of the receptor (determined by molecular docking). When Ser was placed in
the fourth position binding and activity decreased. A lowered Emax was identified for
compounds 3 and 6, indicating that they act as a partial agonists when targeting GHSR1a. Compound 5 in Chapter 4 still has the potential to be labelled with 18F, however
it has a greater potential as a drug therapeutic for diseases where GHS-R1a activation
is lowered.
The final stage of this peptidomimetic work was to see if it was possible to change
the prosthetic group of the C-terminal Lys a third time while leaving the Tyr in the
fourth position (Chapter 5). An alkyne containing ammonium methyltrifluoroborate
(AMBF3) was chosen as the new prosthetic group for its ease in conjugation to a
peptide as well as an efficient radiosynthetic route. This particular prosthetic group is
easily installed onto the previous peptide (compound 5 in Chapter 4) by copper click
chemistry using a Lys azide on the C-terminus instead of the previous standard Lys
group in the fifth position. Once installed the binding affinity was found to still be
sub-nanomolar, however the cLogP was three-fold less than the original G7039
peptidomimetic. This drastic decrease in cLogP will help with the past issues of the
tracer being retained in lipophilic organs such as the liver. This tracer can now be
directly labelled in one step with no HPLC purification and great radiochemical data.
The “hot” 18F compound displayed a 10 to 12% uptake in cells expressing GHS-R1a.
This chemical tool can now be used as a PET tracer to identify the over expression of
GHS-R1a in an in vivo cancer mouse model.
Despite the challenges (affinity, lipophilicity, and radiosynthetic route), the three
iterations of peptidomimetics each had a positive outcome for its intended purpose.
The Chapter 3 outcome helped guide further SAR studies. Chapter 4 confirmed that
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only select positions of this class of ghrelin peptidomimetic can be altered in order to
maintain affinity and potency when targeting GHS-R1a (confirmed by molecular
docking). Chapter 5 finally was the improved avenue towards a simplistic and
efficient radiosynthetic route for a novel and improved PET tracer. Each of these
unique peptidomimetic ghrelin derivates all have applications towards imaging the
dysregulated GHS-R1a by PET. The three generations of peptidomimetics are
depicted in Figure 7.1.

Figure 7.1 - Three generations of ghrelin peptidomimetics with changes to the
fourth position (highlighted in green from structures A to C) from a naphthylalanine group (structures A) to a tyrosine (structure A and C), and the use of 3
different prosthetic groups (highlighted in red from structures A through C)
from generation 1 through 3 conjugated on to the C-terminal lysine
The final project was the study of GHS-R1a homo-oligomerization, but more so
the design of chemical tools to target this homo-oligomer. This project was the most
challenging due to the complexity of the assays involved in studying this
oligomerization. GHS-R1a has a wide functioning role in human diseases such as
obesity, diabetes, stress, anxiety, and depression. Because of its broad range of
function in the human body it has been shown that GHS-R1a preferentially
oligomerizes with other GPCRs that have similar physiological effects. This makes it
very difficult to target GHS-R1a with potent agonists and antagonists with high
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efficacy. However, by having a greater understanding of receptor oligomerization one
could anticipate designing specific drugs in terms of pharmacological treatment while
minimizing side effects. Jiang et al. in 2006 was able to first observe a GHS-R1a
homo-oligomer in HEK293 cells that were over expressing GHS-R1a-Rluc and GHSR1a-GFP by a BRET signal that gave a hyperbolic shape. GHS-R1a has been shown
to oligomerize with other GPCRs such as the dopamine receptors (D1R and D2R), the
serotonin receptor (5-HT2C), the melanocortin receptor (MC3R), and the cannabinoid
receptors (CB1 and CB2)7. GHS-R1a cross talk has widely had a focus driven
towards the neuroendocrine system in human physiology, however little work has
focussed on the implications of self-oligomerization. The dimerization with other
receptors has been shown to either attenuate or cause an augmentation of the
downstream cascade of signalling events associated with GPCR activation. Examples
of such oligomerization is between GHS-R1a and melanocortin-3 receptor
(homeostatic control of food intake) and this oligomerization causes an attenuation of
signalling when GHS-R1a is activated by ghrelin and simultaneously associated with
melanocortin-3 receptor9. This leads to a reduction in signalling events such as the
slowing down of appetite response, whereas when ghrelin acts alone on its receptor it
causes an increase in appetite.
Many in the field have targeted GPCR hetero-oligomers with two separate
ligands. This approach has a major limitation when it comes to designing a novel drug
for a receptor oligomer in terms of drug dosing and formulation. Knowing that this is
a possible mechanism in which a ligand can bind and change the active state of a
GPCR oligomer, one can develop novel heterobivalent and homobivalent ligands that
would modulate the signalling in a differential fashion when compared to the
monomer. There is still limited knowledge about the GHS-R1a homo-oligomer and
until our work, there are no known homobivalent ligands that can target this homooligomer simultaneously and stabilize its formation. Our studies showed that the
homobivalent ligand (compound 6 in Chapter 6) possesses exceptionally high binding
affinity and can bind to both receptors within the GHS-R1a homo-oligomer in
HEK293 cells. This is indicated by a bivalent binding curve. In addition, we
demonstrated that this chemical probe is a strong agonist by its activation of b-
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arrestin-1 and b-arrestin-2 recruitment in the low nanomolar range. The monomeric
version of the heterobivalent ligand; G7039-L (10), the unmodified G7039
peptidomimetic (9), and the natural ligand for the receptor; ghrelin, are 2-15x less
potent then homobivalent ligand based on EC50 values for b-arrestin-1 and b-arrestin2 recruitment. We determined that there was 3-fold increase in homo-oligomerization
BRET response with the homobivalent ligand (6 ) compared to ghrelin, G7039 (9),
and G7039-L (10). GHS-R1a activation triggers several signaling pathways that can
be harnessed for therapeutic response in disease states (e.g. inflammation, diabetes,
and hypotensive effects), leading to the potential for the homobivalent ligand (6) to be
used as a therapeutic agent. Targeting the homo-oligomer system with a novel ghrelin
homobivalent ligand (6) has caused a 12,000-fold increase in binding compared to
ghrelin targeting the monomer receptor, however there is a reduction in the MAPK
and NF-kB signalling that is partially due to this receptor oligomerization. Being that
NF-kB is a typical protein involved in the inflammation signalling cascade, this is a
promising agonist that could be used in the treatment of diseases lacking GHS-R1a
signalling (i.e. cancer cachexia) but being able to slow down inflammatory signalling
responses. Ligands that are capable of targeting these receptor oligomers holds great
promise as a new class of therapeutics, but equally important, are a powerful chemical
biology tool for understanding the function, mechanism, and disease significance of
GPCR oligomers, for which there is limited knowledge to date.
Overall in my PhD I was able to develop several different styles of chemical
probes targeting GHS-R1a with different degrees of affinity and potency. Each of
these probes was modified in such away to have applications in the direction of either
imaging or therapy and opens the door to further probe development to study this
receptor in human physiology and disease.
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